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INTRODUCTION 
       Siddha system of medicine is one of the greatest to which western medicine owes much in its earlier 
stage of development from the sages of Ancient India to mankind. It is one of the world‘s most ancient 
medical discipline. It is not only the system of medicine in the conventional sense of curing disease but it 
is the way of life. Siddha system of medicine treats man as a whole which is a combination of Body, 
Mind, Soul. 
ஞான஫மிந் த ார்க்கு ந஫னில்லய நாள்த ாறும் 
பான஫ல  யுண்டு பசி஬ினால் - ஞான஫து 
கண்டால் உடலு஬ி ருங்கா஬ம் வலுவாகும் 
உண்டால் அ஫ிர் ஭ச முண். 10 
Therefore it is truly holistic and integrated medical system.  
  அஞ்சுபஞ்ச பூ ம் அமிந் ால் அனித் ி஬ம்தபால் 
அஞ்சு வசப்படுவ ாண்ட னில் - அஞ்சிலனயும் 
கண்டமி தவார்ஞானக் கார்சி ஬ ினிலனவு 
விண்டமி஬ யாத஫ வி ி. 18. 
Above lines are written by the Great saint Tiruvalluvar. Siddhars consider our body as universe and 
compared with panchapudam.  
                     In Siddha system of medicine the physiological components of human body are 
Vatham(Air),Pitham (Fire),Kapham(Earth and Water).When the normal equilibrium of the 3 humors 
disturbed ,the disease is caused,so siddhars  maintained the body equilibrium. 
             Siddhars   explained about the various types of female ailments in their text, the one is 
PERUMBADU which means GREAT SUFFERING of women. YUGIMUNI   siddhar who classified 
perumbadu  as four types[1].  PITHA PERUMPADU is one among them challenging to medical 
practitioners of both   Allopathy and siddha field. Added that it affects mentally, physically,and 
economically.  
            The signs and symptoms of PITHA PERUMPADU can be correlated to the DYSFUNCTIONAL 
UTERINE BLEEDING [DUB]   because  the signs and symptoms of the both are more similar. 
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DUB is more common around the menarche and pre menopause. 1 in 20 women aged 30-49 years consult 
their GP each year for menstrual disorders. Menstrual disorders are the second most common 
gynecological condition to be referred to hospital, accounting for around 12% of all gynecological 
referrals[19]. 
                        The currently available drugs for menorrhagia   had many side effects and play a major 
role in the hormone cycle and alter the regular hormonal secretion of the body. Surgical intervention is the 
only choice in other system of medicine. In this juncture siddha medicine treatment is a boon to the 
society to skip surgical procedure.  
Many herbal and herbo - mineral formulation of medicine practiced in Siddha system of medicine for the 
treatment of PITHA PERUMPADU [DYSFUNCTIONAL UTERINE BLEEDING (DUB)]. 
                Perumpadukku Pittu is one of the best herbal formulation has been mentioned in siddha 
literature Athmarachamirtham ennum vaithiya sarasangirdam, Dr. kandasamymudhaliyar-sep2011[2] 
                The ingredients of the Perumpadukku Pittu are   
1. Bark of Ziziphus  mauritiania.lam  (Ilandapattai)  
2. Bark of Lannea coromandelia(houtt)Merr (Othiyampattai),  
3. Bark of Syzygium cumini.linn(Naavalpattai), 
4. Bark of Ficus racemosa.linn(Athipattai), 
5. Bark of Ficus religiosa.linn(Arasapattai.) 
6. Bark of Mangifera indica.linn(Mampattai),  
7. Bark of Acacia nilotica(Velampattai)  
                    As per the Siddha literature above all the ingredients have Anti-menorrhagic action[3]. 
Backed raw rice powder (pacharasi maavu) will reduce the excessive bleeding present in the young age 
girls. Palm jaggery (panai vellam) will cure the disease caused by thiridosham.  
                   In the view of modern aspect the most of the above mentioned bark had the pharmacological 
action to arrest bleeding. 
               Hence the Author Chosen the drug ―PERUMPADUKKU PITTU‖ for the Pitha Perumpadu as 
dissertation. This medicine is totally herbal it is more safe , and most effective with cost effective.            
The ultimate aim is to save the patient from unwanted hysterectomy procedure. 
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AIM:  
         To evaluate the therapeutic efficacy of Siddha medicine Perumpadukku Pittu in the 
treatment of PithaPerumpadu [Dysfunctional Uterine Bleeding(DUB)]. 
 
OBJECTIVE: 
         
 Botanical identification and authentification of  raw drugs. 
 To prepare the trail drug as per the text ―Athmaratchamirtham Ennum Vaithiya  
Sarasangiratham‖ author Dr.Kandasamy mudhaliyar.( Last edition :Sep 2011).    
 To evaluate the physicochemical analysis of perumpadukku  pittu.  
 To study the efficacy of  the test drug through an open clinical trail. 
 To conduct an open clinical trail in Pitha Perumbadu [Dysfunctional Uterine 
Bleeding(DUB)] patients. 
 To analyze the prevalence of Pitha Perumpadu  among the society through Age, sex, 
occupation, distribution etc. 
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REVIEW OF LITERATURE SIDDHA 
 VIEW ON PITHAM 
The natural shape of Pitham is Atomic. It is sharp and hot. The ghee melts down salt crystaizes 
and jiggery melts because of heat. The heat of Pitham is responsible for many actions and their   
reactions.  
 gpj;jk; cUthFk; tpjk; 
“,Ug;ghd ehb vOgNjhBuh 
apukhd Njfj;jpy; Vyg; ngUehb 
Xf;fjrkj;njhopiy Cf;fjr; thAf;fs; 
jf;fgb vd;Nw rhUk; 
rhUe;jrehb jd;dpy; %yk; %d;W 
NgUkplk; gpq;fiyAk; gpd;dYld; -  khWk; 
ciuf;f tpuw;fhw;Nwhl;Lzu;j;JNk ehrp 
tiur; RopNahikaj;jpy; te;J 
$l;LwT Nufpj;jhy;  $Wk; thjk;  gpj;jk;  
ehl;Lq;fgNkahk; ehL” - rpj;j kUj;Jthq;f RUf;fk; 
The seats of Pitham 
  ”jhdhd gpj;jk; gpd;fiyiag; gw;wpr; 
  rha;thd gpuhzthA tjidr; Nru;e;J 
  Cdhd ePu;g;igapyZfp %yj; 
  JjpnjOe;j tf;fpdpia awT nra;J 
  khNdNf spUjaj;jp ypUg;G khfp 
  Nfhdhd rpue;jdpNy apwf;f khfpf; 
  nfhz;Lepd;w gpj;jepiy $wpNdhNk - -jkpo; itj;jpa rhjfk  
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          According to Tamil vaithiya saathagam, the pingalai, urinary bladder,  stomach, heat the 
places where Pitham sustains. 
 In addition to the above place, the umbilical, epigastric region, stomach, sweat, blood, essence of 
good, eyes and skin are also the place where pitham sustain 
Yugi Muni says that the pitham sustains in urine and the places below the neck. 
1. tapW   2. urjhJ 
3.,uj;jk;   4. Cd; 
5. tpau;it   6. fz;fs; 
7. nghJthf njhg;GSf;FNky; ,UjaJf;F fPo; cs;s gFjpf 
THE CHARACTERSTICS OF PITHAM 
According to Maruthuva thanipadal 
   ― grpjhfk; Xq;nfhspfz; ghu;itgz; lj;J 
   Urpnjup rj;jpntk;ik tPuk; - crpj 
   kjp$u;j;jGj;jptdg; gspj;Jf; fhf;Fk; 
   mjpfhup ahq;fh doy;” 
       -kUj;Jt jdpg;ghly; 
Pitham is responsible for Digestion, Vision; Maintenance of body temperature, Hunger, Thirst, 
Taste etc., its other functions includes Thought, Knowledge, Strength and Softness. 
According to Pathennen Siddhargal Nadi Sasthiram 
  ” gFj;jpLk; gpj;jk; gygyrpe;ijahk; 
  tFj;jpLk; the;jpAk; tha;ePu;kpfT+Wk; 
  kpFj;jpLk; Nkdpapd; khl;b naupg;NgWk; 
  kpFj;Jj;jtdpf;F kpftple;iff;Fnk.” 
-gjpndz; rpj;ju;fs;ehb rh];jpuk; 
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According to Pathinen Siddhargal  Naadi Sasthiram, the character of pitham are vomiting, 
increased salvation, burning sensation of the body and kaippu in the tongue. 
 
gpj;jk; tuyhW 
   “ghulh gpj;jnkd;w fpupr;rde;jhd; 
    gjpndl;L tifahfg; gypj;jNjJ 
   T+ulh apUf;fpd;w ngupNahu; jk;ik 
    nahUf;fhNy gopj;jdhy; te;jghtk; 
   rPulh ghuhky; Jhf\zpj;jy; 
    rptj;jyq;f sijg;hopj;jy; rptNknra;jy; 
   Mulh Nfhgnkd;w ghtj;jhNy 
    ag;gNd gpj;jkJ rpurpd; NkNy  
   NkNywp ajue;jif naOk;gp 
    Nkfnkd;w GutpaJ NghNyahr;R 
   khNywp gpj;Jf;Fk; gpuiknjhd;wp 
    kdk;tpl;Lf; $j;jhb ntspNaNafpf; 
   fNywpg; grhRNghw; wpupe;jnjd;w 
    fhuz;l Nfhgnkd;w fUkj;jhNy 
   ghy;NfhY kdKila ngupNahu; rhgk; 
    gypj;Jjlh Gj;jp nfl;l guprjhNk.” 
      -mfj;jpau; fd;k fhz;lk; - 300 
According to Agasthiyar Kanma Kaandam, due to the above factors the pitha humour may gets 
deranged. 
 
The functions of pitham 
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1. Maintain body temperature  
2. Produces reddish or yellowish color of the body. 
3. Produces heat energy on digestion of food. 
4. Produces sweating, 
5. Induce giddiness. 
6. Produces bold and the excess blood is let out. 
7. Gives yellowish coloration to Skin, Eye, Faces and Urine 
8. Produces Anger, Haughtiness, Burning sensation, Inaction and Determination. 
9. Gives bitter or Sour taste. 
According to Angathipatham, the deranged pitham produce anger, increased  
 gpj;jk; gpuNfhgpf;ff; fhuzq;fs; 
 “MAW gpj;j Nfhg kjpnrak; ntg;Gj; jhfk; 
 Njha;TW kau;T %r;Rr; nrhd;kjk; Gj;jpNgjk; 
 ghAW KdpT tPuk; gutpa Gspg;gpypd;gk; 
 thaW Kjpufz;fs; kyQ;ryk; kQ;rshFk; 
 Fzk;ngWk; Kfq;fs; Nkdp $u; rpue;jpuq;fp tw;wy; 
 fzk; ngWk; kdk;Ntwhff; fl;bLq; Fspu;fhyj;jpy;  
 kzk;ngWryNkw; whfk; itj;J ehbLk;gpd;ntg;ghy; 
 epzk;ngW kjprhuj;ij ePl;bLKdpta;gpj;jk;”. 
-mq;fhjpghjk; 
According to Angathipatham, the de ranged pitham produce anger, increased thirst, tiredness, 
confusion, increased intake of pulippu taste in diet, yellowish coloration of eye, urine and feces, delusion 
and finally results in fatty diarrhoea. 
  gpzpjU gpj;j Nfhgk; ngUfTz;lhFKz;b 
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 fzpngW kbw;rpAg;Gg; Gspg;Giwg; gjpfj; jhYk; 
 gzpjU kJtpdhYk; ghuz kpFjyhY 
 kzpjUntau;T nta;apy; topeil KdptpdhYk;. 
According to Angathipatham, increased intake of uppu, pulippu  uraippu in diet, alcohol, and 
prolonged exposure to sun will derange the pitha humour. 
“epj;jpiu jtpjyhYk; neLNeuk; epw;ifapy; 
Fj;jpu tpjj;jpdhyYq; nfhk;gdhu; kUe;jpl;lhYk; 
Rj;jpapy; yhNjnfhz;l mT\j Njh\j;jhYk; 
gpj;jNk gpuNfhgpj;Jg; ngUe;Jau;   nra;Ae;fhNz.” 
According to Thanvandhari, prolonged standing, sleeplessness and unpurified me medicines will derange 
the pitha humor. 
TYPES OF PITHAM: 
The pitham is of five types depending upon the location and functions of as follows: 
1. Aakkanal ( Anal -  pasaka – pitham) – The fire of digestion 
“moiytifj; njd;gujpy; Kjd;ik ngw;w  
 jhf;fdy;jhd; [k;G+j kakha; kw;iwj; 
joiyAue; je;JGue; jUkhy; cz;l 
 rhjj;ijr; nrupgpgpj;jp urj;ijf; nfhz;L 
foiytpLe; jpg;gpfis ,ug;igf;F kLq; 
 fhupaQ;nra; jhdj;Jf; fpilNa Fbaha; 
koiynkhop khNjNfs; rikf;Fkpj;ij 
 tod;q;tu;fhz; ghrfkh kdy;jh ned;nw.” 
- kUj;Jtj;jdpg;ghly;  
It lies between the stomach and the intestine and causes digestion and dries up ingested substances. 
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2. Vanna eri (Ranjagapitham) – Blood promoting fire 
This is lies in the stomach and gives red color to the chime and produce blood improves blood. 
“,iug;igtho; tz;zntup> wq;fpg; Nghe;j 
 vy;yhT+z; ldf;Fkhw;W epwnkhd; wPe;Nj 
tpiutpyd;d rj;njy;yhk; mLQ;rhiyf;Nf 
 Nktitg;g jpuj;jnkhl;L kpjaj; Nja;e;J 
epiwe;jhw;w yq;fpehSk;kjpNru; nkij 
 newptypahy; tpUk;gpahq;F gzpnra; njey; 
tpiunrwpnky; Nyhjpq;fha; Guf;Fk; nka;ia 
 Tpsk;GuQ;r fQ;rhjf KiwNa ahNk” 
- kUj;Jtj;jdpg;ghly; 
3. Aarralanki ( saadhagapitham) – The fire of energy 
It   controls the whole body. It has the property of fulfillments. 
4. Ozhi thee (Prasagapitam) – The fire of the brightness 
It gives color and complexion and brightness to the skin 
5. Nokhazhal (Alosaga pitham )– The fire of vision 
cupnahspnra; aoyjq;Fe;Njhypyj;ij 
 nahs;nshspj;jP nadtpspg;gu;kPNda; thl;Nry; 
tupnfhs;f;fp eLtpUe;J fz;l fhl;rp 
 tupnfhs;f;fp eLtpUe;J fz;l fhl;rp 
           tif tpsf;f kwptpf;Fk; Nehf;F kq;fp 
 tpupAs Ehy;ty;ehtu; $Wq; fhe;jp 
kpFg;gpuhr fkhNyhr fq;fnsd;W 
 njupTs;j;nj nray; Kiwg;gpj;j ike;jpd; 
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jpfnohsp$u; tpopazq;Nf [ak; ePe;Nj!” 
 kUj;Jtj; jdpg;ghly;  
It lies in the eyes and causes the faculty of vision. It help to visualize things. 
fOj;Jf;Ff; fPo;g;gl;l Neha; tpguk; 
   rPupa fOj;jpd;  fPOs;s gpzpiaj;   
jPu;t jwpe;J jpirngwr; nrg;GNtd; 
ghupa gbAk; guprpy; gpsitAk; 
ngUfpa nfz;il ngUe;njO fTirAk; 
,UkYe; Jk;kYk; <isAk; tskha; 
ePUs; kpFe;J epiwe;;njO NfhitAk; 
ghnuhL nkhopnadg; gue;njO #iyAk; 
jd;dpid tpd;wpj; jtpf;Fk; gpj;jk; 
………………………………………. 
kpQ;fpa that kpFfp uhzpAk; 
Jd;dpa kw;wrj; njhj;jpa %yKk; 
NgUy fwpag; ngUj;j kNfhjuk; 
………………………………………… 
…………………………………………. 
mUrpAk; fhr Rthf Ke;jpaw; 
gpuNkfj;Jld; <isAk; kfhrPj 
fhrKk; kjpNrhzpjKk;  vLf;fpd;w 
Ntz thaRld; Kaq;fpa kaf;fKk; 
-Njiuau; thflk; 
G+g;G Neha;fs;: 
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   G+g;Gf; fhiy NehT kpFjy; 
   Kiwg;gb ehspd; Kd;G G+j;jy; 
   me;eh nsy;iy afd;W G+j;jy; 
   jpq;f spUKiw Kk;Kiw G+j;jy; 
   FUjpaUfy; kpFe;J Njhd;wy;  
   fWj;jy; ntspwy; fOePu; epwq;nfhsy; 
   jpzpe;J FUjp Jzpe;J tPo;;jy; 
   kpff; nfL ehw;wk;  tPry; Eiuj;jy; 
   Ie;J ehspd;   kpf;nfho fpLjy; 
   rijj;jpus; Njhd;wy; vDkpit gpwTk; 
   fUg;ig tspapDk; gpwtpDe; Njhd;Wk; 
   G+g;G Neha;f shnkd nkhopg 
-khd; KUfpak; 
 
 
 
 
PERUMPADU 
Synonyms: 
  Ratha Rogam 
In Ayurvedic 
  Aurukthra nidanam 
  Sonidha pradaram 
  Raktha pratharam 
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 DEFINITION 
1. According to Pararasasekaram 
   tUngUk; ghl;L Nuhf kz;bNa apUe;jhd; thiy 
   jgU tj;jp Ndhu;f;Fe; jq;fpa NrhupjhDk; 
   nghUKa Yjpuk; Nghyg; Nghe;Jtha; fpope;;J ehSk;  
nrhuptJ ngUk;ghnld;W nrhy;Ytu; Kiw Gzu;e;Njhu; 
-guuhrNrfuk; 
Excessive and profuse menstrual bleeding is called Perumpadu. 
2. According to Manmurikiyam  
  tFj;j Kiwapd; klthu;f; nfy;yhk; 
  Fwptopf; FUjp kpFe;Je; njhlu;e;Jk; 
  xOfy; ngUk;gh lhFkJNt 
- khd;KUfpak; 
Abnormal excessive blood loss is defined as aurukthra nidanam, sonidh aradaram. 
 
 
3. According to Agathiyar Gunavagadam 
  tUfpd;w ,uj;je;jhd; ngUk;ghnld; ghu; 
   td;ikAs;s ,uj;je;jhd; mjpfkhdhy; 
  njupfpd;w ehspdpNy epd;wplhky; 
   jpNufj;jpy; rpyehl;fs;  tbe;jhYe; jhd; 
-mfj;jpau; Fzthlk; 
4. According to Anubava Vaidhya Devaragasiyam 
 Abnormal, Profuse, Prolonged discolored menstrual blood flow is defined as ― Perumpadu‖ 
19 
 
 Etiology  for  permpadu 
 Pitha perumbadu comes under the classification of perumpadu. There fore etiology for 
perumbadu is applicable for pitha perumpadu also. 
Etiology  for  permpadu 
fUjpNa fdkhd nfhLik nra;J 
 fztidNa epe;jidjhd; nrhd;d NgUk; 
gUjpapd; Kd; kyrj;ij tpl;l NgUk; 
 guNjrpNa iofisg; gopf;fpd; Nwhu;f;F 
FUjpNa apiuf;fpd;w fhye; jd;dpy; 
 $rhkw; GU\rq;if gz;zpNdhu;f;Fk; 
RUjpNa guNahfk; tpUk;gp Ndhu;f;Fk; 
 RUf;fpNy ngUk;gh Lw;gtpf;Fe; jhNk 
jhndd;w fhuzpfs; kpFf;if ahYk; 
 rz;lhsf; Nfhgj;jpd; rypg;gp dhYk; 
Cndd;w khkprq;f nghrpj;j yhYk; 
 Cwf;fkd;wp tpopjyh Yhopj; jPahy; 
ghndd;w  grpad;wpg; nghrpf;if ahYk; 
 ghukhQ; Rikthq;fy; gfYwf;fk; 
$ndd;w FWf;fyhk; Klf;fpj; Jhq;fy; 
 F&ukhk; ngUk;ghL nfhl;Le; jhNd 
     -A+fp itj;jpa  rpe;jhkzp. 
1. According to Yugivaidhya sinthamani: 
 The person who may give / show severe cruel activity to husband  
 Voiding of urine and feces infront of the sun. 
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 Committing the poverty people. 
 Make intercourse at the time of menstrual periods. 
 Excessive intercourse 
 Over consumption of spicy food 
 Vigorous angry 
 Taking non veg. 
 Sleeplessness 
 Intake of food during anorexia inactiveness 
 Day sleep 
 Lifting heavy load 
 Increased body temperature 
 
 
 
2. According to Pararasasekaam 
   jhdpit tUKw; gj;jp jidr; nrhypd; ntg;gpdhYk;  
   khzt upltp lhNj  kUTj yhYq; nfu;g;gg; 
   gPdnkhl; bj;J nehe;J gpse;jpl yhY Nkhfk; 
   thd;Kiy kle;ij ey;yha; tUj;j jyhY Kz;Nl 
-guuhrNrfuk; 
Perumabdu is caused by  
 Excessive heat 
 Sexual indulgence. 
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                 cz;b dq; fiwah fhNj Af;fpu kpFjpahYk; 
kz;bNa gpj;jthjk; tUfpNyw; gdk;g ifj;Jf; 
nfhz;bU Kjuq; nfu;g;g Kile;jplf; Fly;f yq;fpj; 
jpz;bww; Fod;kh ju;f;Fr; rpe;jpLk; ngUk;ghld;Nw 
-guuhrNrfuk; 
Excessive heat, anger, etc disturbance of pitha Vatham and then the confluence agitated Kabam leads to 
Perumbadu. 
3. According to Manmurikiyam 
  - Alcoholic beverages 
  - Walking long distances 
  - Starvation 
  - Long traveling 
  - Hard work 
  - Sexual indulgence. 
                         - Emotion.  
  - Anxiety 
  - Depression. 
  - Sleeplessness. 
  - Sleeping during day time 
  - Leucorrhea. 
tspKjy; %d;Wq; fUg;igAw;Wr; 
 rpdtypd; tpisAk; vd;gu;  Gytu; 
fg;igapd; nkd;Nwhy; Njhd;wY kopjYk; 
 mbf;fb epfOe; jd;ikahYk; 
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tspapw; nfl;l FUjp Ajdpy; 
 jq;FjyhYk; tpisA kJNt 
      -khd; KUfpak; 
Three humors gain access into the uterine cavity and get associated with the endometrium causing 
to waxing and waning periodically re presented by growth and shedding. 
4. According to Agathiyar  Gunavagadam 
  ghNueP ngUk;ghL tUk; tifiaf; Nfsha; 
   gf;Fthkha; tUfpd;w fz;l khiy 
  CNueP %j;jpuf; Fz;bf;fhapd; Nuhfk; 
   cj;jkNd gPypfh Nuhfe; jhDk; 
  NjNueP ehs;gl;l ghz;L Nuhfk; 
   njspthf ,e;jNuhfk; jd;dh iyah 
  rPNueP rpidg;igf;Fk; fUg;igf;F kg;gh 
   rpwg;ghf mjpfuj;j NkWq;fhNz    -   mfj;jpau; Fzthflk; 
Permubadu is caused by  
       Thyroid disorders 
Chronic renal diseases 
Splenic Pathology 
Chronic anemia 
Ovarian and uterine disorders. 
fhZtha; #jfk; ntspahF kg;gh 
 fUg;igjhd; moiy nfhz;L NghtjhNy  
G+Ztha; rk;Nghf kjpfj; jhYk; 
 nghy;yhj Gj;Jfshw; fl;bahYk; 
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     NgZtha; ngUk;gh Lz;lh nkd;W 
 ngykhfj; jhd; nrhy;tha; cyfj;Njhu;f;F 
fhZtha; mg;NghJ fUg;ig epd;W 
 fUthd ,uj;je;jhd; tUfe; jhNd 
-mfj;jpau; Fzthflk; 
Permubadu is caused by  
  Inflammation of uterus 
  Excessive sexual indulgence 
  Malignant and benign tumors of uterus. 
5. According to Jeevarakshanmirtham 
 Perumbadu is caused by  
  Gluttony, 
  Over eating, 
  Lying over rough surfaces 
  Excessive coitus 
  Menstrual disorders 
  Excessive heat 
  Immorality 
  Possesed. 
6. According to Anubava Vaidhya Devaragasiyam 
 Perumbadu is caused by 
  Consuming hot food, 
  Over eating 
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  Indigestion 
  Inflammation of uterus 
  Mountaineering 
  Accustomed exercise 
  Fasting / Starvation 
  Trauma 
  Altered sleep rhythm  
CLASSIFICATIONS OF PERUMPADU IN SOME BOOKS 
Sl. No Names of the Books Types 
1. Yoogi Vaithiya Sinthamani 4 
2. ManMurkiyam 4 
3. Anubava vaidhya Devaragasiam 4 
    1.According to Manmurikiyam 
tsp Kjy; %d;We; jdpj;Jq; fye;Jk; 
tUjypd; mJehy; tifg;gL nkd;g 
-khd;   KUfpak; 
Perumbadu is classified into 4 type 
1. Vatha Perumpadu 
2. Pith perumpadu 
3. Kabha perumpadu 
4. Thontha perumpadu 
         A.Vatha perumpadu 
fUj;JQ; rpte;Jk; Eiuj;Jk; FUjp 
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 jirfO ePu;Nghy; rpwpJrpwpjhf 
xOFjy;  tspg; ngUk; ghl;bd; FwpNa 
 tspap dpaf;fKe; Njhd;wpL nkd;g 
-khd; KUfpak; 
                           Vatha perumbadu is characterized by  
  -Blackish red frothy bleeding  
  -Thick viscous vaginal discharge 
Small amount of discharge blood as that of  ― a meat wash‖. 
B. Pitha perumbadu 
kQ;rshfpAk; ePy khfpAk; 
 fWj;JQ; rpte;Jk; gythwhf 
ntk;gpAk; tpiue;Jq; FUjp nahOf;fy; 
 md;w ngUk; ghl;bd; Fwpnad nkhopg 
mdw;gpzp gpwTe; Njhd;wpL nkd;g 
-khd; KUfpAk; 
Pitha perumbadu is characterised  by  
 -Yellowish, bluish and blackish, red vaginal discharge 
 -Flow of blood is hot and flushing  
C. Kaba peumbadu 
  ntSj;Jk; girnahL NktpAk; FUjp 
   tupney; fOtpa ePnud nthOfy; 
  Iapd; tUngUk; ghl;bd; FwpNa 
-khd; KUfpAk; 
Kaba perumbadu is characterized by  
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  -Pale white, mucoid, jelly like, vaginal discharge is like a ―paddy was 
2. According to Yugi vaidhya chinthamani 
  ciunra;j ngUk;ghL ehy jhFk; 
   cfe;JNk thj;jpd; rpuht nkhd;W 
  Giunra;j gpj;jj;jpd; rpuht nkhd;W 
   Nguhd Nrl;Lkj;jpd; rpuht nkhd;W 
  Jiunra;j njhe;jkhQ; rpuht nkhd;W 
   Jifnay;yhk; ehtpjr; rpuht khr;R 
  fiunra;j tpjDila cw;gj;jp  nay;yhk; 
   fz;lgb nrhy;yNt fUjplhNa 
       -A+fp itj;jpa rpe;jhkzp 
Saint Yugi classified the perumbadu into 4 types 
1. Vatha perumbadu 
2. Pitha perumbadu 
3. Kaba perumbadu 
4. Thontha perumbadu 
According to Anubava vaidhya devaragasiam 
 Perumbadu is classified into 4 types. They are 
1. Vatha perumbadu 
2. Pitha perumbadu 
3. Kaba perumbadu 
4. Mukkutra perumbadu 
 Clinical features 
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 1. According to Manmurikiyam 
  nrt;tps ePu; Nghy FUjpnahOfy; 
   iffhy; jsu;jy; clk;G fisj;jy; 
  fUf;Fop Ae;jp apitGz; zhjy; 
   Mw;wy; Fiwjy; ntk;gy; Gyk;gy; 
  nghwpfs; jsu;jy; jiy Rod;wpLjy; 
   tapWNehjy; kaYwy; kaq;fy; 
  ntspwy; kbik Fspu;r;rp eLf;fk; 
   nraywy; kaYwy; ,iofs; Nehjy; 
  vDkpit gpwTk; vO ngWk; ghl;by; 
   miljUq; Fwpf yhnkd nkhopg - -khd; KUfpak;  
 Clinical features     
            -Bleeding is like red tender coconut 
-Malaise 
-Fatigue 
-Inflammation of uterine cavity and abdomen viscera 
-Weakness of body organs 
-Lamentation 
-Giddiness 
-Loss of function 
-State of confusion 
-Abdominal pain 
-Tremors 
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According to Athmaraksha mirdham:- 
 irNahfQ; nra;aj; jdpj;j RopNahLk; 
  nka;ahf tpe;J tpotpog; Gz;;zhFk; 
 ikA+Uq; fz;zhl;F kfj;jhk; ngUk;ghlq; 
  nfha;A+Uq; jz;bdpw; nfhg;gspf;F kpuj;jk; 
Perumbadu is characterized by, Profuse menstrual bleeding . 
 According to Davnvantri Vaidhyam – II part. 
ifAld; fhYq; fhe;Jw; fhj;jpu Kyu;e;J tw;W 
 ikayhq; fytpjd;id kWj;jpLq; fu;g;gq; NflhQ; 
nra;aePu; NghYQ;rw;Nw rpte;jpLq; FUjp NghYk; 
 nga;ANk ahfpy; khNd ngUk;ghnld;wwp FtPNu 
It is characterized by 
 -Burning sensation in hands and legs. 
 -Failure of  conception. 
 -Watery reddish discharge from vagina. 
 According to Agathiyar – 2000 
  ,uj;jnkhUf;fy; jifahky; nydntNahL Nghy; tPOk; 
  jpUf;fk; rpuj;jpy; fdg;G Kz;lhFj; jpjkha; rrpjfp(wp) tpOkp uj;jk; 
  rhj;jnuj;j Nuhfnkdr; nrhy;Yk; ey;yty; NyhNu 
It is characterized by 
 -Excessive blood discharge with clots 
 -Head ache 
 According to Sarabebdrar vaidhya  muraigal 
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It is characterized by 
             Countenance 
 Shrunken eyes 
 Excessive coitus 
 Excessive bleeding 
 Aching pain all over the body 
 According to Anubava Vaidhya  Devaragasiyam 
It is characterized by 
 Excessive menstrual bleeding  
 Vague abdominal pain 
 
According to pararasasekaram 
  epd;wly; ntjk;gpr; nrd;dp epj;jK nehe;J fhJ 
   nghd;wNt apbj;Jj; jz;zPu; NghyTk; lhfkhfp 
  md;wNt Alk;ng upj;Jf; fPotapwJ fdj;Jf;  
                 fd;wpl tUj;jQ; nra;Aq; fLngUk; ghl;LNuhfk; 
In addition to the classical signs and symptoms of excessive menstrual bleeding some more 
associated signs and symptoms are also given in Pararasasekaram. 
They are 
  Head ache, 
  Throbbing pain with discharge in the ear 
  Lower abdominal pain. 
According to Yugivaidhya sinthamani 
30 
 
1. Pitha perumbadu 
Symptoms of Pitha perumbadu 
  Loss of Appetite, 
  Yellowish vaginal discharge 
  Pallor of the body 
  Pain in the both lower and upper limbs, 
  Passing of dark blood clots, 
  Burning sensation of the body 
2. Symptoms of vatha perumbadu 
Head ache  
Body pain 
Lumago 
 Complexion changes 
Subjectiv feeling of fullness of the abdomen 
Excessive menstrual bleeding 
Menstrual bleeding reddish black colour with offensive odour 
3. Symptoms of Kapa perumbadu 
Palpitation 
Cough with giddiness 
White colour menstrual  bleeding 
Excessive foul smell 
Ash colour complexion 
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Dyspnoea 
4. Symptoms of Thontha perumbadu  
Abdominal distension 
 Foul smell  
Reddish black      colour of manstural bleeding seen 
Tremor seen in head 
Excessive salivation 
According to T.V.S dictionary explanation 
 An immoderate secretion of the menstrual discharge perumbadu pith perumbadu is one type of 
perumbadu. Menorrhagia of pitha type  is marked by pain in the waist below the naval, in the sides and in 
the chest or breasts. The menstrual flow continues, sometime for the whole month or even two. In some 
varieties the symptoms are burning sensation and pain in the eyes palms of the hand and  the vagina. The 
discharge is mixed with slimy secretions. It may also appear at an interval of 3 or 4  months or even 
longer then that. The breasts may become heavy and swollen and body emaciated.  
 Naadi Nadai for Perumpadu 
gpj;jehb 
 cWjpAs;s gpj;jkJ Njhd;wpy; ntg;G 
  c\;zthA tj;jpRu kjpuh uq;fs; 
 kwjpAld; fpWfpWg;G gapj;jpa Nuhfk; 
  tsu;Nrhif  aonyupT fhe;jy; ifg;G 
 ,Ujaj;jpy; fyj;jkJ kwg;G jhfk; 
  vOq;fdT NkaidT kaf;f %u;;r;ir  
 rpWJngWk; ghLuj;jk;gpuNk fq;fs; 
  Nru;e;J kpF gpzpgyTQ; rpwf;Fe; jhNd 
      -rjf ehb 
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thj kpFjpAld; c\;zKQ; Nru;e;jjhNyw;gLk; FwpFzq;fs;;:- 
 rpwg;ghd thjj;jp Yl;bze; jhNd 
  Nru;e;jpLf yjprhu Kisr;ry; thA 
 ciug;ghd nghUknyhL mf;fpdp ke;jk; 
  cs;shFk; ePu;r;rpWg;G gpuNk fq;fs;  
 Gpwg;ghL kjfupePu; fug;ghd; uj;jk; 
  gpuNkfk; ngUk;ghL GwePu;f;Nfhit 
 mwg;ghd  thA#iy Nrj;Jk Nuhfk; 
  Mdgy gpzpfSNk te;jlUe; jhNd 
     -rjf ehb 
 
mrhj;jpak; - rhj;jpak; 
 #l;baNjh urhj;jpaj;ijr; nrhy;yf;Nfsha; 
  nrhYk;Nrl;g ngUk;ghL njhe;jrrp uhtk; 
 G+l;bdNjh upuz;Lk; gpiof; nfhl; lhJ 
  Gfohd rhj;jpaj;ij tpsk;gf; Nfsha; 
 thl;bdNjhu; thjj;jpd; ngUk;gh NlhL 
  tifahd gpj;jj;jpd; rpuhte; jhDk; 
 jPl;bdNjhu; kUe;Jf;Fr; nraK khFk; 
  nrg;gpdNjhu; ed;Dhiyj; njspe;J ghNu 
      -A+fp itj;jpa  rpe;jhkzp 
Vatha Perumabdu and pitha perumbadu are curable. 
Kaba perumabdu, Thontha perumabdu are incurable. 
ngUk;ghl;bYz;lhk; Njhlf;Fwp Fzq;fs; 
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  Njfj;JhW kdYk; jPjhkjp nyupr;ry; 
  Ntfg;ngUk;ghL ntz;zpwkha;g; - Nghftjpy; 
  ehw;wNky;%r;R etpyf;fg kaf;fk; 
  Njhw;wTly; rhAQ; nrhy; 
     -Neha; ehly; Kjy; ghfk; 
According to Manmurikiyam 
  mbf;fb FUjpnahLfy; ntk;gy; 
   Gdy;Ntl; bLjy; FUjp Fiwjy; 
  Mw;wy; Fiwjy; fha;r;ry; Njhd;wy; 
   vDkpit jPuhf; FwpfshFk; - -khd; KUfpak  
     ; 
If and when the menstrual bleeding in pale in colour with offensive odour and with burning sensation 
over the body breathlessness, palpitation, cough, giddiness, Anaemia, excessive body heat present in that 
patient, this perumbadu is deemed to be incurable. 
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REVIEW 
OF LITERATURE 
B.MODERN ASPECT 
REPRODUCTION 
Reproduction can be defined as the process by which an organism continues its species. In the 
human reproductive process, two kinds of sex cells (gametes), are involved: the male gamete 
(sperm), and the female gamete (egg or ovum). These two gametes meet within the female's 
uterine tubes located one on each side of the upper pelvic cavity, and begin to create a new 
individual. The female needs a male to fertilize her egg; she then carries offspring through 
pregnancy and childbirth. 
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FEMALE REPRODUCTIVE SYSTEM 
 Produces eggs (ova) 
 Secretes sex hormones 
 Receives the male spermatazoa during 
 Protects and nourishes the fertilized egg until it is fully developed 
 Delivers fetus through birth canal 
 Provides nourishment to the baby through milk secreted by mammary glands in the breast 
 
 
External Genitals 
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Vulva 
The external female genitalia is referred to as vulva. It consists of the labia majora and labia 
minora (while these names translate as "large" and "small" lips, often the "minora" can protrude 
outside the "majora"), mons pubis, clitoris, opening of the urethra (meatus), vaginal vestibule, 
vestibular bulbs, vestibular glands. 
Mons Veneris 
The mons veneris, Latin for "mound of Venus" (Roman Goddess of love) is the soft mound at 
the front of the vulva (fatty tissue covering the pubic bone). It is also referred to as the mons 
pubis. The mons veneris protects the pubic bone and vulva from the impact of sexual intercourse. 
After puberty, it is covered with pubic hair, usually in a triangular shape. 
Labia Majora 
The labia majora are the outer "lips" of the vulva. They are pads of loose connective and 
adipose tissue, as well as some smooth muscle. The labia majora wrap around the vulva from the 
mons pubis to the perineum. The labia majora generally hides, partially or entirely, the other 
parts of the vulva. There is also a longitudinal separation called the pudendal cleft. These labia 
are usually covered with pubic hair. The color of the outside skin of the labia majora is usually 
close to the overall color of the individual, although there may be some variation. The inside skin 
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is usually pink to light brown. They contain numerous sweat and oil glands. It has been 
suggested that the scent from these oils are sexually arousing. 
Labia Minora 
Medial to the labia majora are the labia minora. The labia minora are the inner lips of the vulva. 
They are thin stretches of tissue within the labia majora that fold and protect the vagina, urethra, 
and clitoris. The appearance of labia minora can vary widely, from tiny lips that hide between the 
labia majora to large lips that protrude. There is no pubic hair on the labia minora, but there are 
sebaceous glands. The two smaller lips of the labia minora come together longitudinally to form 
the prepuce, a fold that covers part of the clitoris. The labia minora protect the vaginal and 
urethral openings. Both the inner and outer labia are quite sensitive to touch and pressure. 
Clitoris 
 
The clitoris, visible as the small white oval between the top of the labia minora and the clitoral 
hood, is a small body of spongy tissue that functions solely for sexual pleasure. Only the tip or 
glans of the clitoris shows externally, but the organ itself is elongated and branched into two 
forks, the crura, which extend downward along the rim of the vaginal opening toward the 
perineum. Thus the clitoris is much larger than most people think it is, about 4" long on average. 
The clitoral glans or external tip of the clitoris is protected by the prepuce, or clitoral hood, a 
covering of tissue similar to the foreskin of the male penis. However, unlike the penis, the 
clitoris does not contain any part of the urethra. 
During sexual excitement, the clitoris erects and extends, the hood retracts, making the clitoral 
glans more accessible. The size of the clitoris is variable between women. On some, the clitoral 
glans is very small; on others, it is large and the hood does not completely cover it. 
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Urethra 
The opening to the urethra is just below the clitoris. Although it is not related to sex or 
reproduction, it is included in the vulva. The urethra is actually used for the passage of urine. 
The urethra is connected to the bladder. In females the urethra is 1.5 inches long, compared to 
males whose urethra is 8 inches long. Because the urethra is so close to the anus, women should 
always wipe themselves from front to back to avoid infecting the vagina and urethra with 
bacteria. This location issue is the reason for bladder infections being more common among 
females. 
Hymen 
 
The hymen is a thin fold of mucous membrane that separates the lumen of the vagina from the 
urethral sinus. Sometimes it may partially cover the vaginal orifice. The hymen is usually 
perforated during later fetal development. 
Because of the belief that first vaginal penetration would usually tear this membrane and cause 
bleeding, its "intactness" has been considered a guarantor of virginity. However, the hymen is a 
poor indicator of whether a woman has actually engaged in sexual intercourse because a normal 
hymen does not completely block the vaginal opening. The normal hymen is never actually 
"intact" since there is always an opening in it. Furthermore, there is not always bleeding at first 
vaginal penetration. The blood that is sometimes, but not always, observed after first penetration 
can be due to tearing of the hymen, but it can also be from injury to nearby tissues. 
A tear to the hymen, medically referred to as a "transection," can be seen in a small percentage of 
women or girls after first penetration. A transection is caused by penetrating trauma. 
Masturbation and tampon insertion can, but generally are not forceful enough to cause 
penetrating trauma to the hymen. Therefore, the appearance of the hymen is not a reliable 
indicator of virginity or chastity. 
Perineum 
The perineum is the short stretch of skin starting at the bottom of the vulva and extending to the 
anus. It is a diamond shaped area between the symphysis pubis and the coccyx. This area forms 
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the floor of the pelvis and contains the external sex organs and the anal opening. It can be further 
divided into the urogenital triangle in front and the anal triangle in back. 
The perineum in some women may tear during the birth of an infant and this is apparently 
natural. Some physicians however, may cut the perineum preemptively on the grounds that the 
"tearing" may be more harmful than a precise cut by a scalpel. If a physician decides the cut is 
necessary, they will perform it. The cut is called an episiotomy. 
Internal Genitals 
Vagina 
The vagina is a muscular, hollow tube that extends from the vaginal opening to the cervix of the 
uterus. It is situated between the urinary bladder and the rectum. It is about three to five inches 
long in a grown woman. The muscular wall allows the vagina to expand and contract. The 
muscular walls are lined with mucous membranes, which keep it protected and moist. A thin 
sheet of tissue with one or more holes in it, called the hymen, partially covers the opening of the 
vagina. The vagina receives sperm during sexual intercourse from the penis. The sperm that 
survive the acidic condition of the vagina continue on through to the fallopian tubes where 
fertilization may occur. 
The vagina is made up of three layers, an inner mucosal layer, a middle muscularis layer, and an 
outer fibrous layer. The inner layer is made of vaginal rugae that stretch and allow penetration to 
occur. These also help with stimulation of the penis.Microscopically the vaginal rugae has glands 
that secrete an acidic mucus (pH of around 4.0.) that keeps bacterial growth down. The outer 
muscular layer is especially important with delivery of a fetus and placenta. 
Function of the Vagina 
 Receives a male's erect penis and semen during sexual intercourse. 
 Pathway through a woman's body for the baby to take during childbirth. 
 Provides the route for the menstrual blood (menses) from the uterus, to leave the body 
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Clinical Application: 
Pelvic inflammatory disease (PID) is a widespread infection that originates in This condition, 
which occurs in about 10% of women is usually caused by chlamydial or gonorrheal infection, 
other bacteria infecting the vagina may be involved as well. Signs and symptoms include 
tenderness of the lower abdomen, fever, and a vaginal discharge. Even a single episode of PID 
can cause infertility, due to scarring that blocks the uterine tubes. Therefore, patients are 
immediately given broad-spectrum antibiotics whenever PID is suspected. 
Cervix 
The cervix (from Latin "neck") is the lower, narrow portion of the uterus where it joins with the 
top end of the vagina. Where they join together forms an almost 90 degree curve. It is cylindrical 
or conical in shape and protrudes through the upper anterior vaginal wall. Approximately half its 
length is visible with appropriate medical equipment; the remainder lies above the vagina beyond 
view. It is occasionally called "cervix uteri", or "neck of the uterus". 
During menstruation, the cervix stretches open slightly to allow the endometrium to be shed. 
This stretching is believed to be part of the cramping pain that many women experience. 
Evidence for this is given by the fact that some women's cramps subside or disappear after their 
first vaginal birth because the cervical opening has widened. 
The portion projecting into the vagina is referred to as the portio vaginalis or ectocervix. On 
average, the ectocervix is three cm long and two and a half cm wide. It has a convex, elliptical 
surface and is divided into anterior and posterior lips. The ectocervix's opening is called the 
external os. The size and shape of the external os and the ectocervix varies widely with age, 
hormonal state, and whether the woman has had a vaginal birth. In women who have not had a 
vaginal birth the external os appears as a small, circular opening. In women who have had a 
vaginal birth, the ectocervix appears bulkier and the external os appears wider, more slit-like and 
gaping. 
The passageway between the external os and the uterine cavity is referred to as the endocervical 
canal. It varies widely in length and width, along with the cervix overall. Flattened anterior to 
posterior, the endocervical canal measures 7 to 8 mm at its widest in reproductive-aged women. 
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The endocervical canal terminates at the internal os which is the opening of the cervix inside the 
uterine cavity. 
During childbirth, contractions of the uterus will dilate the cervix up to 10 cm in diameter to 
allow the child to pass through. During orgasm, the cervix convulses and the external os dilates. 
Uterus 
The uterus is shaped like an upside-down pear, with a thick lining and muscular walls. Located 
near the floor of the pelvic cavity, it is hollow to allow a blastocyte, or fertilized egg, to implant 
and grow. It also allows for the inner lining of the uterus to build up until a fertilized egg is 
implanted, or it is sloughed off during menses. 
The uterus contains some of the strongest muscles in the female body. These muscles are able to 
expand and contract to accommodate a growing fetus and then help push the baby out during 
labor. These muscles also contract rhythmically during an orgasm in a wave like action. It is 
thought that this is to help push or guide the sperm up the uterus to the fallopian tubes where 
fertilization may be possible. 
The uterus is only about three inches long and two inches wide, but during pregnancy it changes 
rapidly and dramatically. The top rim of the uterus is called the fundus and is a landmark for 
many doctors to track the progress of a pregnancy. The uterine cavity refers to the fundus of the 
uterus and the body of the uterus. 
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Fallopian Tubes 
At the upper corners of the uterus are the fallopian tubes. There are two fallopian tubes, also 
called the uterine tubes or the oviducts. Each fallopian tube attaches to a side of the uterus and 
connects to an ovary. They are positioned between the ligaments that support the uterus. The 
fallopian tubes are about four inches long and about as wide as a piece of spaghetti. Within each 
tube is a tiny passageway no wider than a sewing needle. At the other end of each fallopian tube 
is a fringed area that looks like a funnel. This fringed area, called the infundibulum, lies close to 
the ovary, but is not attached. The ovaries alternately release an egg. When an ovary does 
ovulate, or release an egg, it is swept into the lumen of the fallopian tube by the fimbriae. 
Once the egg is in the fallopian tube, tiny hairs in the tube's lining help push it down the narrow 
passageway toward the uterus. The oocyte, or developing egg cell, takes four to five days to 
travel down the length of the fallopian tube. If enough sperm are ejaculated during sexual 
intercourse and there is an oocyte in the fallopian tube, fertilization will occur. After fertilization 
occurs, the zygote, or fertilized egg, will continue down to the uterus and implant itself in the 
uterine wall where it will grow and develop. 
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Mammary glands 
 
Cross section of the breast of a human female. 
Mammary glands are the organs that produce milk for the sustenance of a baby. These exocrine 
glands are enlarged and modified sweat glands. 
Structure 
The basic components of the mammary gland are the alveoli (hollow cavities, a few millimetres 
large) lined with milk-secreting epithelial cells and surrounded by myoepithelial cells. These 
alveoli join up to form groups known as lobules, and each lobule has a lactiferous duct that 
drains into openings in the nipple. The myoepithelial cells can contract, similar to muscle cells, 
and thereby push the milk from the alveoli through the lactiferous ducts towards the nipple, 
where it collects in widenings (sinuses) of the ducts. A suckling baby essentially squeezes the 
milk out of these sinuses. 
The development of mammary glands is controlled by hormones. The mammary glands exist in 
both sexes, but they are rudimentary until puberty when - in response to ovarian hormones - they 
begin to develop in the female. Estrogen promotes formation, while testosterone inhibits it. 
At the time of birth, the baby has lactiferous ducts but no alveoli. Little branching occurs before 
puberty when ovarian estrogens stimulate branching differentiation of the ducts into spherical 
masses of cells that will become alveoli. True secretory alveoli only develop in pregnancy, where 
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rising levels of estrogen and progesterone cause further branching and differentiation of the duct 
cells, together with an increase in adipose tissue and a richer blood flow. 
Colostrum is secreted in late pregnancy and for the first few days after giving birth. True milk 
secretion (lactation) begins a few days later due to a reduction in circulating progesterone and the 
presence of the hormone prolactin. The suckling of the baby causes the release of the hormone 
oxytocin which stimulates contraction of the myoepithelial cells. 
The cells of mammary glands can easily be induced to grow and multiply by hormones. If this 
growth runs out of control, cancer results. Almost all instances of breast cancer originate in the 
lobules or ducts of the mammary glands[15]. 
STRUCTURE LOCATION & DESCRIPTION FUNCTION 
Breasts 
Upper chest one on each side 
containing alveolar cells (milk 
production), myoepithelial cells 
(contract to expel milk), and duct 
walls (help with extraction of 
milk). 
Lactation milk/nutrition for newborn. 
Cervix 
The lower narrower portion of the 
uterus. 
During childbirth, contractions of the 
uterus will dilate the cervix up to 10 cm in 
diameter to allow the child to pass 
through. During orgasm, the cervix 
convulses and the external os dilates 
Clitoris 
Small erectile organ directly in 
front of the vestibule. 
Sexual excitation, engorged with blood. 
Fallopian tubes 
Extending upper part of the uterus 
on either side. 
Egg transportation from ovary to uterus 
(fertilization usually takes place here). 
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Hymen 
Thin membrane that partially 
covers the vagina in young 
females.  
Labia majora 
Outer skin folds that surround the 
entrance to the vagina. 
Lubrication during mating. 
Labia minora 
Inner skin folds that surround the 
entrance to the vagina. 
Lubrication during mating. 
Mons 
Mound of skin and underlying 
fatty tissue, central in lower 
pelvic region  
Ovaries (female 
gonads) 
Pelvic region on either side of the 
uterus. 
Provides an environment for maturation of 
oocyte. Synthesizes and secretes sex 
hormones (estrogen and progesterone). 
Perineum 
Short stretch of skin starting at 
the bottom of the vulva and 
extending to the anus.  
Urethra 
Pelvic cavity above bladder, 
tilted. 
Passage of urine. 
Uterus Center of pelvic cavity. To house and nourish developing human. 
Vagina 
Canal about 10-8 cm long going 
from the cervix to the outside of 
the body. 
Receives penis during mating. Pathway 
through a womans body for the baby to 
take during childbirth. Provides the route 
for the menstrual blood (menses) from the 
uterus, to leave the body. May hold forms 
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of birth control, such as an IUD, 
diaphragm, neva ring, or female condom 
Vulva 
Surround entrance to the 
reproductive tract.(encompasses 
all external genitalia)  
Endometrium 
The innermost layer of uterine 
wall. 
Contains glands that secrete fluids that 
bathe the utrine lining. 
Myometrium Smooth muscle in uterine wall. Contracts to help expel the baby. 
[22] 
Menstrual cycle 
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[22] 
THE MENSTRUAL CYCLE  
The menstrual cycle is the scientific term for the physiological changes that can occur in fertile 
women for the purposes of sexual reproduction and fertilization. Each menstrual cycle is a 
complex interaction between the Hypothalamus, Pituitary Gland, Ovaries and Endometrium. 
 This can be summarized by the following Cyclic Changes:  
o Gonadotropin Releasing Hormone GnRH, produced by the hypothalamus, acts on the pituitary 
gland o Follicular Stimulating Hormone FSH and Luteinizing Hormone LH, produced by the 
pituitary gland, act on the ovary; resulting in functional as well as morphological changes. 
Ovarian Cycle Events Uterine Cycle Events 
Follicular phase - 
Days 1-13 
FSH secretion begins. 
Menstruation - Days 
2-5 
Endometrium breaks down. 
 
Follicle maturation 
occurs. 
Proliferative phase - 
Days 6-13 
Endometrium rebuilds. 
 
Estrogen secretion is 
prominent.   
Ovulation - Day 
14* 
LH spike occurs. 
  
Luteal phase - 
Days 15-28 
LH secretion 
continues. 
Secretory phase - 
Days 15-28 
Endometrial thickens, and 
glands are secretory. 
 
Corpus luteum forms. 
  
 
Progesterone secretion 
is prominent.   
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 o Changes in the ovary include; follicular maturation, ovulation and corpus luteum formation. 
 o Changes in the endometrium include; proliferation and secretion phases, allowing successful 
implantation of the developing embryo to happen, or the physiological endometrial shedding in 
absence of fertilization (i.e. menstrual cycle) 
HYPOTHALAMIC-PITUITARY AXIS  
o The hypothalamus controls the pituitary gland by ―releasing hormones‖.  
o GnRH, secreted in a pulsatile fashion, is a peptide hormone that is very important in the 
synthesis and release of the trophic hormones of the pituitary 
 o The Gonadotropins; FSH and LH, which are glycoproteins, contain alpha and beta subunits. o 
The beta subunit is specific to every individual while the alpha subunit is same among all 
individuals. 
MENSTRUATION (Ovarian and Uterine Cycles) 
 The menstrual cycle can be described by the ovarian or uterine cycle. The ovarian cycle 
describes changes that occur in the follicles of the ovary whereas the uterine cycle describes 
changes in the endometrial lining of the uterus. Both cycles can be divided into three phases. The 
ovarian cycle consists of the follicular phase, ovulation, and the luteal phase whereas the uterine 
cycle consists of menstruation, proliferative phase, and secretory phase. 
Ovarian cycle 
Follicular phase 
The follicular phase is the first part of the ovarian cycle. During this phase, the ovarian follicles 
mature and get ready to release an egg. The latter part of this phase overlaps with the 
proliferative phase of the through the influence of a rise in follicle stimulating hormone (FSH) 
during the first days of the cycle, a few ovarian follicles are stimulated. These follicles, which 
were present at birth and have been developing for the better part of a year in a process known 
as folliculogenesis, compete with each other for dominance. Under the influence of several 
hormones, all but one of these follicles will stop growing, while one dominant follicle in the 
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ovary will continue to maturity. The follicle that reaches maturity is called a tertiary, or Graffian, 
follicle, and it contains the ovum. 
Ovulation:   
An ovary about to release an egg .Ovulation is the second phase of the ovarian cycle in which a 
mature egg is released from the ovarian follicles into the oviduct. During the follicular 
phase, estradiol suppresses production of luteinizing hormone (LH) from the anterior pituitary 
gland. When the egg has nearly matured, levels of estradiol reach a threshold above which this 
effect is reversed and estrogen stimulates the production of a large amount of LH. This process, 
known as the LH surge, starts around day 12 of the average cycle and may last 48 hours. 
The exact mechanism of these opposite responses of LH levels to estradiol is not well 
understood. In animals, a gonadotropin-releasing hormone (GnRH) surge has been shown to 
precede the LH surge, suggesting that estrogen's main effect is on the hypothalamus, which 
controls GnRH secretion. This may be enabled by the presence of two different estrogen 
receptors in the hypothalamus: estrogen receptor alpha, which is responsible for the negative 
feedback estradiol-LH loop, and estrogen receptor beta, which is responsible for the positive 
estradiol-LH relationship. However, in humans it has been shown that high levels of estradiol 
can provoke abrupt increases in LH, even when GnRH levels and pulse frequencies are held 
constant, suggesting that estrogen acts directly on the pituitary to provoke the LH surge. 
The release of LH matures the egg and weakens the wall of the follicle in the ovary, causing the 
fully developed follicle to release itssecondary oocyte. The secondary oocyte promptly matures 
into an ootid and then becomes a mature ovum. The mature ovum has a diameter of about 
0.2 mm.  
Which of the two ovaries—left or right—ovulates appears essentially random; no known left and 
right co-ordination exists. Occasionally, both ovaries will release an egg; if both eggs are 
fertilized, the result is fraternal twins.  
After being released from the ovary, the egg is swept into the fallopian tube by the fimbria, 
which is a fringe of tissue at the end of each fallopian tube. After about a day, an unfertilized egg 
will disintegrate or dissolve in the fallopian tube. 
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Fertilization by a spermatozoon, when it occurs, usually takes place in the ampulla, the widest 
section of the fallopian tubes. A fertilized egg immediately begins the process of embryogenesis, 
or development. The developing embryo takes about three days to reach the uterus and another 
three days to implant into the endometrium. It has usually reached the blastocyst stage at the time 
of implantation. 
In some women, ovulation features a characteristic pain called mittelschmerz (German term 
meaning middle pain). The sudden change in hormones at the time of ovulation sometimes also 
causes light mid-cycle blood flow.  
Luteal phase 
The luteal phase is the final phase of the ovarian cycle and it corresponds to the secretory phase 
of the uterine cycle. During the luteal phase, the pituitary hormones FSH and LH cause the 
remaining parts of the dominant follicle to transform into the corpus luteum, which produces 
progesterone. The increased progesterone in the adrenals starts to induce the production of 
estrogen. The hormones produced by the corpus luteum also suppress production of the FSH and 
LH that the corpus luteum needs to maintain itself. Consequently, the level of FSH and LH fall 
quickly over time, and the corpus luteum subsequently atrophies. Falling levels of progesterone 
trigger menstruation and the beginning of the next cycle. From the time of ovulation until 
progesterone withdrawal has caused menstruation to begin, the process typically takes about two 
weeks, with 14 days considered normal. For an individual woman, the follicular phase often 
varies in length from cycle to cycle; by contrast, the length of her luteal phase will be fairly 
consistent from cycle to cycle.
.
 
The loss of the corpus luteum is prevented by fertilization of the egg. The syncytiotrophoblast, 
which is the outer layer of the resulting embryo-containing structure (the blastocyst) and later 
also becomes the outer layer of the placenta, produces human chorionic gonadotropin (hCG), 
which is very similar to LH and which preserves the corpus luteum. The corpus luteum can then 
continue to secrete progesterone to maintain the new pregnancy. Most pregnancy tests look for 
the presence of hCG. 
Uterine cycle 
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Menstruation  
Menstruation (also called menstrual bleeding, menses, catamenia or a period) is the first phase of 
the uterine cycle. The flow of menses normally serves as a sign that a woman has not 
become pregnant. (However, this cannot be taken as certainty, as a number of factors can 
cause bleeding during pregnancy; some factors are specific to early pregnancy, and some can 
cause heavy flow.)  
 
Levels of estradiol (the main estrogen),  progesterone, luteinizing hormone, and follicle-
stimulating hormone during the menstrual cycle, taking inter-cycle and inter-woman variability 
into account. 
Eumenorrhea denotes normal, regular menstruation that lasts for a few days (usually 3 to 5 days, 
but anywhere from 2 to 7 days is considered normal) The average blood loss during menstruation 
is 35 milliliters with 10–80 ml considered normal. Women who experience Menorrhagia are 
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more susceptible to iron deficiency than the average person. 
An enzyme called plasmin inhibits clotting in the menstrual fluid. 
Painful cramping in the abdomen, back, or upper thighs is common during the first few days of 
menstruation. Severe uterine pain during menstruation is known as dysmenorrhea, and it is most 
common among adolescents and younger women (affecting about 67.2% of adolescent 
females). When menstruation begins, symptoms of premenstrual syndrome (PMS) such as breast 
tenderness and irritability generally decrease. Many sanitary products are marketed to women for 
use during their menstruation. 
 
Proliferative phase 
The proliferative phase is the second phase of the uterine cycle when estrogen causes the lining 
of the uterus to grow, or proliferate, during this time. As they mature, the ovarian follicles secrete 
increasing amounts of estradiol, and estrogen. The estrogens initiate the formation of a new layer 
of endometrium in the uterus, histologically identified as the proliferative endometrium. The 
estrogen also stimulates crypts in the cervix to produce fertile cervical mucus, which may be 
noticed by women practicing fertility awareness. 
Secretory phase 
The secretory phase is the final phase of the uterine cycle and it corresponds to the luteal phase 
of the ovarian cycle. During the secretory phase, the corpus luteum produces progesterone, 
which plays a vital role in making the endometrium receptive to implantation of the 
blastocyst and supportive of the early pregnancy, by increasing blood flow and uterine secretions 
and reducing the contractility of the smooth muscle in the uterus; it also has the side effect of 
raising the woman's basal body temperature.
.
 
The list of types of Uterus conditions mentioned in various sources includes: 
 Uterus cancer 
 Uterine fibroids 
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 Hysterectomy 
 Uterine polyp 
 Uterine prolapse 
 Pregnancy 
 Breech pregnancy 
 Caesarian Section 
 Ectopic pregnancy 
 Childbirth 
 Menstruation 
 Dysfunctional Uterine Bleeding 
 Pelvic Inflammatory Disease 
 Retroverted uterus 
 Adenomyosis 
 Endometrial conditions 
o Endometrial Cancer 
o Endometriosis 
o Autoimmune Endometriosis 
o Endometrial hyperplasia 
o Endometritis 
 Cervix conditions 
 Abruptio Placentae 
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 Cervical polyps 
 Female infertility 
 Female-only conditions 
 Gynaecological conditions 
 Menstrual conditions 
 Miscarriage 
 Obstetrical conditions 
 Pregnancy-related conditions 
 Premature Birth 
 Premenstrual syndrome 
 Intrauterine Growth Retardation 
 Uterine sarcoma 
 Uterine Cancer 
 IBS associated with endometriosis 
 Amenorrhea 
 Menopause 
 Primary amenorrhea 
 Hypothalamic amenorrhea 
 Dysmenorrhea 
 Primary Dysmenorrhea 
 Secondary Dysmenorrhea 
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 Menarche 
 Perimenopause 
 Uterine leiomyoma 
 Anovulation 
 Metrorrhagia 
 Oligomenorrhea 
 Uterine Hemorrhage 
 Hydatidiform mole 
 Trophoblastic Cancer 
 Endometrial stromal sarcoma 
 Adenosarcoma of the uterus 
 Intrauterine infections 
 Menorrhagia 
 Menstrual cramps 
 Decreased menses 
 Neuroendocrine carcinoma of the cervix 
 Malignant mixed Mullerian tumor 
 Myoma (fibroid) 
 Uterine compression syndrome 
 Mesodermal defects lower type 
 MRKH syndrome 
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 Hand-foot-uterus syndrome 
 Rokitansky-Kuster-Hauser syndrome 
 Rokitansky sequence 
 Asherman Syndrome 
 Tubal ligation syndrome 
 Hypomelia -- mullerian duct anomalies 
 Chapple syndrome 
 Michels-Caskey syndrome 
 Stampe-Sorensen syndrome 
 Double uterus-hemivagina-renal agenesis 
 Czeizel syndrome 
 Yusho disease[16] 
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DYSFUNCTIONAL UTERINE BLEEDING 
DEFINITIONS: 
Dysfunctional Uterine Bleeding (DUB): excessive, prolonged, or irregular uterine bleeding in a 
Reproductive  aged woman who lacks pelvic organ disease or a systemic disorder. 
Menorrhagia: excessive uterine bleeding occurring at the regular intervals of menstruation, the 
period of flow being greater than usual in duration 
Metrorrhagia: uterine bleeding of a normal amount, occurring at completely irregular intervals 
Menometrorrhagia: excessive uterine bleeding occurring both during the menses and at 
Irregular  intervals 
Oligomenorrhoea: markedly diminished menstrual flow; relative amenorrhea; infrequent 
Menstruation. 
Hypermenorrhoea: excessive uterine bleeding occurring at regular intervals, the period of flow 
being of usual duration 
Hypomenorrhoea: uterine bleeding of less than normal amount occurring at regular intervals, 
the 
period of flow being of the same or less than usual duration 
GENERAL CONSIDERATIONS 
                                 10-15% of patients referred to gynecologists are treated for DUB. Half of 
these are 
Pre- menopausal; 20% are pre-menarchal and the rest are in the reproductive age group 
 Most cases of DUB are associated with ovulatory dysfunction. 
THE NORMAL MENSTRUAL CYCLE 
                         • The normal menstrual cycle is a result of complex interaction between 
hypothalamus, 
anterior pituitary, ovary and endometrium. 
                         • Maturation of the endometrium is relatively uncomplicated (compared with the 
maturation of the oocyte) and is solely dependent upon two hormones, estrogen and 
progesterone. 
                             • The first half of the menstrual cycle (proliferative phase) is estrogen 
dependent resulting in growth of the endometrium from 1 to 5 mm at the time of ovulation. 
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                         • The second half of the menstrual cycle (secretory phase) is progesterone 
dominant. 
Progesterone halts the growth of the endometrium and stimulates secretory activity in the 
endometrium. 
                                 • Menstruation occurs when both progesterone and estrogen levels fall after 
the failure of conception. Synchronous shedding of the endometrial lining occurs. 
                               • Note: Random breakdown of the endometrial lining (DUB) does not occur 
when the endometrium has been adequately primed with estrogen and stabilized with 
progesterone. 
                                                    
                         Normal menses: 
                                                • Last 2-7 days 
                                                • Blood loss ranges from 25-70 ml (average 30-35ml) 
                                                • Mean cycle length is 29 days (range 21-40 days) 
EVALUATION OF ABNORMAL UTERINE BLEEDING 
                      1. It is nearly impossible to estimate blood loss from history. Clotting or bleeding > 
7 days 
suggest substantial blood loss but the only objective way to quantitate blood loss is by 
checking  CBC. Hct < 30 implies significant blood loss. 
                   Bleeding at a rate of soaking a tampon or pad in an hour for at least 2 consecutive 
hours 
implies PROFUSE bleeding. Orthostatic hypotension implies hemodynamic instability. 
                   2. The coloration of the blood can often give clues to the etiology of the abnormal 
bleeding. Brown or prune-colored discharge superimposed upon regular red menstrual bleeding 
is most commonly caused by an obstructed genital tract. It may be heavy, initially continuous, 
and most often will be noted immediately after a menstrual period. Endometriosis also causes 
brown discharge but this is usually premenstrual. Cervical endometriosis and stenosis trap blood 
within the endometrial cavity. As the cervix dilates late in the cycle, the trapped old blood and 
by-products are allowed to empty from the cavity. 
                   3. Next decide if the bleeding is ovulatory or an ovulatory. 
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                   4. To determine if the woman is ovulating, it may help to do Basal Body 
Temperature determinations (ovulation should increase body temperature by half a degree or so 
during the last 2 weeks of the cycle). Perform ovulation predictor tests measure progesterone 
levels (>9.5 nmol/li or > 3 ng/ml is evidence that ovulation has taken place), Endometrial biopsy 
showing secretory changes confirms ovulation 
 
  OVULATORY BLEEDING: 
                     Bleeding which occurs at regular intervals and is preceded by premenstrual 
symptoms,  
                             Breast tenderness 
                             Water weight gain 
                             Mood swings 
                             Abdominal cramping                                                                                                                                                                                                                                                                       
 
         ANOVULATORY BLEEDING:         
                             Prolonged bleeding occurring at irregular intervals followed by 
months of amenorrhea. 
 
OVULATORY DUB 
Ovulatory bleeding is more likely to be associated with an anatomic or organic cause such as 
fibroids, infections, lacerations, or polyps. 
• Pregnancy-related causes of DUB: 
• Ectopic pregnancy 
• Spontaneous abortion 
• Incomplete abortion 
• Threatened abortion  
• Retained products of conception 
• Placental products 
• Trauma at delivery 
• Trophoblastic disease 
• Inflammatory causes of DUB: 
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• Endometritis: prolongation of normally timed menses or irregular spotting 
• Cervicitis: prolongation of normally timed menses or irregular spotting 
• Vaginitis: infection with Trichomonas can cause persistent spotting superimposed upon 
normal cyclic bleeding 
• IUD: prolonged heavy bleeding during normally timed menses 
• Foreign body: retained tampon or diaphragm results in irregular spotting usually of oldblood 
• Lacerations 
• Systemic Diseases which cause DUB: 
• Blood dyscrasias (ITP, Von Willebrand‘s): Pts with Von Willebrand‘s may have normal 
PT, PTT but abnormal bleeding times. Von Willebrand‘s disease is the most common 
inherited clotting disorder that can present at menarche as severe menorrhagia. 
• Malnutrition 
• Anticoagulant therapy 
• Thyroid disease 
• Tumors which cause DUB: 
• Fibroids: submucous myomata are notorious for causing prolonged heavy bleeding; 
common in older women and in African Americans. Submucous fibroids are not obvious 
on exam (try endovaginal ultrasound) 
• Adenomyosis 
• Endometriosis: most commonly presents with luteal phase spotting characterized by darkbrown 
or prune colored discharge 
• Polyps 
              o Cervical: often post-coital spotting 
              o Uterine: may present with prolonged trail-off spotting at the conclusion of a 
normally timed menses or persistent spotting throughout the cycle 
• Endometrial hyperplasia 
• Cervical hemangiomas: very heavy bleeding, often after trauma 
• Cancer of the cervix, endometrium, or fallopian tubes  
ANOVULATORY DUB 
                     • Anovulatory DUB can be secondary to chronic unopposed estrogen or estrogen 
withdrawal in chronic unopposed estrogen states, the endometrium is continuously stimulated 
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by estrogen which causes proliferation without the stabilization from progesterone. The 
endometrium sloughs in an irregular and incomplete manner. 
                        Areas that have shed begin to heal under the influence of continuous estrogen. 
                        This random, non-uniform shedding/healing can cause profuse and prolonged 
bleeding. 
                         In estrogen withdrawal states, estrogen levels may rise but insufficiently to 
trigger an LH surge. Bleeding occurs when estrogen levels fall. 
                         • There are both physiologic and pathologic causes of anovulatory bleeding. 
PHYSIOLOGICAL CAUSES: 
                1. Puberty: The first cycles after menarche are anovulatory and the bleeding is 
secondary to 
estrogen withdrawal. This bleeding is usually light to moderate and occurs at 22-45 days 
intervals. 
                 2. Perimenopausal: The peak estrogen level attained as a woman nears menopause will 
not be sufficient to trigger an LH surge and ovulation fails. Bleeding occurs because of estrogen 
withdrawal. 
PATHOLOGIC CAUSES:  
              Dysfunction can occur at any level of the hypothalamic-pituitaryovarian axis. 
              1. Ovarian Failure: can be premature and associated with an autoimmune process 
              2. Hypothalamic amenorrhea: can be from weight loss, emotional stress or chronic 
illness 
              3. Polycystic Ovary Syndrome: associated with obesity, hirsutism, infertility and 
anovulatory DUB 
              4. Other causes: hyperprolactinemia 
 
INDIVIDUALIZED APPROACH TO TREATMENT OF DUB 
Adolescent: 
1. Anovulatory bleeding after menarche is common. 
2. If the bleeding is not significant, then observation alone is sufficient. 
3. Rule out pregnancy, even in the adolescent who denies sexual activity. 
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4. Adolescents who present with heavy vaginal bleeding after several months of amenorrhea 
are best treated with OC‘s. Treatment can be stopped after 3-6months to see if a normal 
menstrual cycle has been established. 
Acute Anovulation: 
1. Most women with normal menstrual cycles will occasionally have an anovulatory cycle 
that can result in protracted bleeding. 
2. Rule out pregnancy first and then treat with a single course of a progestational agent such 
as  
10mg Provera for 5-10 d. If the bleeding does not resolve in 48-72 hours, then rule out 
another                        cause of the bleeding 
Chronic Anovulation: 
1. Monthly administration of a progestational agent will result in regular endometrial 
shedding which will protect against endometrial cancer. 
2. A 12 day course of med roxy progesterone at 10 mg/d should be adequate. 
3. If occasional ovulation cannot be ruled out and the woman does not desire 
pregnancy, then oral contraceptives are a better choice. 
4. Any woman with at least a 1 year history of anovulation should be referred to a 
gynecologist for endometrial biopsy 
 
Perimenopausal Women: 
1. Many perimenopausal women fluctuate between ovulatory and anovulatory cycles. 
2. Low dose oral contraceptives can be used to provide a monthly withdrawal bleed 
and  provide contraception as well. 
3. The FDA has approved use of oral contraceptives in women up to the time of menopause 
as long as there is no contraindication such as smoking, HTN, clotting disorders or 
hyperlipidemia. 
4. To determine that a woman has entered menopause, an FSH > 40 on day 6 or 7 of the 
placebo pills confirms ovarian failure and the patient can then be switched to hormone 
replacement therapy[18&19]. 
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MATERIALS AND METHODS 
STUDY DESIGN 
Study Type      :  An Open Clinical Trial 
Study Place    :   Ayothidass Pandithar Hospital (OPD),  
                            National Institute Of Siddha, 
                            Tambaram Sanatorium, 
                            Chennai-47. 
Study Period  : 12 Months  
Sample Size     : 40 Patients(Female). 
TREATMENT 
            Name Of the drug   :  Perumbadukku Pittu 
            Dosage                      :    30gms/ four times a day after food 
            Duration                    :  6 days for 2 consecutive menstrual cycle 
                                                      (Follow Up For 3 Months) 
            Vehicle                      :    Butter 
            Indication                  :    Natpatta Perumbadu  
            Pathiyam                   :    Icha Pathiyam  
            Book Rf                     :    Athmaratcha Mirtham Ennumvaithiya                              
                                            Sarasangiradam  [2]                                     
           Author Name              :    Dr. Kandasamy Mudhaliyar  
           Edition                        :    Sep 2011 (1
st 
) 
: 
STANDARD OPERATING PROCEDURE FOR PERUMPADUKKU PITTU 
SOURCE OF RAW DRUGS                 The required raw drugs were collected from kaveri farm 
virudhachalam. The raw drugs was b authenticated by the Asst. Professor Medicinal botany in 
NIS Chennai. The raw drugs  was purified and the medicine will be prepared as per SOP in 
Gunapadam laboratory of National Institute of siddha. 
 
 
65 
 
REQUIRED RAW DRUGS: 
Bark of  Ziziphus mauritiania,Lam (Ilandapattai)                      - 1 palam  (35gms) 
Bark of  Lannea coromandelia(houtt)Merr (Othiyampattai )    - 1 palam  (35gms) 
Bark of  Syzygium cumini,linn (Naavalpattai)                             - 1 palam  (35gms) 
Bark of  Ficus racemosa.linn(Athipattai)                                    - 1 palam  (35gms) 
Bark of  Ficus religiosa.linn(Arasapattai)                                  - 1 palam  (35gms) 
Bark of  Mangifera indica.linn(Mampattai)                                - 1 palam  (35gms) 
Bark of  Acacia nilotica.linn(Velampattai)                                  - 1 palam  (35gms) 
Raw rice powder(pacharasi maavu)                                            - 7 palam   (245gms) 
Palm jaggery (panai vellam)                                                       - 7 palam   (245gms) 
PURIFICATION OF RAW DRUGS 
                                        1. The ingredients from 1 to 7  will be purified by scrubbing the outer 
skin as per the siddha text  Marundu Sei Iyalum kalaiyum.[5] 
                                         2.Cleaning and drying of raw rice powder 
  METHOD OF PREPARATION: 
   Step 1 :   
             The ingredient from 1 to 7 was pulverized and filtered.  
   step 2 : 
               Add equal amount of raw  rice powder to the above pulverized powder  and then add 
the equal amount of palm jaggery. 
    step 3 : 
                The above mixture was subjected to baking procedure. 
Drug Storage: 
                    The prepared drug will be stored in clean and dry air tight glass container. 
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Dispensing:                                                                                                                             
                     The medicine Perumpadukku Pittu (120gms) was given to the patients in air 
tight glass container. 
 
SUBJECT SELECTION:  
                      Patients reporting at OPD of Maruthuvam with the symptoms of inclusion criteria 
was subjected to screening test and documented using screening proforma. 
 
Inclusion criteria: 
             Age: 16-45 years 
             Patient  having the symptoms of increased menstrual bleeding. 
             Blood clots seen in the mensus bleeding 
             Patient willing to undergo routine blood investigation. 
             Patient  willing to participate in trial and signing in consent form. 
             Usg Abdomen( to rule out the fibroid etc) 
 
Exclusion criteria: 
                Hypertension 
                Diabetes mellitus 
                Cardiac disease 
                Renal disease   
                Pregnancy and lactation 
               Thyroid dysfunction 
                Recent hormone therapy (past one year) 
                Fibroid uterus  
                Endometriosis 
                Adenomyosis 
                Cancer uterus 
                Endometritis 
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Withdrawal criteria: 
                     Intolerance to the drug and development of adverse reactions during the drug trial. 
                     Poor patient compliance & defaulters. 
                     Patients turned unwilling to continue in the course of clinical trial 
                     Patient will not take medication regularly 
                when increase the severity of the symptoms i.e  excess menstrual bleeding above 90 ml 
. 
 
TEST AND ASSESSMENTS: 
1.Clinical assessment 
2.Siddha assessment 
3.Routine Investigations 
4.Special Investigation 
14.1CLINICAL ASSESSMENT: 
               Bleeding or spotting from the vagina between periods. 
               Periods that  occur less than 28 days apart or more than 35 days.  
                Time changes between every menstrual periods. 
                Excessive bleeding (such as passing large clots, needing to change protection during 
the night, soaking through a sanitary pad or tampon every hour for 2 - 3 hours in a row) 
                 Bleeding lasts for more than 7 days 
                 Hot flashes 
                 Mood swings 
                 Tenderness and dryness of the vagina 
                 Tired and fatigue 
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SIDDHA ASSESSMENT  
 Thinai (Living Place)                                                                                                                                                                    
Kurinchi (Hill Areas)                                                                                                                                                      
Mullai (Forest)                                                                                                                                                
Marutham (Fertile Land)                                                                                                                                              
Neithal (Costal land)                                                                                                                                                                          
Paalai (Desert)                                                                                                                                                  
Paruvakaalam (Season):                                                                                                                                                    
Kaar Kaalam                                                                                                                                                              
Koothir Kaalam                                                                                                                                                                      
Munpani Kaalam                                                                                                                                                  
Pinpani Kaalam                                                                                                                                                          
Elavenil Kaalam 
Muthuvenil Kaalam 
Poripulankal: 
Mei (Skin) 
Vaai (Tongue) 
Kan (Eye) 
Mooku (Nose) 
Sevi (Ear) 
Gnanenthiriyam And Kanmenthiriyam: 
Vaai (Buccal Cavity) 
Kaal (Lower Limb) 
Kai (Upper Limb) 
Eruvaai (Anorectal Region) 
Karuvaai (Uro- Genital Region) 
Ezhu Udal Kattugal: 
Saram 
Senneer 
Uoon 
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Kozhuppu 
Enbu 
Moolai 
Sukkilam/Suronitham 
 Enn Vagai Thervu(Eight Diagnostic Methods) 
Naadi 
Sparisam 
Naa 
Niram 
Mozhi 
Vizhi 
Malam 
Moothiram 
       Neerkuri 
        Neikuri 
Routine Investigations  
Hematology  :  
Hb  (gms/dl)    
PCV 
MCV 
MCHC 
MCV 
Bleeding Time 
Clotting Time 
Smear Study      
Total RBC (million/Cu.mm) 
Total WBC (cubic mm) 
Differential Count : (%) 
      Polymorphs  
      Lymphocytes   
      Monocytes      
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      Esinophils       
      Basophils 
ESR(mm/Hr) 
Blood Sugar Level  - Fasting (mg/dl) 
                                Post Prandial (mg/dl) 
                                      Random (mg/dl) 
                                                
 
SPECIFIC INVESTIGATIONS 
PBAC SCORE[7] 
[PICTORIAL BLEEDING ASSESSMENT CHART] 
DATA COLLECTION FORMS: 
                         Required Information was collected from each patient by using the following 
forms.  
Forms: 
FORM I                   :  Screening & Selection Proforma  
FORM Il              : Case Record Form 
FORM Ill                 : Laboratory Investigation Form 
FORM IV                 : Drug Compliance Form 
FORM V                   : Patient Information Sheet 
 
FORM VI         : Informed Consent Form 
FORM VII        : Withdrawal Form/ Adverse Reaction form, (Pharmacovigilence Form) 
FORM VIII         :  Dietary Advice Form 
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PATIENT SCREENING 
Inclusion/Exclusion 
 
INCLUSION CRITERIA EXCLUSION CRITERIA 
EXCLUDED FROM TRIAL 
METHODOLOGY 
       STUDY NUMBER 
     HISTORY TAKING 
LAB INVESTIGATION 
 TRIAL DRUG  
CLINICAL ASSESSMENT 
OUTCOME 
INFORM ABOUT STUDY 
AND TRIAL DRUG 
 
INFORMED CONSENT FORM 
 
ADVERSE REACTION 
ADVICED TO TAKE 
TREATMENT IN OPD 
ABNORMAL VALUES 
VALUES 
         REFERRED TO 
PHARMACOVIGILANCE            
DEPARTMENT,    NIS 
 ADVISED TO TAKE 
TREATMENT IN OPD 
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STUDY ENROLMENT: 
              Patient reporting at the NIS, OPD with clinical features of loss of appetite, inflammation 
of vagina, pallor of whole body, upper & lower limb pain, yellow colored decaying odor like 
bleeding, sometimes dark black colored  blood clots  had been chosen for enrolment based on the 
inclusion criteria. The enrolled patients were informed about the study trial drug, possible 
outcomes and the objectives of the study in their own language and terms understandable to them 
and the informed consent was obtained from them in the consent form. 
 CONDUCT OF THE STUDY 
              On the first day  onwards the trial drug perumpaduku pittu was given for 3 days.The 
trial drug was  given by the investigator in the OP Department of Maruthuvam, NIS, Chennai. 
The patients was asked to have a regular treatment in the OP department once in 3 days. In every 
visit the clinical assessment was recorded in the prescribed proforma (form no:II). The laboratory 
investigation was done before and after treatment and recorded in the prescribed format (form 
no: iii).  At the end of the trial the patients was advised to come for follow up for  3 months for 
observation.  
DATA MANAGEMENT: 
After enrolling the patient in the study, a separate file for each patient was opened and all forms 
was filed in the file. Study no. and patient no. was entered on the top of file for easy 
identification.  Whenever the study patient visits OPD during the study period, the respective 
patient‘s file was taken and necessary recordings was made at the case record form or other 
suitable forms. 
The screening forms  was filed separately. 
The data recordings was  monitored for completion by guide (HOD, Dept. of Maruthuvam), SRO 
(statistics) and the adverse event was monitored by the members of the pharmacovigilance 
department of NIS. All forms was further scrutinized in presence of investigator by Senior 
Research Officer (statistics) for logical errors and incompleteness of data to avoid any bias. No 
modification in the results is permitted for unbiased reports. 
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   statystical analysis : 
          All collected data was entered into computer using ms access / ms excel software by the 
investigator. The data was analyzed using stata  software under the guidance of SRO(stat), NIS. 
The level of significance will be 0.05 descriptive analysis was made and necessary tables/graphs 
generated to understand the profile of the patients included in the study. Student ‗t‘ test and chi-
square test are proposed to be performed for quantitative and qualitative data. 
OUTCOME OF TREATMENT  
PRIMARY OUTCOME:  
          It was assessed by the reduction of Menstrual bleeding   before and after Treatment. 
PBAC SCORE[PICTORIAL BLOOD ASSESSEENT CHART SCORE] 
[Ref:Leading the way experimental and clinical research in haematology, 
Author:Hannenore Rott, Guenther Kappert,Manuela siebert, 
Blood 2013 122:4772] 
PBAC SCORE 
Month:----------------------------- 
 
 Pads Tampons Clots Flooding Score 
Date 
 
 
Light 
(1 Pt 
Each) 
Medium 
(5pts 
Each) 
Heavy 
20pts 
Each 
Light 
Each 
1pt 
Medium 
5ptseach 
Heavy 
10pts 
Ea 
5 
Cent 
Size 
(1 Pt 
Each) 
50 
Cent 
Size 
(5 Pts 
Each) 
1 Pt 
Each 
Episode 
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1           
2           
3           
4           
5           
6           
7           
8           
9           
10           
11           
12           
13           
14           
15           
16           
17           
18           
19           
20           
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21           
22           
23           
24           
25           
26           
27           
28           
29           
30           
31           
Total  
 
Each Row Represents A Day Of The Month Count The Number Of Sanitary Pads And/Or 
Tampons You Use Each Day (24 Hour Period). Calculate A Score For Each Day, Then Add Up 
The Score At The End Of The Month. 
 Bleeding Between Periods ‐ If You Also Experienced Bleeding Between Periods That Required 
Sanitary Protection Please Record This On The Relevant Days. 
 Clots – If You Pass Clots, Please Indicate This On The Relevant Days And The Approximate 
Size (Ie. Closer To An Australian 5 Cent Or 50 Cent Piece). 
 Flooding – If You Experience Any Episodes Of ‗Flooding‘/Overflowing/Staining Of 
Clothing/Underwear Please Indicate The Number Of Episodes On The Relevant Days. 
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 Double Protection – If You Have Used Both A Pad And Tampon Simultaneously And Both 
Sanitary Items Were Stained With Blood Don‘t Forget To Include Both Sanitary Items On The 
PBAC.  
PBAC Scoring System 
 
Pads 
1 Point 
 
For Each Lightly Stained 
Pad  
 
 
5 Points For Each Moderately 
Stained Pad  
 
20 Points  For Each Completely 
Saturated Pad  
 
 
 
Tampons 
1 Point  For Each Lightly Stained 
Tampon  
 
 
5 Points  For Each Moderately 
Stained Tampon  
 
 
10 Points  
 
For Each Completely 
Saturated Tampon  
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Clots/Flooding 
1 Point  
 
N 5 Cent Coin)  
For Each Small Clot 
(Australia 
 
5 Points  
 
N 50 Cent Coin)  
For Each Large Clot 
(Australia 
 
5 Points  
 
For Each Episode Of 
Flooding  
 
 
 
SECONDARY OUTCOME : 
                                  Reduction of other symptoms. 
ADVERSE EFFECT AND SERIOUS EFFECT MANAGEMENT: 
             If the trial patient develops any adverse reactions the patient was referred to the 
pharmacovigilance department of NIS and documented. For any adverse effect the investigator 
took the step for further & proper management in the OPD.  
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Ethical issues:  
1. Informed consent will be obtained from the patients after explaining about the clinical 
trial in an understandable language. 
2. After the consent of the patient (through consent form) they will be enrolled in the study. 
3. Treatment will be provided free of cost 
4. No other medicines will be used except the trial drug 
5. Usg- abdomen will be taken in the nabl certified laboratories and charges      will be 
borne by the patient. 
6. To prevent any infection, while collecting blood sample from the patient, only 
7. Disposable syringes, disposable gloves, with proper sterilization of lab       equipments 
will be used.  
8. The data collected from the patient will be kept confidentially. The patient will be 
informed about the diagnosis, treatment and follow up. 
9. The patients who are excluded (as per the exclusion criteria) are given proper treatment 
with full care at OPD. 
10. In conditions of treatment failure, adverse reactions patients will be given alternative 
treatment at the OPD with full care through the end. 
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OBSERVATION 
AND 
RESULTS 
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OBSERVATION AND RESULTS 
 
For the clinical study 40 outpatients  were selected and treated in PG Maruthuvam Department , 
Ayothidoss Pandithar Hospital, National Institute Siddha,Chennai-47. 
          Results were observed with respect to following criteria. 
1. Age distribution 
2. Occupational status 
3. Marital status 
4. Food habits 
5. Family history 
6. Thinai 
7. Paruvakaalam 
8. Yakkai 
9. Kosangal 
10. Mukkutram 
11. Ezhu Udal Thathukal 
12. Enn Vagai Thervu 
13. Chronicity of illness 
 14.Clinical Manifestation 
  15. Results 
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1.AGE DISTRIBUTION 
 
            AGE(years)               NO. OF CASES            PERCENTAGE 
               19 -25                         8                     20% 
               26-30 
 
                        6                     15% 
               31-35                         5                    12% 
               36-40                         5                   13% 
               41-45                         16                    40% 
             TOTAL                       40                   100% 
 
 
  
INFERENCE:  Among 40 cases, 8 cases(20%)  were in age group 19-25, 6 cases(15%)  were in 
age group 26-30,5 cases(13%)  were in age group 31-35, 5 cases(12%)  were in age group 36-40,                  
16 cases(40%) were in age group 41-45. 
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2.OCCUPATIONAL STATUS 
 
 
 
INFERENCE: Out of  40 cases, 18(45%)working people, 19(47%) non-working people,                               
3 (8%)are student 
 
 
 
        OCCUPATIONAL 
STATUS 
 
                      NO. OF CASES 
 
               PERCENTAGE 
 
                    WORKING 
 
                               18 
 
                       45  
 
                     NON-WORKNG 
 
                               19 
 
                       47 
 
                     STUDENT     
 
                               3 
 
                       8 
 
                    TOTAL 
 
                               40 
 
                     100 
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3.MARITAL STATUS 
 
 
MARITAL STATUS 
 
  
INFERENCE: Out of 40 cases, 33(82%) were married, 7(18%) were unmarried. 
 
 
 
MARITAL STATUS 
 
NO. OF CASES 
 
                                MARRIED 
 
                                   33 
 
                                UNMARRIED 
 
                                   7 
 
                                 WIDOW 
 
                                    0 
 
                                 TOTAL 
 
                                   40 
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4.FOOD HABITS 
 
FOOD HABITS 
 
NO. OF CASES PERCENTAGE 
Vegetarian  3 7% 
Non-vegetarian 37 93% 
Total 40 100% 
 
 
7%
93%
Veg Non-veg
FOOD HABITS 
 
INFERENCE: Non Vegetarian  are more  prone to Pitha Perumpadu than Vegetarian.  
 
 
 
 
 
 
85 
 
 
5.FAMILY HISTORY 
 
 
       FAMILY HISTORY              
 
          NO. OF CASES 
 
             PERCENTAGE 
 
                PRESENT   
 
                     10 
 
                   25% 
 
                ABSENT 
 
                     30 
 
                   75% 
 
                  TOTAL 
 
                     40 
 
                  100% 
 
 
 
INFERENCE: Out of 40 cases, 75% of cases had no positive family history for Dysfunctional 
Uterine bleeding, 25% of  cases related with family history. 
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6.THINAI 
 
THINAI (LIVING PLACE) NO. OF CASES PERCENTAGE 
                      KURINJI 3 7% 
                      MULLAI 4 10% 
 MARUTHAM 3 8% 
                     NEIDHAL 30 75% 
                     PAALAI 0 0% 
 
 
 
 
INFERENCE: Out of   40 cases Pitha Perumbadu affects the people  more in the Neidhal  
75%,then Mullai 10%, 8% in Marutham , and 7% in Kurinji. 
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7. PARUVAKAALAM 
  
PARUVAKAALAM               NO. OF CASES          PERCENTAGE  
Kaarkaalam                     10 25% 
Koothirkaalam                       3 7% 
Munpanikaalam                      7 18% 
Pinpanikaalam                      4 10% 
Ilavenilkaalam                      8 20% 
Muthuvenikaalam                      8 20% 
 
 
 
INFERENCE: Out of 40 cases, Disease  got worsen at 10 cases(25%) in kaarkaalam, 3 cases 
(7%)  in koothirkaalam, 7 cases(18%)  in Munpanikaalam, 4 cases(10%)  in Pinpanikaalam, 8 
cases(20%) in ilavenilkaalam, 8 cases(20%) in Muthuvenil. kaalam 
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8.YAKKAI 
           
 
 
 
 
 
 
          
          
 
 
 
 
                
Inference: 25 %(10) cases were vathapitha thegi, 15%(6) cases were vathakaba thegi, 35 %(14) 
cases were pithavatha thegi, 15%(6) cases were pithakaba thegi, 5%(2) cases were kabavatha 
thegi, 5%(2) cases were kabapitha thegi 
S.NO YAKKAI NO.OF CASES PERCENTAGE 
(%) 
1 VALI 0 0 
2 VALIAZHAL 10 25 
3 VALIIYYAM 0 0 
4 AZHAL 20 50 
5 AZHALVALI 3 7.5 
6 AZHALIYYAM 3 7.5 
7 IYYAM 8 20 
8 IYYAVALI 0 0 
9 IYYAAZHAL 0 0 
 TOTAL 40 100 
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9.KOSANGAL 
 
Kosangal 
       
 
 
INFERENCE: Pranamayakosam (mild dyspnoea) was affected in 50% of cases , 
Vignanamayakosam was affected in 37.5 % of cases. Anandhamayakosam(Excessive menstrual 
bleeding)) was affected in all cases. 
Kosam No of Cases  Percentage % 
Annamayakosam   
Pranamayakosam 20 50 
Manomayakosam  
Vignanamayakosam 15 37.5 
Aanandhamayakosam 40 100 
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10.INCIDENCE  ACCORDING TO MUKKUTRANGAL                               
VAATHAM 
 
0
20
40
60
80
100
120
VAATHAM
 
 
 INFERENCE:Pranan( Mild dyspnoea present) was affected in 50% cases.Abanan (excessive 
menstrual bleeding) was affected in 100% cases.Udhanan(tiredness) was affected in 87.5% 
cases. Viyanan(Pain present in the upper &lowerlimb) was affected in 37.5% cases. Samanan 
was affected in 100%. Kirukaran (polyphagia)was affected in 13% cases and Nagan (burning 
sensation present in both eyes) was affected in 7.5% cases and Devathaththan (tiredness, anxiety) 
was affected in 100% cases. Koorman was affected in 2.5%cases. 
 
S.NO VAATHAM NO. OF CASES OUT 
OF 40 
PERCENTAGE % 
1 Praanan 20 50 
2 Abaanan 40 100 
3 Udhaanan 35 87.5 
4 Viyaanan 15 37.5 
5 Samaanan 40 100 
6 Naagan 3 7.5 
7 Koorman 1 2.5 
8 Kirukaran 5 12.5 
9 Devathaththan 40 100 
10 Thananjeyan - 0 
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PITHAM 
 
S.NO PITHAM NO. OF CASES OUT 
OF 40 
PERCENTAGE 
1 Anal 10 25 
2 Ranjagam 35 87.5 
3 Pirasagam 25 62.5 
4 Saathagam 40 100 
5 Aalosagam 5 12.5 
 
                                                                                           
          
INFERENCE: Among 40 cases Saathaga pittham(general tiredness) was affected in 
100%(40)cases. Anal pittham(Increased appetite) was affected in 25% of cases(10). Ranjaga 
pitham (Altered blood Hb ) was affected in 87.5%(35) cases, Pirasaga pittham(Pallor of  skin) 
was affected in 62.5% cases(25). Aalosaga pitham(dullness of vision) was affected in 12.5% of 
cases(5). 
  
92 
 
 KAPHAM 
 
S.NO KAPHAM NO. OF CASES OUT 
OF 40 
PERCENTAGE 
1 AVALAMBAGAM 20 50 
2 KILETHAGAM 2 5 
3 POTHAGAM 10 25 
4 THARPAGAM 5 12.5 
5 SANTHIGAM 15 37.5 
 
 
INFERENCE: Avalambagam(breathing difficulty) was affected in 50%(20 cases), kilethagam 
(increased appetite) was affected in 5% (2 cases),Pothagam was affected in25%(10 cases), 
Tharpagam(dullness of vision) affected in12.5%.(5 cases) Santhigam(Joint pain) was affected in 
37.5%(15) . 
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 11.EZHU UDAL THATHUKKAL 
 
          
INFERENCE: In Udal Thathukkal,  Saarm (general tiredness) was affected in 40 cases(100%) & 
Chenneer (altered blood Hb level) was affected in all cases.Oon(muscular pain)  affected in 25 
cases(62.5%) Kozhuppu (obesity) was affected in 25% (10) of cases. Enbu (joint pain) was 
affected in 37.5% (15) of cases.Suronitham (Increased menstrual bleeding) was affected in 100 
%(40) of cases. 
S.NO UDAL 
THATHUKKAL 
NO. OF CASES OUT 
OF 40 
PERCENTAGE  % 
1 Saaram 40 100 
2 Chenneer 35 87.5 
3 Oon 25 62.5 
4 Kozhuppu 10 25 
5 Enbu 15 37.5 
6 Moolai   
7 Suronitham 40 100 
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12.ENNVAGAITHERVUGAL 
S.no Ennvagaithervugal No. of cases out of 40 Percentage (%) 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
 
 
8. 
 
 
 
 
Sparisam 
Naa 
Niram 
Mozhi 
Vizhi 
Malam 
Mooththiram 
i) slowly spread 
ii)Fastly spread 
Naadi 
i)ValiAzhal 
Ii)AzhalVali 
Iii)AzhalIyyam 
 
- 
35 
25 
- 
5 
2 
 
22 
18 
 
14 
23 
3 
 
- 
85 
62.5 
- 
12.5 
5 
 
55 
45 
 
35 
57.5 
7.5 
 
NAA           - (Pale/Dryness/coating/fissure/glossitis) 
NIRAM      -   Pale 
VIZHI        - (pale/yellow/redness) 
MALAM    – constipation/diarrhoea 
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      Observatiom: In NAADI 35% of cases are vali azhal, 8% of cases are azhal iyyam, 57% of 
cases are azhal vali.  
 
              
               Observation: In NEIKKURI 55% of cases are slowly spread, 45% of cases are fastly spread.  
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NEIKKURISPREADING PATTERN 
 
SPREADING PATTERN 
 
   NO OF 
CASES 
 
PERCENTAGE(%) 
 
Aravenaneendathu 
(vathaneer - 
lengthening like a snake ) 
 
13 32.5 
Aazhi pol paraviathu 
(pithaneer – spreading like a 
ring ) 
 
14 35 
Muththu pol ninrathu 
(kabaneer – appears like a 
pearl ) 
 
9 22.5 
Other fashions 4 10 
Total 
 
            40 100 
 
          
Observation: In NEIKKURI SPREADING PATTERN 32% of cases are Aravenaneendathu (vathaneer 
-lengthening like a snake), 35% of cases are  Aazhi pol paraviathu (pithaneer – spreading like a 
ring),23% of cases Muththu pol ninrathu (kabaneer – appears like a pearl), 10% of case are other 
fashions. 
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13.CHRONICITY OF ILLNESS 
 
CHRONICITY OF ILLNESS NO. OF CASES PERCENTAGE 
Less than 6 months 16 40% 
6 month-1year 14 35% 
1-2 years 7 17% 
2-3 years 3 8% 
Total 40 100% 
 
 
 
INFERENCE:40% (16) Patients had the history of this disease less than 6 months only,                             
35% (14) Patients suffered for 6months to 1 year, 17% (7) patients for 1-2 years and                              
8%(3) patients for 2-3 years. 
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CLINICAL FEATURES 
1ST VISIT MENSTRUAL PHASE 
 
 
 
S.NO 
 
     
 
CLINICAL 
FEATURE 
 
 
NO. OF CASES 
 
IMPROVEMENT  
 
BEFORE 
TREATMENT 
 
     AFTER TREATMENT 
 
BEFORE 
TREATMENT 
 
AFTER 
TREATMENT  
No 
improvem
ent 
 
Improvement 
1 
2 
3 
4 
Menorrhagia 
Large Blood Clots 
Dysmenorrhoea 
Vaginal 
Tenderness  
40 
18 
15 
2 
17 
9 
13 
2 
 
23 
9 
2 
0 
 
100% 
45% 
37.5% 
5% 
57.5% 
22.5% 
5% 
0% 
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 CLINICAL FEATURES 
2ST VISIT MENSTRUAL PHASE 
 
 
 
S.NO 
 
     
CLINICAL FEATURE 
 
 
NO. OF CASES 
 
IMPROVEMENT  
 
BEFORE 
TREATMENT 
 
AFTER TREATMENT 
 
BEFORE 
TREATMENT 
 
AFTER 
TREATMENT  
No 
improve
ment 
Improv
ement  
1 
2 
3 
4 
Menorrhagia 
Large Blood Clots 
Dysmenorrhea 
Vaginal tenderness 
40 
12 
15 
1 
12 
7 
12 
1 
 
28 
5 
3 
0 
 
100% 
30% 
37.5% 
2.5% 
70% 
12.5% 
7.5% 
2.5% 
 
 
          
  
100 
 
15.RESULT:PBAC [Pictorial Blood Assessment Chart]SCORE[17] 
 
 
 
  
OP.no Age 
PBAC  (PICTORIAL BLOOD ASSESSMENT CHART) 
SCORE 
S.NO 
1ST visit menstrual phase 2nd visit menstrual phase               
Before 
treatment 
After 
treatment 
Before 
treatment 
After 
treatment 
1 H26941 32 570 0 340 0 
2 H30049 22 295 55 315 68 
3 H30700 34 470 96 380 92 
4 H28203 28 278 0 183 0 
5 H32302 24 380 128 280 35 
6 H33883 45 210 0 160 0 
7 H22709 27 433 105 374 86 
8 H35574 25 250 13 238 39 
9 H13670 23 367 77 321 34 
10 H36565 38 243 0 180 0 
11 H37003 26 281 0 236 0 
12 H36989 45 355 0 323 0 
13 H31970 26 236 0 187 0 
14 H28861 34 188 0 176 0 
15 H39438 45 267 0 193 0 
16 H40268 44 332 0 280 0 
17 H40329 38 231 0 232 0 
18 H40473 18 187 27 194 0 
19 H54585 36 396 43 242 0 
20 H43707 42 386 0 291 0 
21 H36057 37 225 0 218 0 
22 H44770 42 262 0 296 0 
23 H41386 20 193 63 210 41 
24 H45383 34 414 128 440 15 
25 H45740 45 460 0 425 0 
26 H36248 30 216 92 316 58 
27 H45524 26 263 18 238 0 
28 H48435 43 412 0 434 0 
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RESULT: 
With the evidence of statistical report, It showed that the significant clinical improvement 
(Arresting /Reduction of menstrual blood flow) with the percentage of 91.5% (p<0.0003)was 
observed at the end of the first menstrual cycle. 
         It is also observed at second menstrual cycle with significant clinical improvement of 93.5 
%(p<0.0001) . 
           Significant degree of clinical improvement between 1
st
 menstrual cycle and   2
nd
 
menstrual cycle is present which is increased with the percentage of 12% (p<0.0001). 
             From the comparison between the two age group[above 30& below 30],the significant 
clinical response was better among the age group  above 30 years than below 30 years 
(P<0.0021).   
 
 
 
 
 
29 H49348 42 363 16 394 0 
30 H43321 40 484 126 465 118 
31 H51792 39 463 39 491 42 
32 H52099 25 116 0 112 0 
33 H51847 40 271 0 115 0 
34 H50801 23 181 0 145 0 
35 H55764 42 242 0 216 0 
36 H54407 45 269 0 247 0 
37 H19379 45 206 0 202 0 
38 H16543 27 418 16 383 26 
39 H19642 39 374 61 278 0 
40 G92380 38 392 10 343 21 
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STATISTICAL 
ANALIYSIS 
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STATISTICAL ANALYSIS                                                                                                                                             
All collected data were entered into computer using MS Excel software.  The data entry eas cross-
checked manually with  CRF. The data was analyzed using STATA software. Mean and standard 
deviation was used to test the significance of treatment using before and after treatment data for two 
consecutive menstrual cycle on PBAC score(pictorial blood assessment chart) 
                The level of signification probability 0.05 was used to test the treatment difference and the 
values are statistically significant. 
 Mean and standard deviation of PBAC score in first menstrual cycle at 
before treatment and after treatment  
Variable Mean Standard error Standard deviation 
*BT  1 314.475 16.50555 104.3903 
**AT 1 27.825 6.613301 41.82619 
 
The Mean ± standard deviation of PBAC score in first menstrual cycle at before treatment and after 
treatment were 314.4 ±16.5 and 104.3903±  41.82619 respectively which is statistically 
significant(t=18.8928p<0.0001) 
        Mean and standard deviation of PBAC score in second menstrual cycle at 
before treatment and after treatment  
Variable Mean Standard error Standard deviation 
# BT  2 277.325 15.53286 98.23843 
## AT 2 16.875 4.741414 29.98734 
 
The Mean ± standard deviation of PBAC score in first menstrual cycle at before treatment and after 
treatment were 277 ±16.8 and 98.238± 29.987respectively which is statistically 
significant(t=18.8957p<0.0001) 
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 Mean and standard deviation of PBAC score difference between first and 
second menstrual cycle 
Variable Mean Standard error Standard deviation 
*BT  1 314.475 16.50555 104.3903 
# BT 2 277.325 15.53286 98.23843 
 
The Mean ± standard deviation of PBAC score difference between first and second menstrual cycle 
314.475 ±277.325 and 104.39 ± 98.238 respectively which is statistically significant(t=3.9178p<0.0003) 
 Mean and standard deviation of PBAC score between age group above 30 
and below 30 
Variable Mean Standard error Standard deviation 
Below 30 272.93 23.86858 92.44262 
Above 30  339.4 20.97379 104.869 
Combined 314.475 16.505 104.3903 
Difference  -66.4466 32.8133  
 
Mean and standard deviation of PBAC score between age group above 30 and below 30  is 272.9±339.4 
and 92.442±104.869 respectively which is statistically significant( t=-2.0256,p>0.04). 
*BT 1-Before Treatment 1
st
 menstrual cycle 
**AT 1-After Treatment 1
st
 menstrual cycle 
#BT 2- Before Treatment 2
nd
  menstrual cycle 
##AT 2-After Treatment 2
nd
  menstrual cycle 
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OBSERVATION OF CLINICAL LABORATORY EXAMINATIONS 
 At the time of admission to the trial, in all the 40 patients the following parameters observed, 
         I.Routine blood investigations,  
             1.Haemoglobin estimation ,  
             2.Total WBC count, 
             3.total RBC count  
             4.Differential count, 
             5.Erythrocyte sedimentation Rate,  
       II. Blood sugar 
       1.Fasting  
       2.Post prandial  
      III. Liver function test, 
       IV. Renal function test, 
       V Serum Lipid Profile 
       VI. Urine examination    
       1.Albumin 2.Sugar 3.deposit 
      VII. Neer kuri,Nei kuri also observed. 
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Before treatment 1-20. 
S.NO OP.NP AGE 
Hb(gms%) T.RBC TC DC% ESR B.S 
      P L E M  1/2hr 1hr FA PP 
1 H26941 32 8.4 3.9 10600 63 33 3 1 20 54 89 116 
2 H30049 22 10.7 5.2 7700 50 46   4 10 24 83 103 
3 H30700 34 11.4 4.6 9600 56 38 4 2 6 12 92 136 
4 H28203 28 10.6 4.1 9000 54 41 4 1 40 82 94 113 
5 H32302 24 12.5 4.6 9800 54 39 7 10 24 90 150 
6 H33883 45 9.8 4.5 9900 69 25 4 2 12 26 103 127 
7 H22709 27 8 4.4 9200 61 36   3 20 46 101 115 
8 H35574 25 9.7 5.2 9000 63 32 5 4 10 89 66 
9 H13670 23 9.5 4.2 7900 65 29 4 2 40 86 101 120 
10 H36565 38 10 4.8 9500 58 36 4 2 16 24 86 107 
11 H37003 26 8 4.2 9200 62 34 3 1 10 20 104 116 
12 H36989 45 11.6 4.3 5200 59 37 4 0 16 32 100 88 
13 H31970 26 14.6 5.1 8200 51 44 4 1 6 12 80 112 
14 H28861 34 11.7 4.5 6700 55 41 4   20 42 108 148 
15 H39438 45 11.7 4.1 9900 71 25 4 12 28 119 135 
16 H40268 44 8 3.8 7000 59 37 3 1 32 66 98 136 
17 H40329 38 11 4.3 6400 69 26 4 1 8 16 93 99 
18 H40473 18 10.7 5.2 7700 50 46   4 10 24 83 103 
19 H54585 36 8.4 3.9 10600 63 33 3 1 20 54 89 116 
20 H43707 42 12.5 4.6 8600 65 33 2   6 12 98 
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Before treatment 21-40 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.NO OP.NP AGE HB(gm%) T.RBC TC 
DC% ESR B.S 
P L E M 
 
1/2hr 1hr FA PP 
21 H36057 37 11.4 4 7000 60 34 5 1 14 28 122 146 
22 H44770 42 9.5 4.3 6000 60 35 5 20 40 102 120 
23 H41386 20 8.4 3.4 6000 55 38 4 3 30 62 64 101 
24 H45383 34 13.7 4.8 8200 53 42 4 1 8 16 85 106 
25 H45740 45 10.7 4.1 9000 71 25 4 12 28 120 130 
26 H36248 30 99 4.5 8000 54 43 3   24 50 98 128 
27 H45524 26 10.8 4.4 6900 55 40 4 1 6 12 78 102 
28 H48435 43 10.2 4.5 8100 70 24 4 2 30 64 63 96 
29 H49348 42 10.5 4.4 10300 58 36 4 2 14 28 84 158 
30 H43321 40 13.4 4.2 5600 56 37 3 5 10 20 98 120 
31 H51792 39 11.3 4.6 8600 61 34 4 1 12 26 103 121 
32 H52099 25 13 4.1 5600 66 30 3 1 2 6 84 90 
33 H51847 40 10 5 9500 57 38 4 1 16 34 116 125 
34 H50801 23 11.5 4.6 7600 50 45 3 2 12 24 95 115 
35 H55764 42 11.6 4.6 7000 50 46 2 2 16 32 82 104 
36 H54407 45 9 4.3 8900 65 30 4 1 30 62 96 124 
37 H19379 45 10.7 4.1 9000 71 25 4 12 28 120 130 
38 H16543 27 10.8 4.4 6900 55 40 4 1 6 12 78 102 
39 H19642 39 10 4.8 9500 58 36 4 2 16 24 86 107 
40 G92380 38 11 4.3 6400 69 26 4 1 8 16 93 99 
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After treatment 1-20 
S.NO OP.NP AGE HB(gm%) T.RBC TC 
DC% ESR B.S 
P L E M  1/2hr 1hr FA PP 
1 H26941 32 9.8 9.1 10600 63 33 3 1 10 14 98 130 
2 H30049 22 11 5.2 7600 51 45 1 3 4 12 78 120 
3 H30700 34 10.8 4.6 9600 54 38 4 2 10 20 80 110 
4 H28203 28 10 4.1 8800 63 36 1 20 40 86 140 
5 H32302 24 12 4.2 9600 56 37 4 1 12 24 86 168 
6 H33883 45 10 4.8 10600 66 28 4 2 10 20 116 140 
7 H22709 27 8.4 4.2 9200 63 35 3 1 6 12 98 120 
8 H35574 25 10 5.1 8800 62 33 3 2 10 20 86 92 
9 H13670 23 11 5.2 7600 51 45 1 3 4 12 78 120 
10 H36565 38 10.8 9.8 8600 58 34 4 4 14 28 98 120 
11 H37003 26 8.4 4.2 9200 63 35 3 1 6 12 98 120 
12 H36989 45 11.7 4.1 7800 61 33 4 2 10 22 106 136 
13 H31970 26 14.2 5.1 8200 51 43 4 2 6 12 78 110 
14 H28861 34 12.6 4.5 6300 56 42 2   10 12 116 150 
15 H39438 45 11.7 4.1 7800 61 33 4 2 12 28 106 136 
16 H40268 44 8.6 3.8 6400 62 36 1 1 28 52 86 140 
17 H40329 38 12 4.3 6800 70 25 4 1 8 16 110 150 
18 H40473 18 9 3.6 6000 56 37 2 4 22 46 74 98 
19 H54585 36 9.2 4 10300 62 34 3 1 20 48 110 125 
20 H43707 42 12.8 4.6 8600 65 32 2 1 6 12 110 
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After treatment 21-40 
S.NO OP.NP AGE HB(gm%) T.RBC TC 
DC% ESR B.S 
P L E M 
 
1/2hr 1hr FA PP 
21 H36057 37 12 4.1 7200 60 24 4 1 12 24 120 150 
22 H44770 42 10.5 4.5 6800 61 34 5 20 40 116 124 
23 H41386 20 9 3.6 6000 56 37 2 4 22 46 74 98 
24 H45383 34 13.2 4.8 8600 56 40 2 2 10 16 99 125 
25 H45740 45 11.7 4.1 7800 61 33 4 2 10 22 106 136 
26 H36248 30 10.6 4.5 8200 54 42 3 1 16 24 96 116 
27 H45524 26 11.2 4.6 7000 56 42 1 1 6 10 64 120 
28 H48435 43 11.6 4.4 8600 68 26 4 2 10 20 68 102 
29 H49348 42 11.6 4.4 9800 59 37 3 1 10 20 96 160 
30 H43321 40 13.8 4.4 5400 58 39 2 1 6 11 86 108 
31 H51792 39 12.1 4.8 8200 60 33 4 1 8 12 113 177 
32 H52099 25 12.9 4.3 5000 58 36 4 2 2 4 72 99 
33 H51847 40 11.2 5 9500 56 37 4 
2/b-
1 14 28 115 
34 H50801 23 12.6 4.6 7800 56 43 1 10 20 84 105 
35 H55764 42 12.2 4.6 8600 56 42 2 12 24 96 110 
36 H54407 45 9.8 4.3 8600 65 31 2 2 20 40 86 128 
37 H19379 45 11.7 4.1 7800 61 33 4 2 10 22 106 136 
38 H16543 27 11.2 4.6 7000 56 42 1 1 6 10 64 120 
39 H19642 39 10.8 9.8 8600 58 34 4 4 14 28 98 120 
40 G92380 38 12 4.3 6800 70 25 4 1 8 16 110 150 
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Before treatment 1-20 
 
T.CH0 HDL LDL VLDL TGL U Cr U.A T.B D.B I.B OT PT ALK T.P(gm ALB(g GL(gm Ca(m P(m
(mg/dl) (mg/dl) (mg/dl) (IU/L)(IU/L) (IU/L) s%) ms%) s%) g/dl) g/dl)
1 H26941 32 115 42 80 10 51 15 0.7 3.5 0.6 0.3 0.3 16 17 112 7.5 4.1 3.4 7.9 2.5
2 H30049 22 125 44 69 15 74 16 0.8 5.1 0.4 0.1 0.3 17 17 87 8 4.5 3.5 8.6 4.5
3 H30700 34 150 47 68 27 134 15 0.7 3.5 0.6 0.3 0.3 16 17 112 7.5 4.1 3.4 8.4 3.9
4 H28203 28 176 63 78 15 73 17 0.8 4.9 0.4 0.2 0.2 18 20 71 7.8 4.4 3.4 8.2 3.4
5 H32302 24 112 44 63 13 63 14 0.7 3.5 0.4 0.2 0.2 19 18 109 8 4.4 3.6 9.1 3.8
6 H33883 45 164 51 101 27 133 15 0.8 4.7 0.5 0.2 0.3 11 10 90 8 4.5 3.5 8.1 4
7 H22709 27 170 59 92 17 87 14 0.8 6.3 0.6 0.2 0.4 19 16 61 8 4.6 3.4 9.8 7.2
8 H35574 25 164 48 98 29 140 26 0.8 2.6 0.8 0.4 0.4 28 30 80 8 4.2 3.8 8.6 3.6
9 H13670 23 173 42 97 17 87 19 1 4.2 0.9 0.4 0.5 24 26 98 6.2 3.1 3.1 8.2 3
10 H36565 38 185 40 86 38 192 24 0.9 5.1 0.3 0.1 0.2 18 20 86 7.4 4 3.4 8.7 3.6
11 H37003 26 170 60 92 17 87 14 0.8 6.3 0.6 0.2 0.4 19 16 61 8.6 4.6 3.4 9.8 7.2
12 H36989 45 254 51 97 30 149 14 0.9 4.9 1.2 0.4 0.8 25 32 91 7.7 4.6 3.1 9.1 3.3
13 H31970 26 174 51 97 30 149 17 0.9 4.9 1.2 0.4 0.8 25 32 91 7.7 4.6 3.1 9.1 3.3
14 H28861 34 146 60 80 11 57 15 0.8 4.3 0.5 0.2 0.3 17 13 72 7.3 4.2 3.1 7.4 4
15 H39438 45 184 47 112 45 225 22 0.9 5.2 0.5 0.2 0.3 18 15 50 7.4 4.4 3 8.8 6.4
16 H40268 44 142 55 86 50 251 19 1.1 5 0.2 0.1 0.1 18 12 55 7.2 3.7 3.5 7.7 2.8
17 H40329 38 168 69 97 16 79 15 0.9 3 0.9 0.3 0.6 14 17 42 7.4 4.4 3 8.1 3.6
18 H40473 18 125 44 69 15 74 16 0.8 5.1 0.4 0.1 0.3 17 17 87 8 4.5 3.5 8.6 4.5
19 H54585 36 115 42 80 10 51 15 0.7 3.5 0.6 0.3 0.3 16 17 112 7.5 4.1 3.4 7.9 2.5
20 H43707 42 181 48 110 36 179 15 0.9 3.7 1.1 0.4 0.7 16 15 57 7.6 4.5 3.1 8.3 4
LIVER FUNCTION TEST
S.no OP.NO AGE
LIPID PROFILE(mg/dl) RFT(mg/dl)
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Before treatment 21-40 
T.CH0 HDL LDL VLDL TGL U Cr U.A T.B D.B I.B OT PT ALK T.P(gm ALB(g GL(gm Ca(m P(m
(mg/dl) (mg/dl) (mg/dl) (IU/L) (IU/L) (IU/L) s%) ms%) s%) g/dl) g/dl)
21 H36057 37 168 57 102 23 115 19 0.9 4.6 1.1 0.4 0.7 18 12 76 7.6 4.1 3.5 8.1 2.4
22 H44770 42 147 32 92 40 201 13 0.3 2.1 0.7 0.3 0.4 15 17 69 7.6 4.6 3 8.6 2.5
23 H41386 20 134 43 80 17 87 17 1.1 3.6 0.9 0.3 0.6 21 19 86 7.9 4.4 3.5 10.5 3.5
24 H45383 34 227 57 134 48 216 20 1 2.7 0.4 0.2 0.2 20 21 46 8.2 4.7 3.5 9.3 3.7
25 H45740 45 184 47 112 45 225 22 0.9 5.2 0.5 0.2 0.3 18 15 50 7.4 4.4 3 8.8 6.4
26 H36248 30 168 56 102 17 86 25 0.9 2.6 0.2 0.1 0.1 11 7 60 6.8 3.6 3.2 8.7 3.6
27 H45524 26 144 53 77 9 44 26 0.9 1.4 0.5 0.2 0.3 22 24 65 7.4 4.1 3.3 8.7 3.1
28 H48435 43 126 37 69 26 128 17 0.8 2.8 0.3 0.1 0.2 13 13 51 6.6 3.1 4.5 8.8 2.4
29 H49348 42 152 43 94 25 128 20 0.8 4.2 0.4 0.2 0.2 13 11 73 7.3 4.2 3 7.9 3.8
30 H43321 40 168 56 102 17 86 15 0.7 4.4 0.4 0.1 0.3 17 20 64 8.1 4.5 3.6 8.7 2.9
31 H51792 39 173 54 95 22 110 24 0.9 4.4 0.4 0.1 0.3 17 20 64 8.1 4.5 3.6 8.7 2.9
32 H52099 25 237 51 147 27 137 11 0.9 5.2 0.4 0.2 0.2 28 13 0.5 7.4 4.5 2.9 8.3 4.9
33 H51847 44 199 53 117 20 98 27 0.7 3.1 0.6 0.2 0.4 21 19 71 7.5 4.2 3.3 8.9 3.3
34 H50801 23 140 38 82 32 160 14 0.8 3.9 0.3 0.1 0.2 17 13 49 7.5 4.1 3.1 9.2 6.1
35 H55764 42 192 50 121 38 191 17 0.8 4.5 0.3 0.2 0.1 22 13 68 6.9 4 3 8.3 4.4
36 H54407 45 183 53 107 26 131 22 0.8 3.8 0.4 0.2 0.2 15 12 57 6.5 3.9 2.6 7.5 5.9
37 H19379 45 184 47 112 45 225 22 0.9 5.2 0.5 0.2 0.3 18 15 50 7.4 4.4 3 8.8 6.4
38 H16543 27 144 53 77 9 44 26 0.9 1.4 0.5 0.2 0.3 22 24 65 7.4 4.1 3.3 8.7 3.1
39 H19642 39 185 40 86 38 192 24 0.9 5.1 0.3 0.1 0.2 18 20 86 7.4 4 3.4 8.7 3.6
40 G92380 38 168 69 97 16 79 15 0.9 3 0.9 0.3 0.6 14 17 42 7.4 4.4 3 8.1 3.6
LIVER FUNCTION TEST
S.no OP.NO AGE
LIPID PROFILE(mg/dl) RFT(mg/dl)
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After treatment 1-20 
T.CH0 HDL LDL VLDL TGL U Cr U.A T.B D.B I.B OT PT ALK T.P(gm ALB(g GL(gm Ca(m P(m
(mg/dl) (mg/dl) (mg/dl) (IU/L) (IU/L) (IU/L) s%) ms%) s%) g/dl) g/dl)
1 H26941 32 116 88 76 14 78 15 0.7 3.5 0.8 0.4 0.4 19 19 120 7.5 9.2 3.3 8.2 2.5
2 H30049 22 125 45 68 17 80 16 0.9 5 0.4 0.1 0.3 17 17 87 8 4.5 3.5 8.5 4.5
3 H30700 34 168 52 58 19 152 26 0.6 3.5 0.6 0.2 0.4 16 19 116 7.6 4.2 3.4 8.4 3.9
4 H28203 180 60 18 98 18 0.8 3.6 0.6 0.3 0.3 18 20 71 7.8 3.4 4.4 8.2 3.4
5 H32302 24 168 57 108 23 115 19 0.9 4.6 1.1 0.4 0.7 18 12 76 7.6 4.1 3.5 8.1 2.4
6 H33883 45 158 54 96 24 140 16 0.8 4.6 0.5 0.2 0.3 16 12 98 8 4.5 3.5 8.6 4
7 H22709 27 180 58 89 19 87 18 0.7 6.1 0.6 0.4 0.2 19 18 65 8.6 3.4 4.6 10.2 7.2
8 H35574 25 162 49 84 29 140 26 0.8 2.6 0.8 0.4 0.4 28 30 82 8 4.3 3.7 8.8 3.6
9 H13670 23 125 45 68 17 80 16 0.9 5 0.4 0.1 0.3 17 17 87 8 4.5 3.5 8.5 4.5
10 H36565 38 192 46 48 210 21 0.9 5.1 0.3 0.1 0.2 18 20 86 7.4 4 3 8 3.6
11 H37003 26 180 58 89 19 87 18 0.7 6.1 0.6 0.4 0.2 19 18 65 8.6 3.4 4.6 10.2 7.2
12 H36989 45 186 48 120 39 391 21 0.8 5 0.3 0.1 0.2 19 16 53 7.4 4 3.4 9.5 4
13 H31970 26 172 56 95 30 158 16 0.8 5 1.2 0.4 0.8 25 32 79 7.7 4.6 3.1 9.2 3.3
14 H28861 34 132 61 82 18 56 16 0.6 3.8 0.6 0.4 0.2 18 19 80 7.6 4.3 3.3 7.8 3.8
15 H39438 45 186 48 120 39 391 21 0.8 5 0.3 0.1 0.2 19 16 53 7.4 4 3.4 9.5 4
16 H40268 44 146 52 84 50 25 26 1.2 4.8 0.2 0.1 0.1 28 26 89 7.8 3.4 4.4 7.8 2.6
17 H40329 38 164 66 94 18 98 15 0.9 3 0.9 3 0.6 14 17 42 7.4 4.4 3 8.1 3.6
18 H40473 18 126 41 86 16 94 16 1.1 3.8 0.7 0.4 0.3 19 18 94 8.2 4.2 4 10.6 3.6
19 H54585 36 120 36 18 58 16 0.8 3.6 0.6 0.3 0.3 16 19 106 7.5 4.1 3.4 8.1 2.5
20 H43707 42 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
LIVER FUNCTION TEST
S.no OP.NO AGE
LIPID PROFILE(mg/dl) RFT(mg/dl)
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After treatment 21-40 
T.CH0 HDL LDL VLDL TGL U Cr U.A T.B D.B I.B OT PT ALK T.P(gm ALB(g GL(gm Ca(m P(m
(mg/dl) (mg/dl) (mg/dl) (IU/L) (IU/L) (IU/L) s%) ms%) s%) g/dl) g/dl)
21 H36057 37 160 52 98 22 116 18 8 4.4 1.1 0.4 0.7 18 12 76 7.6 4.1 3.5 8.1 2.4
22 H44770 42 152 38 98 46 210 14 0.7 3.5 0.4 0.2 0.2 15 17 69 7.6 4.6 3 8.9 2.5
23 H41386 20 126 41 86 16 94 16 1.1 3.8 0.7 0.4 0.3 19 18 94 8.2 4.2 4 10.6 3.6
24 H45383 34 230 56 140 41 225 20 0.9 2.8 0.5 0.2 0.3 20 26 58 8.2 4.7 3.5 9.3 3.7
25 H45740 45 186 48 120 39 391 21 0.8 5 0.3 0.1 0.2 19 16 53 7.4 4 3.4 9.5 4
26 H36248 30 159 62 104 17 90 26 0.8 2.4 0.2 0.1 0.1 11 14 60 6.6 3.4 3.2 8.7 3.6
27 H45524 26 132 54 68 20 44 26 0.9 2 0.5 0.2 0.3 22 24 65 6.8 3.4 3.4 8.7 3.1
28 H48435 43 135 42 68 24 128 18 0.9 2.8 0.3 0.1 0.2 15 17 58 6.8 3.2 4.6 8.9 2.4
29 H49348 42 148 42 96 29 160 20 0.8 4.2 0.4 0.2 0.2 13 11 73 7.3 4.3 3 7.9 3.8
30 H43321 40 156 58 97 17 103 16 0.8 4.2 0.4 0.1 0.2 18 21 68 8 3.8 4.2 8.8 2.6
31 H51792 39 170 51 96 23 120 24 0.9 4.4 0.4 0.1 0.3 17 20 64 8.1 4.5 3.6 9 2.9
32 H52099 25 195 64 28 27 133 11 0.7 6.3 0.4 0.2 0.2 11 11 111 7.7 4.3 4.4 9 8.2
33 H51847 44 210 53 118 21 98 27 0.8 3.1 0.6 0.2 0.4 22 20 70 7.5 4.2 3.3 9 3.3
34 H50801 23 142 36 83 34 160 16 0.8 3.8 0.3 0.1 0.2 18 16 50 7.6 4.4 3.2 9.2 6.1
35 H55764 42 191 56 120 29 191 18 0.8 4.6 0.4 0.2 0.2 22 13 18 6.8 4.6 3.2 8.6 4.4
36 H54407 45 186 48 120 39 391 21 0.8 5 0.3 0.1 0.2 19 16 53 7.4 4 3.4 9.5 4
37 H19379 45 135 42 68 24 128 18 0.9 2.8 0.3 0.1 0.2 15 17 58 6.8 3.2 4.6 8.9 2.4
38 H16543 27 180 58 89 19 87 18 0.7 6.1 0.6 0.4 0.2 19 18 65 8.6 3.4 4.6 10.2 7.2
39 H19642 39 192 46 0 48 210 21 0.9 5.1 0.3 0.1 0.2 18 20 86 7.4 4 3 8 3.6
40 G92380 38 164 66 94 18 98 15 0.9 3 0.9 3 0.6 14 17 42 7.4 4.4 3 8.1 3.6
LIVER FUNCTION TEST
S.no OP.NO AGE
LIPID PROFILE(mg/dl) RFT(mg/dl)
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Before and After treatment 1-20 
FA PP
pus  cells Ep i cells
FA PP Puscells Ep i cells
1 H26941 32 Nil Nil Nil 1-3 1-3 Pale yellow, clear Pearl shape Nil Nil Normal Nil Nil Nil 1-2 1-2 Pale yellow, clear Pearl shape Nil Nil Normal
2 H30049 22 Nil Nil Nil 10-12 12-16Pale yellow, cloudy Pearl shape Nil Nil Normal Nil Nil Nil 1-2 1-2 Pale yellow, clear Pearl shape Nil Nil Normal
3 H30700 34 Nil Nil Nil 2-4 2-4 Colourless, clear Pearl shape Nil Nil Normal Nil Nil Nil 2-4 1-2 Pale yellow Round shape Nil Nil Normal
4 H28203 28 Nil Nil Nil 2-4 3-5  Yellow colour Pearl shape Nil Nil Normal Nil Nil Nil 1-2 1-2 Pale yellow Pearl shape Nil Nil Normal
5 H32302 24 Nil Nil Nil
2-4 2-4
Colourless, 
notclear, cloudy 
appearance
Irregular 
shape, 
moderaters 
Nil Nil Normal Nil Nil Nil 2-3 1-2 Colourless, clear
Semi circle, 
slowly 
spread
Nil Nil Normal
6 H33883 45 Nil Nil Nil 1-2 4-5 Colourless, clear
Semi circle, 
slowly 
Nil Nil Normal Nil Nil Nil 6-7 1-2 Colourless, clear Pearl shape Nil Nil Normal
7 H22709 27 Nil Nil Nil 1-2 1-2 Pale yellow Round shapeNil Nil Normal Nil Nil Nil 2-4 2-4 Pale yellow depositRound shape Nil Nil Normal
8 H35574 25 Nil Nil Nil 2-4 1-2 Pale yellow, clear Pearl shape Nil Nil Normal Nil Nil Nil 1-2 1-2 Pale yellow, clear Pearl shape Nil Nil Normal
9 H13670 23 Nil Nil Nil 2-4 2-4  Yellow colour Pearl shape Nil Nil Normal Nil Nil Nil 2-4 2-4 Pale yellow Sieve pattern Nil Nil Normal
10 H36565 38 Nil Nil Nil 3-5 2-4 Colourless, clear Bean shape Nil Nil Normal Nil Nil Nil 1-2 2-3 Pale yellow Round shape Nil Nil Normal
11 H37003 26 Nil Nil Nil 3-5 4-6 Lemon yellow Round shapeNil Nil Normal Nil Nil Nil 2-4 1-2  Yellow colour Pearl shape Nil Nil Normal
12 H36989 45 Nil Nil Nil 2-3 2-3 Pale yellow Pearl shape Nil Nil Normal Nil Nil Nil 1-2 2-3 Colourless, clear Round shape Nil Nil Normal
13 H31970 26 Nil Nil Nil 2-4 2-4 Pale yellow Sieve patternNil Nil Normal Nil Nil Nil 3-5 2-4 Pale yellow Pearl shape Nil Nil Normal
14 H28861 34 Nil Nil Nil 20-25 Pale yellow Round shapeNil Nil Normal Nil Nil Nil 2-4 2-4 Colourless, clear Pearl shape Nil Nil Normal
15 H39438 45 Nil Nil Nil 10-12 12-16 Pale yellow, clear Round shapeNil Nil Normal Nil Nil Nil 1-2 1-2 Colourless, clear Round shape Nil Nil Normal
16 H40268 44 Nil Nil Nil 2-4 2-4 Pale yellow, cloudy Pearl shape Nil Nil Normal Nil Nil Nil 2-4 2-4
Pale yellow depositPearl shape Nil Nil Normal
17 H40329 38 Nil Nil Nil 2-4 3-5 Colourless, clear Pearl shape Nil Nil Normal Nil Nil Nil 1-2 2-3 Pale yellow, clear Sieve pattern Nil Nil Normal
18 H40473 18 Nil Nil Nil 2-4 2-4  Yellow colour Bean shape Nil Nil Normal Nil Nil Nil 2-4 1-2 Pale yellow Round shape Nil Nil Normal
19 H54585 36 Nil Nil Nil
1-2 4-5
Colourless, 
notclear, cloudy 
appearance
Round shapeNil Nil Normal Nil Nil Nil 1-2 2-3 Pale yellow Pearl shape Nil Nil Normal
20 H43707 42 Nil Nil Nil 1-2 1-2 Colourless, clear Pearl shape Nil Nil Normal Nil Nil Nil 3-5 2-4  Yellow colour Round shape Nil Nil Normal
Neerkuri Neerkuri Neikuri BS BPBP Uro.Bili AlbNeikuri
          Deposit      Sugar
BEFORE TREATMENT AFTER TREATMENT
S.no OP.NO
Age
/ sex
Alb
      Sugar          Deposit
Uro.BiliBS
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Before and After treatment 21-40 
FA PP Puscells Epi cells FA PP Puscells Epi cells
21 H36057 37 Nil Nil Nil 1-3 1-3 Pale yellow, clear Pearl shape Nil Nil Normal Nil Nil Nil 1-2 1-2 Pale yellow, clear Pearl shape Nil Nil Normal
22 H44770 42 Nil Nil Nil 10-12 12-16 Pale yellow, cloudyPearl shape Nil Nil Normal Nil Nil Nil 1-2 1-2 Pale yellow, clear Pearl shape Nil Nil Normal
23 H41386 20 Nil Nil Nil 2-4 2-4 Colourless, clear Pearl shape Nil Nil Normal Nil Nil Nil 2-4 1-2 Pale yellow Round shape Nil Nil Normal
24 H45383 34 Nil Nil Nil 2-4 3-5  Yellow colour Pearl shape Nil Nil Normal Nil Nil Nil 1-2 1-2 Pale yellow Pearl shape Nil Nil Normal
25
H45740 45
Nil Nil Nil
2-4 2-4
Colourless, 
notclear, cloudy 
appearance
Irregular 
shape, 
moderater
s spread
Nil Nil Normal Nil Nil Nil 2-3 1-2 Colourless, clear
Semi circle, 
slowly 
spread
Nil Nil Normal
26
H36248 30
Nil Nil Nil
1-2 4-5
Colourless, clear
Semi 
circle, 
slowly 
spread
Nil Nil Normal Nil Nil Nil 6-7 1-2 Colourless, clear Pearl shape Nil Nil Normal
27 H45524 26 Nil Nil Nil 1-2 1-2 Pale yellow Round shape Nil Nil Normal Nil Nil Nil 2-4 2-4 Pale yellow depositRound shape Nil Nil Normal
28 H48435 43 Nil Nil Nil 2-4 1-2 Pale yellow, clear Pearl shape Nil Nil Normal Nil Nil Nil 1-2 1-2 Pale yellow, clear Pearl shape Nil Nil Normal
29 H49348 42 Nil Nil Nil 2-4 2-4  Yellow colour Pearl shape Nil Nil Normal Nil Nil Nil 2-4 2-4 Pale yellow Sieve pattern Nil Nil Normal
30 H43321 40 Nil Nil Nil 3-5 2-4 Colourless, clear Bean shape Nil Nil Normal Nil Nil Nil 1-2 2-3 Pale yellow Round shape Nil Nil Normal
31 H51792 39 Nil Nil Nil 3-5 4-6 Lemon yellow Round shape Nil Nil Normal Nil Nil Nil 2-4 1-2  Yellow colour Pearl shape Nil Nil Normal
32 H52099 25 Nil Nil Nil 2-3 2-3 Pale yellow Pearl shape Nil Nil Normal Nil Nil Nil 1-2 2-3 Colourless, clear Round shape Nil Nil Normal
33 H51847 40 Nil Nil Nil 2-4 2-4 Pale yellow Sieve patternNil Nil Normal Nil Nil Nil 3-5 2-4 Pale yellow Pearl shape Nil Nil Normal
34 H50801 23 Nil Nil Nil 20-25 1-3 Pale yellow Round shape Nil Nil Normal Nil Nil Nil 6-7 1-2 Colourless, clear Pearl shape Nil Nil Normal
35 H55764 42 Nil Nil Nil 2-4 1-2  Yellow colour Round shape Nil Nil Normal Nil Nil Nil 2-4 2-4 Pale yellow depositRound shape Nil Nil Normal
36
H54407 45
Nil Nil Nil
2-4 2-4
Colourless, 
notclear, cloudy 
appearance
Pearl shape Nil Nil Normal Nil Nil Nil 1-2 1-2 Pale yellow, clear Pearl shape Nil Nil Normal
37 H19379 45 Nil Nil Nil 3-5 2-4 Colourless, clear Pearl shape Nil Nil Normal Nil Nil Nil 2-4 2-4 Pale yellow Sieve pattern Nil Nil Normal
38 H16543 27 Nil Nil Nil 3-5 4-6 Pale yellow Bean shape Nil Nil Normal Nil Nil Nil 1-2 2-3 Pale yellow Round shape Nil Nil Normal
39 H19642 39 Nil Nil Nil 2-3 2-3 Pale yellow, clear Round shape Nil Nil Normal Nil Nil Nil 2-4 1-2  Yellow colour Pearl shape Nil Nil Normal
40 G92380 38 Nil Nil Nil 2-4 2-4  Yellow colour Pearl shape Nil Nil Normal Nil Nil Nil 1-2 2-3 Colourless, clear Round shape Nil Nil Normal
Uro.Bili
BEFORE TREATMENT AFTER TREATMENT
S.NO OP. No 
Age
/ 
sex
BPUro.Bili AlbAlb
      Sugar           Deposit
Neerkuri Neikuri BS BP
      Sugar           Deposit
Neerkuri Neikuri BS
 
 
 
 
 
116 
 
 
 
 
 
 
 
 
 
   DISCUSSION 
 
 
 
 
 
 
 
 
 
117 
 
DISCUSSION 
The main aim of the treatment is to evaluate the therapeutic effect of the trial drug 
Perumpadukku Pittu(internal) in the disease PITHA PERUMPADU. 
The present study is a preliminary case study of which 40 cases were selected according to 
the clinical features mentioned in Yugi Vaidhya Chinthamani[1]. Siddha method of 
diagnosis was carried out for all the patients and also modern investigations were done as 
per the protocol.  
 
The clinical features of Pitha Perumpadu of can be correlated with Dysfunctional Uterine         
Bleeding(DUB) in Modern science.As per yougi vathiya chinthamani[1] text, Pitha 
Perumpadu is   charecterised by Excessive menstrual bleeding ,Low Abdominal  
pain,Nausea,vomiting,tenderness in vagina. 
 
Institutional ethical committee clearance was obtained for this study[IEC approved no: 
NIS/IEC/8-14/5-26-08-2014]. 
 
The safety of the trial drug usage and standardization of the trial drug through biochemical 
analysis were also ensured during the study.  
 
The drug ―PERUMPADUKKU PITTU  possess Anti-menorrhagic activity.                                                                                
as per Siddha literature  Athmarachamirtham ennum vaithiya sarasangirdam,           
Editor.Dr.kandasamymudhaliyar-sep2011[2]. 
As per Standard operative procedure the drug was prepared at Gunapadam Lab in  NIS,                                          
Medicine Name : PERUMPADUKKU PITTU                                                                        
Dose :30 gms (four times a day) after food.                                                                                                                 
Duration : 6 days medicine for consecutive 2 menstrual cycle 
 
Haematological and Urine analysis were done for the patients at NIS laboratory before the 
treatment  as well as after the treatment.  
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     The drug was subjected to qualitative biochemical analysis in biochemistry laboratory at NIS.  
The clinical study was conducted with a well defined protocol and a proper proforma after 
the approval of the Institutional Ethical Committee (IEC). 
After the screening of 75cases reporting at the OPD of department of Maruthuvam,50 cases 
were inducted to the trial .Before enrollment to the trial the informed consent was obtained 
from the patients.  
 
The patient were treated for a period of 6 days with PERUMPADUKKU PITTU.(internal) at 
the dose of 30 gms (four times a day) after food for consecutive 2 menstrual cycle 
Clinical assessment was done during each visit in OPD patients( 6 days once) and the data 
were noted in the prescribed proforma.   
After the screening of more than 75 cases ,50 cases are shortlisted and among them 40 cases 
were diagnosed to have Pitha Perumbadu.All the cases were seen in OPD of Ayothidoss 
Pandithar Hospital ,National Institute of Siddha,Chennai-47                                                                                                                    
Incidence with reference to age disribution:                                                                               
Among 40 cases, 8 cases(20%)  were in age group 19-25, 6 cases(20%)  were in age group 
26-30,5 cases(12%)  were in age group 31-35, 5 cases(12%)  were in age group 36-40, 16 
cases(40%) were in age group 41-45.                                                                                   
From this study It is observed that the disease  occurs only after the age of 30 years.                                                                                                                                                                                                                                                     
Incidence with reference to food habits:                                                                                
According to Yugi literature[1] heavy intake of animal foods leads to Pitha perumpadu.Non 
vegetarian(93%) are more prone to Pitha Perumbadu than vegetarians(7%).In the author 
study  93% of the cases are Non vegetarian.                                                                                                                                            
Incidence with reference to family history;                                                                                              
Out of 40 cases, 75% of cases had no positive family history for Dysfunctional Uterine 
bleeding, 25% of  cases related with family history.                                                                                
Incidence with reference to Occupational status:                                                                                          
Out of  40 cases, 18(45%)working people, 19(47%) non-working people.  3 (8% ) are 
student. There is no major difference in the occupational status But the severity of the disease 
increased due to heavy work.                                                                                               
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Incidence with reference to yaakkai:                                                                                                                    
25 %(10) cases were vathapitha thegi, 50%(20) cases were Pitha  thegi, 7.5 %(3) cases were 
pithavatha thegi, 7.5%(3) cases were pithakaba thegi, 20%(8) cases were kabavatha thegi, 
5%(2) cases were kabapitha thegi.Among 40 cases 65% of the cases are belong to the 
Pitham.                                                                                                                                        
Incidence with reference to kosangal:                                                                                                            
Pranamayakosam (mild dyspnoea) was affected in 50% of cases , Vignanamayakosam was 
affected in 37.5 % of cases. Anandhamayakosam(Excessive menstrual bleeding)) was 
affected in all cases.                                                                
                                                                                                                                                       
Incidence with reference to Ezhu udal thathukkal:                                                                                                                           
In Udal Thathukkal, Saarm (general tiredness) was affected in 40 cases(100%) & Chenneer 
(altered blood Hb level) was affected in all cases.Oon(muscular pain)  affected in 25 
cases(62.5%) Kozhuppu (obesity) was affected in 25% (10) of cases. Enbu (joint pain) was 
affected in 37.5% (15) of cases.Suronitham (Increased menstrual bleeding) was affected in 
100 %(40) of cases.                                                                                          
    Incidence with reference to vatham:                                                                                        
Pranan( Mild dyspnoea present) was affected in 50% cases.Abanan (excessive menstrual 
bleeding) was affected in 100% cases.Udhanan(tiredness) was affected in 88% cases. 
Viyanan(Pain present in the upper &lowerlimb) was affected in 38% cases. Samanan was 
affected in 100%. Kirukaran (polyphagia)was affected in 13% cases and Nagan (burning 
sensation present in both eyes) was affected in 8% cases and Devathaththan (tiredness,anxity) 
was affected in 100% cases. Koorman was affected in 2.5%cases.                                                           
Incidence with reference to pitham:                                                                                      
Among 40 cases Saathaga pittham(general tiredness) was affected in 90%(36) cases. Anal 
pittham(Increased appetite) was affected in 90% of cases(36). Ranjaga pitham(Altered blood 
sugar) was affected in 12.5%(5) cases, Pirasaga pittham(Dryness of skin) was affected in 
12.5% cases(5). Aalosaga pitham(dullness of vision) was affected in 15% of cases(6).                                                                                                                                             
Incidence with reference to kabham:                                                                                                 
Avalambagam(breathing difficulty) was affected in 50%(20 cases), kilethagam (increased 
appetite) was affected in 5% (2 cases),Pothagam was affected in25%(10 cases), 
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Tharpagam(dullness of vision) affected in12.5%.(5 cases) Santhigam(Joint pain) was affected 
in 37.5%(15).                                                                                                                            
Incidence with reference to Naadi:                                                                                                     
In NAADI 35% of cases were vali azhal, 8% of cases are azhal iyyam, 57% of cases were 
Azhal vali.                                                                                                                                                          
Incidence with reference to Neerkuri,Neikuri:                                                                                       
In Ennvagai thervugal oil in urine(Neikuri) was slowly spreaded in 55%cases.fastly spreaded 
in 45% cases. Neikuri revealed that 32.5%(13) cases had vaathaneer. 14 cases (35 % ) had 
pithaneer, 9 cases ( 22.5 % ) had kabaneer, and 4(10%) cases had other fashions.                
Incidence with reference to clinical manifestation:                                                                                              
FIRST MENSTRUAL CYCLE :                                                                                     100% 
(40 cases ) patients complained of menorrhagia &it was reduce to 57.5% (23 cases) and 45% 
(18 cases)patients complained of large blood clots & it was reduce to22.5%(9cases)and  37.5% 
(15 cases)patients complained of Dysmenorrrhoea & it was reduce to 5%(2cases) and 5% (2 
cases) patients complained of  vaginal tenderness & there was no improvement.                                                                                                                               
SECOND MENSTRUAL CYCLE  :    100% (40 cases ) patients complained of menorrhagia 
&it was reduce to 70% (28 cases) and30% (12 cases)   patients complained of large blood clots 
& it was reduce to 12.5%(5cases) and 37.5% (15 cases) patients complained of 
Dysmenorrrhoea & it was reduce to 7.5%(3cases) and 2.5% (1 case) patients complained of 
tenderfull vagina & there was no improvement.  
Bio-chemical study: 
                     Presence of tannin in the medicine is mainly exhibits the  
Anti menorrhagic action.  
                        Presence of iron  maintain  & improve the Hemoglobin level during 
menstruation.   
 Presence of chloride is needed to maintain the body‘s acid base balance..As one of the mineral 
electrolytes, chloride works closely with sodium and water to help the distribution of body fluids. 
Chloride may also be helpful in allowing the liver to clear waste products.     
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OUTCOME: 
           With the evidence of statistical report, It showed that the significant clinical improvement 
(Arresting /Reduction of menstrual blood flow) with the percentage of 91.5% (p<0.0003)was 
observed at the end of the first menstrual cycle. 
         It was  also observed at second menstrual cycle with significant clinical improvement of 
93.5 %(p<0.0001) . 
           Significant degree of clinical improvement between 1
st
 menstrual cycle and   2
nd
 
menstrual cycle was observed  which was  increased with the percentage of 12% (p<0.0001). 
             From the comparison between the two age group[above 30& below 30], significant 
clinical response was better among the age group  above 30 years than below 30 years 
(P<0.0021).   
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SUMMARY  
 This study has been approved by IEC of NIS [IEC approved no: NIS/IEC/8-14/5-26-08-2014]. 
 The clinical study on PITHA PERUMBADU with reference to its etiology, pathogenesis, 
investigations, clinical features, diagnosis and treatment were conducted at the department of 
Maruthuvam, Ayothidoss Pandithar Hospital, National Institute of Siddha, Chennai – 47. 
 The required raw drugs for the preparation of PERUMPADUKKU PITTU (internal) and were  
purchased from Kaveri farm in Virudhachalam and the raw drugs were authenticated by 
Medicinal Botany Asst Prof Dr.Aravind in NIS. 
 The medicine  were prepared by the Author in the Gunapadam practical laboratory of  National 
Institute of Siddha 
 
 50 cases of female with the signs and symptoms of  Pitha Perumpadu were recruited in the age 
group within 19 to 45 for the study.40 cases were treated in the Out- Patient Department for  6 
days for consecutive 2 menstrual cycle at the time of menstruation with the trial drugs. 
 All the details about the study and the drugs were informed to the patients in their vernacular 
language, dietary regimen and information sheet were given to them and signed consent forms 
were obtained from them. Before starting the treatment, the blood samples of the selected 
patients were subjected to clinical laboratory and all the patients were subjected to USG whole 
Abdomen scan. 
 The patients were treated for a period of 6  days for consecutive 2 menstrual cycle at the time 
of menstruation.The trial medicine selected for internal treatment as per Siddha literature  
Athmarachamirtham ennum vaithiya sarasangirdam.EditorDr.kandasamymudhaliyar-
sep2011[2]  
        Clinical assessment was done during each visit in OPD patients( 6 days once) and the data 
was noted in the prescribed proforma.  
        Required lab investigation were carried out before and after treatment and the concerned 
data was recorded in the proforma 
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During the study period there was no event of any adverse reactions owing to the drug and 
disease.  
 
As per Siddha materia medica the ingredients of the trial drug were found to posses Anti 
Menorrhagic  action.  
 
The biochemical study of the trial drug reveals the presence of Tannin, iron , reducing sugar, 
etc.  
          With the evidence of statistical report, It showed that the significant clinical improvement 
(Arresting /Reduction of menstrual blood flow) with the percentage of 91.5% (p<0.0003)was 
observed at the end of the first menstrual cycle. 
         It was  also observed at second menstrual cycle with significant clinical improvement of 
93.5 %(p<0.0001) . 
           Significant degree of clinical improvement between 1
st
 menstrual cycle and   2
nd
 
menstrual cycle was observed  which was  increased with the percentage of 12% (p<0.0001). 
             From the comparison between the two age group[above 30& below 30], significant 
clinical response was better among the age group  above 30 years than below 30 years 
(P<0.0021).   
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CONCLUSION 
             In Siddha system of medicine many medicines are found tobe good  for Pitha 
perumpadu.Among these medicines Perumpaduku pittu is one of the best medicine to 
arrest/reduce the bleeding in Dysfunctional Uterine Bleeding. 
       Perumpadukku Pittu is undoubtly proved that it does not produced any harmful side effects. 
       With the evidence of statistical report, It showed that the significant clinical improvement 
(Arresting /Reduction of menstrual blood flow) with the percentage of 91.5% (p<0.0003)was 
observed at the end of the first menstrual cycle. 
         It was  also observed at second menstrual cycle with significant clinical improvement of 
93.5 %(p<0.0001) . 
           Significant degree of clinical improvement between 1
st
 menstrual cycle and   2
nd
 
menstrual cycle was observed  which was  increased with the percentage of 12% (p<0.0001). 
             From the comparison between the two age group[above 30& below 30], significant 
clinical response was better among the age group  above 30 years than below 30 years 
(P<0.0021).   
 
 
 
127 
 
 
 
 
 
 
 
 
 
 
  ANNEXURES 
 
 
128 
 
 
 
 
 
                                             
  
 
 
 
 
 
 
 
 
PROFORMA  
 
 
 
 
 
 
 
 
 
 
 
129 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
 AYOTHIDOSS PANDITHAR HOSPITAL  
DEPARTMENT OF   MARUTHUVAM 
 
 A CLINICAL STUDY ON “PITHA PERUMBADU” (DYSFUNCTIONAL UTERINE BLEEDING) AND 
 THE DRUG OF CHOICE IS “PERUMPADUKU PITTU” (INTERNAL) 
FORM l - SCREENING AND SELECTION PROFORMA 
OP NO:                        NAME: ……………………                         AGE: ……GENDER: …  
OCCUPATION: ……………………………   
 ADDRESS: 
CONTACT NO:              
INCLUSION CRITERIA  
 Age: 19-45 Years                                                                                                     Yes/No 
  Patient  Having The Symptoms Of Increased Menstrual Bleeding.                       Yes/No 
 .Blood Clots Seen In The Mensus Bleeding                                                            Yes/No 
 Patient Willing To Undergo Routine Blood Investigation.                                      Yes/No 
 Patient  Willing To Participate In Trial And Signing In ConsentForm.                   Yes/No 
 Patient  Willing To  takeUSG_Abdomen( To Rule Out The Fibroid Etc)               Yes/No 
EXCLUSION CRITERIA:  
 History of hypertension                     Yes / No 
 History of diabetes mellitus                     Yes / No 
 History of cardiac disease        Yes / No 
 Pregnancy and lactation         Yes / No 
 History of thyroid dysfunction                       Yes / No                                                                                 
 History of recent hormone therapy (Past one year)                                         Yes / No 
 History of Fibroid Uterus                                                                                           Yes/No                                                                                       
 History of Endometriosis                                                                                           Yes/No 
 History of Adenomyosis                                                                                            Yes /No 
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 History of Cancer Uterus                                                                                           Yes/No 
 History of Endometritis                                                                                              Yes/No 
ADMITTED TO TRIAL  
              YES           NO  
   
                           If Yes Serial NO: 
Date: 
Station: 
Signature of the Investigator: 
Signature of the Lecturer      :                                                                       Signature of H.O.D 
                                 
                                       NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
                                                AYOTHIDOSS PANDITHAR HOSPITAL  
                                                   DEPARTMENT OF MARUTHUVAM 
 
 CLINICAL STUDY ON “PITHA PERUMPADU” (DYSFUNCTIONAL UTERINE BLEEDING) AND  
THE DRUG OF CHOICE IS “PERUMPADUKU PITTU”  (INTERNAL) 
FORM II- CASE RECORD FORM 
1. STUDY NO -----------                              2. OP/IP NO ------------------           REG NO:  
3.  NAME ---------------------------                4. . Age (years): ________    Height: ____ m Weight: ______ Kg                               
5. Educational Status: 
1) Literate        2) Illiterate                                  
6. Occupation:                                            
7. Marital Status:   1.Married             2 .Unmarried 
If married;     Gravidity                            Parity 
Dyspareunia -    Present                          Absent 
8. Complaints and Duration:   
________________________________________________________________________ 
________________________________________________________________________ 
________________________________________________________________________ 
 
MENSTURAL AND OBSTETRIC HISTORY 
1. Age at menarche _______ year 
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      2. Regularly of cycle     Regular                              Irregular  
      3. Length of cycle [Days] 
      4. Duration of flow [Days] 
      5. Level of flow       Low                   Moderate                          Heavy 
      6.  LMP 
      7. Passage of big clots                           Yes / No 
           
      8. Dysmenorrhoea started at age _______ years 
   
 
    9. Onset of abdominal pain 
         
  Starts at the time of menstruation           Prior by _____ hours 
                                                                          At that time 
                                                           After _____ hours 
     10. Presence of abdominal pain other than around the time of menstruation 
 
     1. Yes                     2.No 
 
   12. Drug history:       H/O Previous hormonal therapy   1. Yes                       2.No 
 
MEDICAL/SURGICAL HISTORY 
            Diabetes mellitus:                                 1.Yes                             2.No 
            Thyroidism:                                          1.Yes                             2.No 
            Whether epileptic?                               1. Yes                             2.No 
            Whether asthmatic?                              1. Yes                            2.No 
            Presence of  cardiac/renal problem        1. Yes                            2.No            
            Fibroid uterus                                        1.Yes                             2.No 
            Uterus carcinoma                                   1.Yes                            2.No 
             Endometriosis/Endometritis                  1.Yes                            2.No 
FAMILY HISTORY 
              Whether this problem runs in family?     1. Yes                2.No            
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              If yes, mention the relationship of affected person(s) 
                                               1._________________ 
                                               2._________________ 
                                               3._________________ 
DIETARY STYLE     
  1.Pure vegetarian                                 2.Non-vegetarian               
BOWEL HABITS & MICTURITION: 
             History of habitual constipation              1.Yes               2.No                                                       
             History of frequent diarrhoea                  1.Yes              2.No                                                         
 
               History of frequent dysuria                      1.Yes              2.No                        
 
 
7. THEGI: [TYPE OF BODY CONSTITUTION]    
Vatham predominant  Kabam predominant  
Pitham predominant  Thondha udal  
 
8. NILAM: [LAND WHERE PATIENT LIVED MOST]               
Kurinji               Mullai                 Marutham             Neithal              Palai   
(Hilly terrain)      (Plains)                (Coastal belt)        (Aridregions)    (Forest range) 
  
9. KAALAM:[SEASON] 
Kaarkalam           Pinpanikalam      
Koothirkalam   Ilavenil  
Munpanikalam   Muthuvenil 
 
10. GUNAM:[CHARACTER] 
Sathuvam                        Rasatham                       Thamasam                                   
 DAY OF ASSESSMENT   :    
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FIRST VISIT MENSTRUAL PHASE SECOND VIST MENSTRUAL PHASE 
0
th
  day 
 
 0 th day  
6
th
 day  6 th day  
12
th
 day  
 
 
 
12 th day 
 
 
. 
 
 
SIDDHA SYSTEM OF EXAMINATION: 
1. ENVAGAI THERVU: [EIGHT-FOLD EXAMINATION] 
 I.NAADI: [PULSE PERCEPTION] 
 
  
II.NAA:[TONGUE] 
 
1st visit menstrual phase 
2nd visit menstrual phase 
 0th day 6
th
 day 12
th
 day  0
th
 day 6
th
 day 12
th
 day 90
th
  Day 
Date        
Colour normal/ 
Red 
pale/yellow 
normal/ Red 
pale/yellow 
normal/ Red 
pale/yellow 
normal/ Red 
pale/yellow 
normal/ Red 
pale/yellow 
normal/ Red 
pale/yellow 
normal/ Red 
pale/yellow 
Taste Sweet/Sour/ 
Pungent/ 
Bitter/None 
Sweet/Sour/ 
Pungent/ 
Bitter/None 
Sweet/Sour/ 
Pungent/ 
Bitter/None 
Sweet/Sour/ 
Pungent/ 
Bitter/None 
Sweet/Sour/ 
Pungent/ 
Bitter/None 
Sweet/Sour/ 
Pungent/ 
Bitter/None 
Sweet/Sour/ 
Pungent/ 
Bitter/None 
 1st visit menstrual phase 2nd visit menstrual phase  
 0
th
 day 
 
6
th
 day 12
th
 day 0
th
  day     6
th
  day       12
th
  day   90
th
  day 
Date                                                  
Vali        
Azhal        
Iyyam        
Vali Azhal        
Azhal vali        
Iyya vali        
Vali Iyyam        
Azhal Iyyam        
Iyya Azhal        
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Coating Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Fissure Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Saliva Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Dryness Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Glossitis Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Baldness Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
 
 
 
 
III.NIRAM: [COMPLEXION]    
 
             1
st
 visit menstrual phase                                       
2nd visit menstrual phase 
 90
th
 Day 
0
th
 day 6
th
  day 12
th
 day 0
th
 day 6
th
 day 12
th
 day 
Date       
Dark/pale/ 
Yellow tinted/ 
wheatish 
brown 
Dark/pale/ 
 
Yellow tinted/ 
wheatish brown 
Dark/pale/ 
Yellow tinted/ 
wheatish brown 
Dark/pale/ 
Yellow tinted/ 
wheatish brown 
Dark/pale/ 
Yellow tinted/ 
wheatish brown 
Dark/pale/ 
Yellow 
tinted/ 
wheatish 
brown 
Dark/pale/ 
Yellow tinted/ 
wheatish brown 
 
 
IV.MOZHI: [VOICE] 
 
1st visit menstrual phase 2nd visit menstrual phase 
0
th
 day 6
th
  day 12
th
 day 0
th
 day  6
th
  day 12
th
 day  90
th
 Day 
Date       
Medium/ 
High/ 
Low pitched 
Medium/ 
High/ 
Low pitched 
Medium/ 
High/ 
Low pitched 
Medium/ 
High/ 
Low pitched 
Medium/ 
High/ 
Low pitched 
Medium/ 
High/ 
Low pitched 
Medium/ 
High/ 
Low pitched 
 
   
V.VIZHI: [EYES] (Lower palpebral conjunctiva)    
 
 1st visit menstrual phase 2nd visit menstrual phase 
0
th
 day 6
th
  day 12
th
  day 0
th
  day 6
th
 day  12
th
 day 90
th
  Day 
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Date       
normal/ Red 
pale/yellow 
Normal/Red 
pale/yellow 
normal/Red 
pale/yellow 
normal/ Red 
pale/yellow 
normal/ Red 
pale/yellow 
normal/ Red 
pale/yellow 
normal/Red 
pale/yellow 
                                                  
 VI. MALAM:[BOWEL HABITS / STOOLS] 
 
1st visit menstrual phase 2nd visit menstrual phase 
 0
th
 day 6
th
  day 12
th
 day  0
th
 day  6
th
 day  12
th
 day  90
th
 Day 
Date        
Colour Dark/pale/ 
yellow/ 
Red 
Dark/pale/ 
yellow/ 
Red 
Dark/pale/ 
Yellow/ 
Red 
Dark/pale/ 
yellow/ 
Red 
Dark/pale/ 
yellow/ 
Red 
Dark/pale/ 
yellow/ 
Red 
Dark/pale/ 
yellow/ 
Red 
Consisten
cy 
Solid/ 
Semisolid/Wa
tery 
Solid/ 
Semisolid/Wa
tery 
Solid/ 
Semisolid/Wa
tery 
Solid/ 
Semisolid/Wa
tery 
Solid/ 
Semisolid/Wa
tery 
Solid/ 
Semisolid/Wa
tery 
Solid/ 
Semisolid/Wa
tery 
stool  
bulk                          
Normal/ 
Reduced 
Normal/ 
Reduced 
Normal/ 
Reduced 
Normal/ 
Reduced 
Normal/ 
Reduced 
Normal/ 
Reduced 
Normal/ 
Reduced 
Constipat
ion   
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Diaarhoe
a 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
 
 
 
VII.MOOTHIRAM: [URINE EXAMINATION]  
 
1st visit menstrual phase 2nd visit menstrual phase 
Neerkkuri 0
th
 day  6
th
 day 12
th
 day  0
th
 day 6
th
  day  12
th
 day 90
th
  day 
Date        
Niram[Colour]   Yellow/ 
Red/ 
White/ 
Straw 
coloured/ 
Crystal 
clear 
Yellow/ 
Red/ 
White/ 
Straw 
coloured/ 
Crystal 
clear 
Yellow/ 
Red/ 
White/ 
Straw 
coloured/ 
Crystal 
clear 
Yellow/ 
Red/ 
White/ 
Straw 
coloured/ 
Crystal clear 
Yellow/ 
Red/ 
White/ 
Straw 
coloured/ 
Crystal clear 
Yellow/ 
Red/ 
White/ 
Straw 
coloured/ 
Crystal clear 
Yellow/ 
Red/ 
White/ 
Straw 
coloured/ 
Crystal clear 
Manam[Odour] Present/ 
Absent 
 Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
 Present/  
Absent 
Present/ 
Absent 
Nurai[Froth] Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Edai[Sp.gravit]                                Normal/
Increased/ 
Reduced  
Normal/ 
Increased/ 
Reduced  
Normal/ 
Increased/ 
Reduced  
Normal/ 
Increased/ 
Reduced  
Normal/ 
Increased/ 
Reduced  
Normal/ 
Increased/ 
Reduced  
Normal/ 
Increased/ 
Reduced  
Enjal[Deposits] Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Volume   Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
                                      
136 
 
1st visit menstrual phase 2nd visit menstrual phase 
Neikkuri  0
th
 day 6
th
 Day 12
th
  day 0
th
  day 6
th
 day  12
th
 day 90
th
  day 
Date        
Serpentine 
fashion 
at___mints at___ mints at___ mints at___ mints at___ mints at__mints at__mints 
Annular/Ringed 
fashion 
at___mints at___ mints at___ mints at___ mints at___ mints at__mints  
Pearl beaded 
fashion    
at___mints at___ mints at___ mints at___ mints at___ mints at__mints at__mints 
Mixed fashion at___mints at___ mints at___ mints at___ mints at___ mints at__mints at__mints 
Other fashion at___mints at___ mints at___ mints at___ mints at___ mints at__mints at__mints 
 
 
 
 
 
VIII. SPARISAM: [PALPATORY PERCEPTION] 
 
1st visit menstrual phase 2nd visit menstrual phase 
0
th
 day 6
th
 day 12
th
 day  0
th
 day 6
th
  day 12
th
  day  90
th
 Day 
Date       
Warmth/Hot/ 
cold/ Sweat 
Warmth/Hot/cold/ 
Sweat 
Warmth/Hot 
/cold/ Sweat 
Warmth/Hot/ 
cold/ Sweat 
Warmth/Hot/ 
cold/ Sweat 
Warmth/Hot/ 
cold/ Sweat 
Warmth/Hot/ 
cold/ Sweat 
 
2. IYMPORIGAL:[SENSORY ORGANS] 
1st visit menstrual phase 2nd visit menstrual phase 
 0
th
 day  6
th
 day  12
th
 day 0
th
 day 6
th
  day 12
th
  day 90
th
 Day 
Date        
 Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Mei [Skin]        
Vaai[Buccal 
cavity]  
       
Kan [Eyes]        
Mooku[Nose]        
Sevi [ear]        
 
3. IYMPULANGAL: [MOTOR ORGANS] 
 
1st visit menstrual phase 2nd visit menstrual phase 
 0
th
 day 6
th
 day 12
th
 day 0
th
  day  6
th
 day 12
th
 day  90
th
 Day 
Date        
 Normal/  
Affected      
Normal/  
Affected   
Normal/  
Affected      
Normal/  
Affected      
Normal/  
Affected       
Normal/  
Affected     
Normal/  
Affected       
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Kai [upperlimb]        
Kal [lowerlimb]     
 
   
Vai[Buccal cavity]        
Eruvai  
[excretory organ] 
       
Karuvai[Reporduc-
tive organ] 
       
 
 
 
 
 
 
 
 
 
4,KOSAM: [SHEATHS] 
 
1st visit menstrual phase 2nd visit menstrual phase 
  
 
0
th
 day 6
th
 day 12
th
  day 0
th
 day 6
th
 day  12
th
 day  90thDay 
Date        
 Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Annamaya kosam 
 
       
PranamayaKosam        
Manonmayakosam 
 
       
Vingyanamaya 
kosam 
       
Anandhamaya 
kosam 
       
 
 
 
 
 
5. MUKKUTRAM: [AFFECTION OF THREE HUMORS 
A) VATHAM:        
                                                                   
1st visit menstrual phase 2nd visit menstrual phase 
 0
th
 day 6
th
 day 12
th
 day 0
th
  day 6
th
 day 12
th
  day  90
th
 Day 
Date        
 Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Praanan        
Abaanan         
Samaanan        
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Udhaanan        
Viyaanan        
Naahan        
Koorman        
Kirukaran        
Devathathan        
Dhananjeyan .....  ......   ......    -----   -------   ------   ------ 
 
 
 
 
 
 
B. PITHAM:           
     
1st visit menstrual phase 2nd visit menstrual phase 
 0
th
 day 6
th
  day 12
th
  day 0
th
  day 6
th
 day 12
th
  day  90
th
 Day 
 Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Date        
Analapitham        
 Prasakam        
Ranjakam        
Aalosakam        
Saathakam        
 
 
C. KABAM:        
                 
1st visit menstrual phase 2nd visit menstrual phase 
 0
th
 day  6
th
 day 12
th
  day  0
th
 day  6
th
 day 12
th
 day  90
th
 Day 
 Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Date        
Avalambagam        
Kilethagam        
Pothagam        
Tharpagam         
Santhigam        
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6. SEVEN DHATHUS: [SEVEN SOMATIC COMPONENTS]      
   
  1st visit menstrual phase 2nd visit menstrual phase 
                                0
th
 day 6
th
  Day  12
th
 day 0
th
  day  6
th
 day 12
th
 Day   90
th
 day 
Date        
 Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Saaram[chyme]        
Senneer[Blood]         
Oon[Muscle]        
Kozhuppu[Fat]        
Enbu[Bones]        
Moolai[Bonemarrow]        
Sukkilam/Suronitham  
[Genital discharges] 
       
 
7. SYSTEMIC EXAMINATION: 
 
1st visit menstrual phase 2nd visit menstrual phase 
 0
th
 day 6
th
  day 12
th
 day 0
th
  day 6
th
  day 12
th
  Day 90
th
 Day 
Date        
CardioVascular System  
          
       
Respiratory  System    
    
       
Gastrointestinal System 
     
       
 
8. GENERAL EXAMINATION: 
 
1st visit menstrual phase 2nd visit menstrual phase 
 0
th
 day 6
th
  day 12
th
  day 0
th
  day 6
th
 day  12
th
 Day 90
th
  Day 
Date        
Height (cms)               
Weight (kg)        
Temperature(°F)           
Pulse rate (per min)        
Heart rate (per 
min) 
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Respiratoryrate(per 
min) 
       
Blood 
pressure(mm/Hg) 
       
Pallor        
Jaundice        
Cyanosis        
Lymphadenopathy        
Pedal edema        
Clubbing        
Jugular vein 
pulsation 
       
9. CLINICAL SYMPTOMS: 
1st visit menstrual phase 2nd visit menstrual phase 
 0
th
 day  6
th
 day 12
th
 day  0
th
 day 6
th
 day  12
th
 Day  90
th
 Day 
Date        
Menorrhagia        
Dysmenorrhoea 
 
       
 Large Blood clots 
 
       
 Tenderfull vagina 
 
      
Date: 
Station: 
Signature of the Investigator: 
 
Signature of the Lecturer:                                                               Signature of the HOD 
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                                             NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDOSS PANDITHAR HOSPITAL 
DEPARTMENT OF MARUTHUVAM 
 
 A CLINICAL STUDY ON “PITHA PERUMPADU” (DYSFUNCTIONAL UTERINE BLEEDING) AND 
 THE DRUG OF CHOICE IS “PERUMPADUKU PITTU” (INTERNAL) 
 
FORM III   LABORATORY INVESTIGATION FORM 
1. OP/IP No: ________                          2 .S. No:                                  3.Reg no:  32111202/2013-14 
       
BLOOD INVESTIGATION 
Before 
treatment 
Date: 
After 
treatment 
Date: 
NORMAL VALUES 
HB (gms %)              11-15 
T.RBC(milli/cu.mm)              3.5-5.5 
ESR (mm) 
½ hr.    
1 hr.              0-20 
T.WBC (cu.mm) 
 
                       
       4000-11,000 
 
 
DIFFERENTIAL 
COUNT (%) 
Polymorphs   40-75 
Lymphocytes   20-35 
Monocytes   2-10 
Eosinophils   1-6 
Basophils   0-1 
Blood glucose (mg/dl) 
Fasting   80-120 
PP   <130 
Random   <140 
Lipid profile (mg/dl) 
Serum cholesterol           150-250 
HDL             30-60 
LDL          Upto 130 
VLDL               40 
TGL         Upto 160 
RFT (mg/dl) 
Blood urea                     16-50 
Serum creatinine                     0.6-1.2 
Serum Uric acid                  2.5-7.5 
LFT (mg/dl) 
Total bilirubin            0.2-1.2 
Direct bilirubin             0.1-1.2 
Indirect bilirubin             0.2-0.7 
Serum total protein              6-8 
Serum Albumin             3.5-5.5 
Serum globulin             2-3.5 
Serum fibrinogen    
Serum calcium             9-11 
Serum phosphorous             2-5 
SGOT   IU/L             0-40 
SGPT  IU/L              0-35 
Alkaline phosphatase  
IU/L 
            80-290 
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Thyroid profile Before treatment After treatment 
 
 
 
 
 
 
 
 
 
  URINE INVESTIGATION 
Urine investigation Before TMT(with Date) After TMT (With Date) 
Albumin   
Fasting sugar   
PP sugar   
Random Sugar   
Deposits   
Bile salts   
Bile pigments   
Urobilinogen 
  
                                                                                                                                                                         
USG ABDOMEN 
ENDOCARDIOGRAM 
               Specific Investigation   
 Before treatment After treatment 
PBAC score   
   
 
 Date: 
 Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                                             Signature of the HOD 
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         NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47, AYOTHIDOSS PANDITHAR HOSPITAL 
                            DEPARTMENT OF   MARUTHUVAM 
 A CLINICAL STUDY ON “PITHA PERUMPADU” (DYSFUNCTIONAL UTERINE BLEEDING) AND 
 THE DRUG OF CHOICEI “PERUMPADUKU PITTU” (INTERNAL) 
 FORM IV -DRUG COMPLIANCE FORM 
S. NO: ---------   OPD/IPD NO: --------------- NAME: -----------------------        REG NO: 32111202/2013-14 
Name Of The Drug : PERUMPADUKU PITTU  30gms/four times a  day After Food for 6 days 
FIRST VISIT MENORRHAGIC PHASE OF MENSTRUAL CYCLE  
 DATE MORNING AFTERNOON EVENING NIGHT 
DAY 1      
DAY 2      
DAY 3      
DAY 4      
DAY 5      
DAY 6      
SECOND VISIT MENORRHAGIC PHASE OF MENSTRUAL CYCLE 
 DATE MORNING AFTERNOON EVENING NIGHT 
DAY 1      
DAY 2      
DAY 3      
DAY 4      
DAY 5      
DAY 6      
DATE:                                                            STATION: 
SIGNATURE OF THE INVESTIGATOR: 
SIGNATURE OF THE LECTURER:                                                  SIGNATURE OF H.O.D 
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                                                      NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
 AYOTHIDASS PANDITHAR HOSPITAL  
DEPARTMENT OF   MARUTHUVAM 
 A CLINICAL STUDY ON “PITHA PERUMPADU” (DYSFUNCTIONAL UTRINE BLEEDING) AND  
                THE DRUG OF CHOICE IS “PERUMPADUKU PITTU” (INTERNAL)                                                                 
FORM V- PATIENT INFORMATION SHEET 
Name of the Principal Investigator: Dr.P.Kamalasoundaram (PG Scholar)                                                 
Name of the Institution                   : National Institute of Siddha 
                                                           TambaramSanatorium 
                                                             Chennai-47.                                                                         
I Dr.P.Kamalasoundaram studying M.D (Siddha) in National Institute of Siddha, Chennai. I                     
am doing a clinical trial on the study of PITHA PERUMBADU(Dysfunctional Uterine 
Bleeding).Menorrhagia Is The Second Most Common Gynaecologial Condition Needs 
Hospitalization.1 In 20 Women Aged 30 Years To 40 Years Consult The Doctor For Increased 
Bleeding During Mensus 40% To 60% Of Those Who Complain Of Excessive   Bleeding Have 
No Pathology Is Called DUB (Dysfunctional Uterine Bleeding).It includes the symptoms of 
increased bleeding in menstruation. This condition is being treated in NIS with many siddha 
formulations. As a part of M.D(S) research programme and developing new efficacious medicine, 
I have proposed to study the drug Perumpaduku Pittu for treating this condition. This 
formulation has been mentioned in siddha literature and empirical evidence with contemporary 
tools is required for documentation. You can receive medicines free of cost. The duration of 
treatment period is 3months. You have to visit NIS 6 days once and collect drugs for 6 days. The 
diagnosis tests will be carried out free of cost. However, a particular test USG Abdomen has to 
be taken from outside lab and charges to be borne by you. We will assess the effect of treatment 
after completion of 3months of treatment using clinical and lab parameters. 
               In this regard, I need to ask you few questions. I will maintain confidentiality of your 
comments and data obtained from you. There will be no risk of disclosing your identity and no 
physical, psychological or professional risk is involved by taking part in this study. 
               Taking part in this study is voluntary. No compensation will be paid to you for taking 
part in this study. You can choose not to answer any specific question. There is no specific 
benefit for you if you take part in the study, but you will be under our clinical monitoring and 
specific attention will be given for your health. Taking part in the study may be of benefit to the 
community, as it may help us to develop medicine for Pitha Perumpadu. In case of any adverse 
symptoms like severe bleeding according to Pictorial Blood Assesssment Chart(PBAC)more than 
300 during the treatment shall be reported to me and care will be taken in NIS for relief. You can 
withdraw from the study at the midst of treatment period, if you are not interested to continue and 
you will receive our usual treatment without condition. 
              The information collect in this study, will remain between you and me as a principal 
investigator. I will ask you a few questions through questionnaire. I will not write your name on 
different forms which sent to different investigating/analysis sections and I will use a code instead 
given by the principal investigator. Only the principal investigator will know the key to this code 
which will be kept in safe custody. If you agree to be a participant in this study, you will be 
screened as per the study protocol.  
              If you wish to find out more about this study before taking part, you can ask me all the 
questions you want or contact Dr.P.KAMALASOUNDARAM.PG Scholar principal investigator of this 
study, attached to the National Institute of Siddha, Chennai (Mobile phone no:9789042305). You 
can also contact the Chairman/Member-secretary of Ethics committee, National Institute of 
Siddha, Chennai – 600047, Tel no: 91-44-22411611, for rights and participation in the study. 
 
145 
 
          §¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ, ¦ºý¨É 47 
  «§Â¡ò¾¢¾¡º÷ ÀñÊ¾÷ ÁÕòÐÅÁ¨É 
 
À¢ò¾¦ÀÕõÀ¡Î §¿¡öì¸¡É º¢ò¾ ÁÕó¾¢ý (¦ÀÕõÀ¡ÎìÌ À¢ðÎ)  ÀÃ¢¸Ã¢ôÒò ¾¢È¨Éì 
¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢ü¸¡É ¾¸Åø ÀÊÅõ  
 
FORM V- ¾¸Åø ÀÊÅõ 
 
Ó¾ý¨Á ¬Ã¡öîº¢Â¡Ç÷ ¦ÀÂ÷ :  Dr. À¡.¸ÁÄ¡¦ºÇó¾Ãõ 
 ¿¢ÚÅÉò¾¢ý ¦ÀÂ÷                  :  §¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ 
                                                  ¾¡õÀÃõ º¡Éð§¼¡Ã¢Âõ 
                                                  ¦ºý¨É 47 
 
              Dr.À¡.¸ÁÄ¡¦ºÇó¾Ãõ ¬¸¢Â ¿¡ý §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨ÉÂ¢ø Àð¼ §ÁüÀÊôÒ ÀÂ¢ýÚ ÅÕ¸¢§Èý. À¢ò¾¦ÀÕõÀ¡Î 
±ýÛõ §¿¡Â¡ÉÐ Á¡¾Å¢¼¡ö ¸¡Äí¸Ç¢ø «¾¢¸ ÌÕ¾¢§À¡ì¨¸ ²üÀÎòÐõ ´Õ §¿¡Â¡Ìõ. þó§¿¡Â¡ÉÐ Á¡¾Å¢¼¡Â¢ý ¦À¡ØÐ «¾¢¸ 
ÌÕ¾¢§À¡ìÌ, ¸ðÊ,¸ðÊÂ¡¸ Å¢Ø¾ø, ¯¼ø ¦ÅÙò¾ø §À¡ýÈ ÌÈ¢Ì½í¸¨Çò §¾¡üÚÅ¢ìÌõ. þó§¿¡öìÌ §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨ÉÂ¢ø 
ÀÄ º¢ò¾ ÁÕóÐ¸û ÀÂýÀÎò¾ôÀðÎ ÅÕ¸¢ýÈÐ. º¢ò¾ ÁÕòÐÅ Àð¼ §ÁüÀÊôÀ¢ø, ¬öÅ¢ý ´Õ ÀÌ¾¢Â¡¸ Ò¾¢Â ÁÕóÐ¸¨Ç 
ÀÂýÀÎòÐõ §¿¡ì¸¢ø ¦ÀÕõÀ¡ÎìÌ À¢ðÎ ±ýÛõ ÁÕó¾¢¨É þó§¿¡öìÌ ÅÆí¸ ÀÃ¢óÐ¨Ã ¦ºö¸¢§È¡õ. þó¾ ÁÕó¾¢ý ¦ºöÓ¨È, «Ç×, 
«ÛÀ¡Éõ ÁüÚõ ÁÕòÐÅ ÀÂý¸û «¨ÉòÐõ «í¸£¸Ã¢ì¸ôÀð¼ º¢ò¾ ÁÕòÐÅ áÄ¢ø ÜÈôÀðÎûÇÐ. ±ó¾Å¢¾ ¸ð¼½ÓÁ¢ýÈ¢ ¾¡í¸û 
þó¾ ÁÕó¾¢¨É ¦ÀüÚì¦¸¡ûÇÄ¡õ. þó¾ ¬öÅ¢ø ÁÕóÐ ¯ð¦¸¡ûÙõ ¸¡Äõ 3 Á¡¾í¸û ¬Ìõ. 6 ¿¡û¸ÙìÌ ´ÕÓ¨È §¾º¢Â º¢ò¾ 
ÁÕòÐÅÁ¨ÉìÌ §¿Ã¢ø ÅóÐ ÁÕó¾¢¨É ¦ÀüÚì¦¸¡ûÇ §ÅñÎõ. þó¾ ¬ö× ºõÀó¾Á¡É ¬öÅ¸ ÀÃ¢§º¡¾¨É¸û ¸ð¼½Á¢ýÈ¢ ¦ºöÂôÀÎõ. 
§ÁÖõ þó§¿¡öì¸¡É, ÌÈ¢ôÀ¢ð¼ USG ABDOMEN ÀÃ¢§º¡¾¨É ¦ÅÇ¢ ¬ö×ìÜ¼ò¾¢ø ¾í¸û ¦ºÄÅ¢§Ä§Â ¦ºöÐ ¦¸¡ûÇ §ÅñÎõ. 3 
Á¡¾í¸û ÁÕóÐ ¯ð¦¸¡ûÙõ ¸¡Äõ ÓÊó¾ À¢ÈÌ §¿¡öì¸¡É ÌÈ¢Ì½í¸û ÁüÚõ ¬öÅ¸ ÀÃ¢§º¡¾¨É¸û þÅüÈ¢ý ÓÊ×¸Ç¢ý «ÊôÀ¨¼Â¢ø 
ÁÕó¾¢ý ÀÃ¢¸Ã¢ôÒò¾¢Èý ¸ñ¼È¢ÂôÀÎõ.  
        
 þó¾ ¬ö× ºõÀó¾Á¡¸ º¢Ä §¸ûÅ¢¸¨Ç ¾í¸Ç¢¼õ §¸ð¸ þÕì¸¢§Èý. ¾í¸Ç¢¼Á¢ÕóÐ ¦ÀÈôÀÎõ ¸ÕòÐì¸û ÁüÚõ ÌÈ¢ôÒ¸û 
«¨ÉòÐõ ¿õÀ¢ì¨¸Â¡¸ À¾¢× ¦ºöÂôÀÎõ.þó¾ ¬öÅ¢ø ¾í¸¨Ç ¯ðÀÎò¾¢ì¦¸¡ûÅ¾¢ý ãÄõ ±ó¾ Å¨¸Â¢Öõ À¡¾¢ôÒìÌûÇ¡¸ Á¡ðË÷¸û 
±É ¯Ú¾¢ «Ç¢ì¸¢§Èý. 
        
 ±ó¾Å¢¾ ÅüÒÚò¾ÖÁ¢ýÈ¢, þó¾ ¬öÅ¢ø Àí§¸ü¸×õ, þó¾ ¬ö× ºõÀó¾Á¡¸ §¸ð¸ôÀÎõ §¸ûÅ¢¸ÙìÌ À¾¢ø ÜÈ×õ 
¾í¸ÙìÌ ÓØ Í¾ó¾¢Ãõ «Ç¢ì¸ôÀÎ¸¢ÈÐ. þó¾ ¬öÅ¢ø Àí§¸üÀ¾üÌ ±ó¾ ºýÁ¡ÉÓõ ÅÆí¸ôÀ¼Á¡ð¼¡Ð.  ¬É¡ø, ¬ö× ÓØÅÐõ 
±ÉÐ §ÁüÀ¡÷¨ÅÂ¢Öõ, ¾í¸û ¯¼ø¿Äý ÌÈ¢ò¾ ¾É¢ ¸ÅÉò¾¢Öõ ¬ö× §Áü¦¸¡ûÇôÀÎõ. ¦¸÷ôÀ Å¡Ô §¿¡öì¸¡É Ò¾¢Â ÁÕó¾¢ý 
ÀÃ¢¸Ã¢ôÒò¾¢È¨É ºã¸ò¾¢üÌ ¯½÷òÐõ Å¨¸Â¢ø þó¾ ¬ö× §Áü¦¸¡ûÇôÀÎ¸¢ÈÐ. þó¾ ¬öÅ¢ø, ÁÕóÐ ¯ð¦¸¡ûÙõ ¸¡Äò¾¢ø 
º¢ÄÕìÌ«¾¢¸ ÌÕ¾¢§À¡ìÌ (PBAC score->300), ¾¡í¸ÓÊÂ¡¾ ÅÂ¢üÚ ÅÄ¢ §À¡ýÈ Á¡ÚÀð¼ ÌÈ¢Ì½í¸û ¦¾¡¼÷óÐ þÕìÌõ 
Àðºò¾¢ø, Ó¾ý¨Á ¬Ã¡öîº¢Â¡ÇÃ¡É ±ýÉ¢¼õ ¦¾Ã¢Å¢ì¸ôÀðÎ, §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨ÉÂ¢ø «¾üì¸¡É ¾£÷× ÅÆí¸ôÀÎõ. 
þó¾ ¬öÅ¢¨Éò ¦¾¡¼Ã ¾í¸ÙìÌ Å¢ÕôÀõ þø¨Ä¦ÂÉ¢ø, ±ô¦À¡ØÐ §ÅñÎÁ¡ÉÖõ ¬öÅ¢ý þ¨¼Â¢ø Å¢Ä¸¢ì¦¸¡ûÇ×õ, 
þõÁÕòÐÅÁ¨ÉÂ¢ø ÅÆí¸ôÀÎõ þó§¿¡öì¸¡É ÅÆì¸Á¡É ÁÕóÐ¸¨Ç ¦ÀüÚì¦¸¡ûÇ×õ «È¢×Úò¾ôÀÎ¸¢È£÷¸û. 
        
 þó¾ ¬öÅ¢ø §º¸Ã¢ì¸ôÀÎõ Å¢ÀÃí¸û «¨ÉòÐõ ¾í¸ÙìÌõ Ó¾ý¨Á ¬Ã¡öîº¢Â¡ÇÃ¡É ±ÉìÌõ þ¨¼Â¢ø þÃ¸º¢ÂÁ¡¸ ¨Åì¸ôÀÎõ. 
§¸ûÅ¢ À¾¢ø ÅÊÅò¾¢ø ¾í¸Ç¢¼õ §¸ûÅ¢¸û §¸ð¸ôÀÎõ. «¨ÉòÐô ÀÊÅí¸Ç¢Öõ ¾í¸Ç¢ý ¦ÀÂ÷ ¾Å¢÷ì¸ôÀðÎ ¬öÅ¡ÇÃ¡ø 
¾í¸Ùì¦¸É ¾É¢ì ÌÈ¢Â£Î ÅÆí¸ôÀÎõ. «ó¾ì ÌÈ¢Â£Î ¬öÅ¡ÇÕìÌ ÁðÎ§Á ¦¾Ã¢ó¾¾¡¸ þÕìÌõ. ¿£í¸û þó¾ ¬öÅ¢ø Àí§¸ü¸ 
Å¢ÕôÀôÀð¼¡ø, ¾¢ð¼ Å¨Ã× ÀÊ §¾÷× ¦ºöÂôÀÎÅ£÷¸û. 
         
 ¿£í¸û þó¾ ¬öÅ¢ø Àí§¸üÌõ Óý, þó¾ ¬öÅ¢¨Éô ÀüÈ¢Â §ÁÖõ Å¢ÀÃí¸û ¦ÀÈ §ÅñÎ¦ÁÉ Å¢ÕôÀôÀð¼¡ø, þó¾ 
¬öÅ¢ý Ó¾ý¨Á ¬Ã¡öîº¢Â¡Ç÷ ÁüÚõ §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨É, Àð¼ §ÁüÀÊôÒòÐ¨È Á¡½Å÷  Dr.À¡.¸ÁÄ¡¦ºÇó¾Ãõ  ¬¸¢Â 
±ý¨É 9789042305 ±ýÈ ±ñ½¢ø ¦¾¡¼÷Ò ¦¸¡ûÇÄ¡õ. §ÁÖõ, ¿£í¸û þó¾ ¬öÅ¢ø, ¯í¸ÇÐ Àí§¸üÒ ÁüÚõ ¯Ã¢¨Á ÀüÈ¢ ¦¾Ã¢óÐ 
¦¸¡ûÇ §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨É, ¾¨ÄÅ÷/¦ºÂüìÌØ ¯ÚôÀ¢É÷ «Å÷¸¨ÇÔõ 91-44-22411611 ±ýÈ ±ñ½¢ø ¦¾¡¼÷Ò ¦¸¡ûÇÄ¡õ.   
 
 
 
 
 
 
 
 
 
 
 
 
146 
 
                                          NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
                                                  AYOTHIDOSS PANDITHAR HOSPITAL 
             DEPARTMENT OF   MARUTHUVAM 
 
CLINICAL STUDY ON “PITHA PERUMPADU” (DYSFUNCTIONAL UTERINE BLEEDING) AND  
THE DRUG OF CHOICE IS “PERUMPADUKU PITTU”  (INTERNAL) 
                                                    FORM VI –INFORMED CONSENT FORM 
 “I have read the foregoing information, or it has been read to me. I have had the opportunity 
to ask questions about it and any questions I have asked have been answered to my satisfaction.  
            I   consent voluntarily to participate in this study and understand that I have the right to 
withdraw from the study at any time without in any way it affecting my further medical care”. 
 
"I have received a copy of the information sheet/consent form". 
Date: 
Signature of the participant 
In case of illiterate participant 
  “I have witnessed the accurate reading of the consent form to the potential participant, and 
the individual has had the opportunity to ask questions. I confirm that the individual has given consent 
freely.”                                                   
 
 
Date: 
 
 Signature of a witness                                            Left thumb Impression of the Participant     
 
(Selected by the participant bearing no connection with the survey team)      
 Date:    
Station: 
                                                                                  
Signature of participant:                                                 
Signature of the Investigator: 
Signature of the Lecturer:                                                          Signature of the HOD 
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§¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ 
«§Â¡ò¾¢¾¡º ÀñÊ¾÷ ÁÕòÐÅÁ¨É, ¦ºý¨É - 47. 
Àð¼ §ÁüÀÊôÒ ÁÕòÐÅòÐ¨È 
   
À¢ò¾¦ÀÕõÀ¡Î §¿¡öì¸¡É º¢ò¾ ÁÕó¾¢ý (¦ÀÕõÀ¡ÎìÌ À¢ðÎ)  ÀÃ¢¸Ã¢ôÒò ¾¢È¨Éì 
¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢ü¸¡É ¾¸Åø ÀÊÅõ  
 
FORM  VI-  ´ôÒ¾ø ÀÊÅõ 
 
                ¿¡ý §ÁüÜÈ¢Â  ¾¸Åø  ÀÊÅò¨¾ ÀÊòÐ «øÄÐ ÀÊì¸ §¸ðÎ ¦¸¡ñ§¼ý. Ð ¦¾¡¼÷À¡É 
Å¢Çì¸í¸¨ÇÔõ §¸ðÎ ¦¾Ã¢óÐ ¦¸¡ñ§¼ý. ±ó¾ Å¢¾ ÅüÒÚò¾Ä¢ýÈ¢, ±ý ¦º¡ó¾ Å¢ÕôÀò¾¢ý 
§ÀÃ¢ø ±ý¨É ó¾ ¬Ã¡öîº¢ìÌ ¯ðÀÎò¾ ±ý ÓØÁÉ§¾¡Îõ ÍÂ¿¢¨É§Å¡Îõ ºõÁ¾õ ¦¾Ã¢Å¢ì¸¢§Èý. 
±ÉìÌ Å¢ÕôÀÁ¢øÄ¡¾ Àðºò¾¢ø இó¾ ¬Ã¡öîº¢Â¢ø இÕóÐ ±ý¨É ±ô§À¡Ð§ÅñÎÁ¡É¡Öõ 
Å¢ÎÅ¢òÐ ¦¸¡ûÙõ ¯Ã¢¨Á¨Â ¦ÀüÚû§Çý ±ýÀ¨¾Ôõ «È¢§Åý. 
§¾¾¢:                                                                             
இ¼õ:                                                                             º¡ðº¢ì¸¡Ã÷ ¨¸¦Â¡ôÀõ: 
                                                                                       ¦ÀÂ÷: 
¨¸¦Â¡ôÀõ:                                                                     ¯È×Ó¨È         :                      
                                                                                                                                                
¦ÀÂ÷     : 
NATIONAL PHARMACOVIGILANCE PROGRAMME FOR 
SIDDHA DRUGS 
 
 
 
 
Reporting Form for Suspected Adverse Reactions to Siddha Drugs 
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Please note:  i.  All consumers / patients and reporters information will remain confidential. 
         ii. It is requested to report all suspected reactions to the concerned, even if  
             it does not have complete data, as soon as possible. 
Peripheral Center code:     State:  
1. Patient / consumer identification (please complete or tick boxes below as appropriate) 
 
Name  Father name 
 
Patient / Record No. 
Ethnicity  Occupation 
Address  
Village / Town 
Post / Via 
District / State    
Date of Birth / Age: 
 
Sex:     Male / Female  
Weight : 
Degam: 
 
2. Description of the suspected Adverse Reactions (please complete boxes below) 
 
Date and time  of initial 
observation 
 Season: 
Description of reaction   
 
 Geographical area: 
 
3. List of all medicines / Formulations including drugs of other systems used by the patient during 
the reporting period: 
 
Medicine Daily 
dose 
Route of 
administration 
& Vehicle - 
Adjuvant 
Date  Diagnosis for which 
medicine taken  
Starting Stopped 
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Siddha 
 
 
 
 
     
Any other system 
of medicines 
 
 
     
 
4. Brief details of the Siddha Medicine which seems to be toxic : 
 
Details Drug – 1 Drug – 2 Drug - 3 
a) Name of the medicine    
b) Manufacturing unit and batch 
No. and date 
   
c) Expiry date    
d) Purchased and obtained from    
e) Composition of the 
formulation / Part of the drug 
used 
   
 
 
b) Dietary Restrictions if any 
c) Whether the drug is consumed under Institutionally qualified medical supervision or used as self 
medication.  
d) Any other relevant information. 
 
5. Treatment provided for adverse reaction: 
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6. The result of the adverse reaction / side effect / untoward effects (please complete the boxes 
below) 
 
Recovered:           Not 
recovered: 
 Unknown: Fatal: If Fatal 
Date of death: 
Severe:   Yes   /   No. Reaction abated after drug stopped or dose reduced: 
 
Reaction reappeared after re introduction: 
 
 
Was the patient admitted to hospital? If yes, 
give name and address of hospital 
 
 
7. Any laboratory investigations done to evaluate other possibilities?  If Yes specify:  
 
8. Whether the patient is suffering with any chronic disorders? 
Hepatic    Renal    Cardiac    Diabetes    Malnutrition    
 
Any Others  
9. H/O previous allergies / Drug reactions:  
 
10. Other illness (please describe): 
 
11. Identification of the reporter: 
 
Type (please tick):  Nurse / Doctor / Pharmacist / Health worker / Patient / Attendant / Manufacturer /                                                                      
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                                Distributor / Supplier / Any others (please specify) 
Name: 
 
Address: 
 
Telephone / E – mail if any : 
 
 
 
Signature of the reporter:       Date: 
 
Please send the completed form to:  
           The Director 
            National Institute of Siddha, 
                                                           (Pharmacovigilance Regional Centre For Siddha Medicine), 
                                                           Tambaram Sanatorium, Chennai-600 047. 
                                                            (O) 044-22381314       Fax : 044 – 22381314 
        Website : www.nischennai.org  
        Email: nischennaisiddha@yahoo.co.in   
 
 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * ** * * * *  
This filled-in ADR report may be sent within one month of observation /occurrence of ADR   
 
 
 
Date:                                                                              
Who Can Report?     
 Any Health care professionals like Siddha Doctors /  Nurses / Siddha 
Pharmacists / Patients etc.  
What to Report?  
 All reactions,  Drug interactions,  
Confidentiality  
 The patient’s identity will be held in strict confidence and protected to the 
fullest extent.  
 Submission of report will be taken up for remedial measures only not for legal 
claim  
Name & address of the RRC-
ASU / PPC-ASU 
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Station:  
 
Signature of the Investigator: 
Signature of the Lecturer:                                                             
 
          
Date:      
Station: 
 
Signature of the Investigator: 
 
Signature of the Lecturer:                                                       Signature of the HOD 
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASS PANDITHAR HOSPITAL 
DEPARTMENT OF MARUTHUVAM 
 
 A CLINICAL STUDY ON “PITHA PERUMPADU” (DYSFUNCTIONAL UTERINE BLEEDING) AND 
 THE DRUG OF CHOICE IS “PERUMPADUKU PITTU” (INTERNAL) 
FORM VIII- DIETARY ADVICE FORM 
 
The following diet to be taken: 
  Drink adequate water 
 Goose berry 
 Green vegetables/spinach 
 Egg 
 Mutton liver 
 Watermelon 
 Coriander 
 Beetroot 
  Soya beans 
 Nuts 
 Pumpkin 
 Apple 
 Fig fruit 
 Honey 
 Banana flower 
 Pomogranate 
 Dates 
The following food should be avoided: 
 Bitter gourd                                
 Mango                          
 Chicken                                           
 Chocolate                            
 Horse gram                                                                 
 Tamarind  
 Packaged food                              
 Fatty food stuffs                              
 Sweetened beverages 
 Preserved cool drinks 
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 Bakery food items 
 Oily food 
 Excess salty ,spicy food 
 Hot foods 
 
§¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ, ¦ºý¨É 47 
  «§Â¡ò¾¢¾¡º÷ ÀñÊ¾÷ ÁÕòÐÅÁ¨É 
¦¸÷ôÀ Å¡Ô §¿¡öì¸¡É º¢ò¾ ÁÕó¾¢ý (Ý¾¸Å¡Ô §Ä¸¢ÂòÐ¼ý Å£Æ¢ ±ñ¦½ö)  ÀÃ¢¸Ã¢ôÒò 
¾¢È¨Éì ¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢ü¸¡É ¾¸Åø ÀÊÅõ. 
 
                                                    FORM VIII – DIETARY ADVICE FORM 
 
§º÷ì¸ ÜÊÂ ¯½× Å¨¸¸û                                                          
 ¦¿øÄ¢ì¸¡ö                                                                                                                                                                      
 Àî¨º ¸¡ö¸È¢¸û  
 «ò¾¢ôÀÆõ 
 §ÀÃ£î¨º                    
  Á¡Ð¨Ç                        
 §º¡Â¡ À£ýÍ 
 ¸£¨Ã¸û 
 Óð¨¼ 
 ¬ðÎ®Ãø 
 ¾÷âº½¢ 
 ¦¸¡òÐÁøÄ¢ 
 À£ðåð 
 À¡¾¡õ 
 âº½¢ 
 ¬ôÀ¢û 
 §¾ý 
 Å¡¨Æôâ 
 
¾Å¢÷ì¸ ÜÊÂ ¯½× Å¨¸¸û 
 À¡¸ø  
 Á¡õÀÆõ  
 §¸¡Æ¢ì¸È¢  
 «¾¢ þÉ¢ôÒûÇ ¯½×¸û 
 ¦¸¡ûÙ 
 ÒÇ¢  
 ±ñ¦½ö, ¦¸¡ØôÒûÇ ¯½×¸û 
 «¾¢¸ ¯ôÒ, Áº¡Ä¡ ¦À¡Õð¸û 
 ¦ÅôÀÁ¡É ¯½×¸û 
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PREPARATION 
OF THE TRAIL 
DRUG 
 
 
 
 
 
 
 
 
 
 
           PREPARATION OF THE DRUGS 
SOURCE OF RAW DRUGS                  
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                            The required raw drugs were collected from kaveri farm virudhachalam. 
The raw drugs was b authenticated by the Asst. Professor Medicinal botany in NIS 
Chennai. The raw drugs  was purified and the medicine will be prepared as per SOP in 
Gunapadam laboratory of National Institute of siddha. 
           REQUIRED RAW DRUGS: 
 Bark of  Ziziphus mauritiania,Lam (Ilandapattai)                      - 1 palam  (35gms) 
 Bark of  Lannea coromandelia(houtt)Merr (Othiyampattai )    - 1 palam  (35gms) 
 Bark of  Syzygium cumini,linn (Naavalpattai)                             - 1 palam  (35gms) 
 Bark of  Ficus racemosa.linn(Athipattai)                                    - 1 palam  (35gms) 
 Bark of  Ficus religiosa.linn(Arasapattai)                                  - 1 palam  (35gms) 
 Bark of  Mangifera indica.linn(Mampattai)                                - 1 palam  (35gms) 
 Bark of  Acacia nilotica.linn(Velampattai)                                  - 1 palam  (35gms) 
 Raw rice powder(pacharasi maavu)                                            - 7 palam   (245gms) 
 Palm jaggery (panai vellam)                                                       - 7 palam   (245gms) 
 
PURIFICATION OF RAW DRUGS 
                                        1. The ingredients from 1 to 7  will be purified by scrubbing the 
outer skin as per the siddha text  Marundu Sei Iyalum kalaiyum.[5] 
                                         2.Cleaning and drying of raw rice powder 
  METHOD OF PREPARATION: 
[Ref: Athmaratcha Mirtham Ennumvaithiya Sarasangiradam ;Dr.KandasamyMudliyar  
Sep 2011 (1
st 
) [2]] 
 
   Step 1 :   
             The ingredient from 1 to 7 was pulverized and filtered.  
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   step 2 : 
               Add equal amount of raw  rice powder to the above pulverized powder  and then 
add the equal amount of palm jaggery. 
    step 3 : 
                The above mixture was subjected to baking procedure. 
Drug Storage: 
                 The prepared drug will be stored in clean and dry air tight glass container. 
    
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
158 
 
 
 
 
 DRUG REVIEW 
  
 
 
 
 
 
 
 
 
 
           DRUG REVIEW 
 RAW DRUGS: 
 Bark of  Ziziphus mauritiania,Lam (Ilandapattai) 
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 Bark of  Lannea coromandelia(houtt)Merr (Othiyampattai )     
 Bark of  Syzygium cumini,linn (Naavalpattai) 
 Bark of  Ficus racemosa.linn(Athipattai) 
 Bark of  Ficus religiosa.linn(Arasapattai) 
 Bark of  Mangifera indica.linn(Mampattai) 
 Bark of  Acacia nilotica.linn(Velampattai) 
 Raw rice powder(pacharasi maavu) 
 Palm jaggery (panai vellam)                                                        
 
fUNty; gl;il 
NtWngau;: 
   fUNtyk;> Nty; 
Botanical Name ;Acacia nilotica,linn. 
Family:Mimosaceae 
 Rit – Jtu;g;G 
 jd;ik – jl;gk; 
 gpupT- ,dpg;G 
nra;if 
  Jtu;g;gp 
 
 
nghJ Fzk;: 
  je;jk;  ,UFe; jdpr;;R+jg; Gz;;zhWk; 
  te;jRuk; gpj;jk; kbAq;fhz; - ge;j 
  kUNt afyh kyusf khNj! 
  fUNtyk; gl;ilf;Ff; fhz.; 
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                                 mfj;jpau; Fzthflk; 
          Bark of the Acacia nilotica contains  
                                 Catechin-5-galloyl ester,  
                                  novel polyphenol , 
                                  Gallic acid, 
                                  Methyl ester, 
                                   Naringenin.[20&21] 
khk; gl;il 
NtWngau;fs;: 
Mapuk;. Mk;gpuk;> vfpd;>  rpQ;rk;> nfhf;F> #jk;> Nu\k;> Fjpiu> Xik> Nrjhuk;> khio> khe;jp. 
Botanical Name: 
  Mangifera indica Linn. 
Family:   ANACARDIACEAE 
 
 Rit Jtu;g;G 
 jd;ik: ntg;gk; 
 gpupT: fhu;g;G 
 nra;if: 
   Jtu;g;gp 
   cukhf;fp 
    Bark of the Mangifera contains 
                                    16-20% of Tannins 
                                     Mangiferine[20&21] 
 
mj;jpg;gl;il 
NtWngau;fs;: 
 Mjk> mjT> cJk;guk;> Nfhsp> Rg;gpuj\;lk; 
Botanical name: 
   Ficus racemosa linn . 
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                Family: MORACEAE 
Rit  Jtu;g;G 
      jd;ik: jl;gk; 
       gpupT: ,dpg;G 
nra;if: Jtu;g;gp 
nghJ Fzk;: 
   tPW fLg;gpuj;jk; ntz;rPj uj;jnkhL 
   ehWtpu zq;fnsyhk; ehlhthk; $Wq;fhy; 
   mj;jpU Nkfk; Nghk; MapioNa! ve;ehd;Wk; 
   mj;jpg;ghy; gl;ilf; fwp 
- mfj;jpau; Fzthflk; 
nghUs;: 
gl;il> fPo;tha;fLg;G FUjpNghf;F> rPjf;fopr;ry;> ehw;wKs;s Gz;fs;>   
nts;is Mfpaitfisg; Nghf;Fk;. 
                     Bark of Ficus racemosa contains  
                                             Glycoside 
                                             Beta –D-Carboxy benzoic acid, 
                                             Bergenins, 
                                             Ferulic acid, [20&21]. 
 
 
 
 
 
murk;gl;il 
NtWngau;fs;: 
M];tj;jk;> mr;Rtj;jk;> jpUkuk;> ftiy> Ngjp> ghid> fztk;> ruhrdk;> 
gpg;gpyk; 
Botanical Name:Ficus religiosa, linn 
 Family: MORACEAE 
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Rit: Jtu;g;G>  ifg;G 
jd;ik: jl;gk; 
gpupT: ,dpg;G 
nra;if 
           Jtu;g;gp 
Bark of the Ficus religiosa contains 
                                           Alpha-octcosmol, 
                                           Methyl oleomolate, 
                                            Lanosterol, 
                                            Beta-sitosterol 
                                             Stigmasterol. [20&21] 
 
ehty;gl;il 
NtWngau;fs;: 
et;ty;> ek;G> rk;G> rhjtk;> MUfjk;> NeNuL> NeNulk;> rhl;Ltyk;> rhk;gy;> 
Rugpgj;jpiu. 
Botanical Name: Syzygium cumini ( linn) Sheels 
Family:MYRTACEAE 
Rit: Jtu;g;G 
jd;ik: jl;gk; 
gpupT: fhu;g;G 
nra;if: 
  Jtu;g;gp 
 
 
nghJ Fzk;: 
  MrpaNeha; fhrk; mrpu;f;fue;R thrtpid 
  NfrKW ghyrpufNeha; - Ngrupa  
khtpaq;f  yhQ;rd kpt td;gpizna yhNkUk; 
ehtYW gl;ilajdhy; 
163 
 
- mfj;jpau; Fzthflk; 
 
nghUs;: gl;ilapdhy;> thapw;gpwf;Fk; Neha;fs;> ,Uky;> ngUk;ghL> <is 
Foe;ijfSf;Fz;lhFk; gs; KjypaFw;wk; ePq;Fk; 
Bark of the Syzygium contains  
                                   Berginin, 
                                  Gallic acid , 
                                   Ethyl gallate, 
                                   Ellagic acid.  [20&21] 
 
Xjpak;gl;il 
NtW ngau;: Nkhjfk; 
Botanical Name:Lannea coromandelica ,(Houtt)Merr 
Family:ANACARDIACEAE 
Rit:  Jtu;g;G 
jd;ik: ntg;gk; 
gpupT:  fhu;g;G  
nra;if: Jtu;g;gp 
   cukhf;fp 
   FUjpg; ngUf;flf;fp 
   Njhj;J GOtfw;wp 
 
 
Bark of Lannea contains 
                                       quercetin ,  
                                      Aralia cerebroside , 
                                     5,5′-dibuthoxy-2,2′-bifuran,  
                                      β-sitosteryl-3β-glucopyranoside-6′-O-palmitate, 
                                             β-sitosterol palmitate ,  
164 
 
                                      myricadiol , protocatechuic acid , p-hydroxybenzoic acidethyl ester , isovanillin , 
trans-cinnamic acid , palmitic acid , and stearic acid[20&21] 
,ye;ijg; gl;il 
     NtW ngau;fs;: 
 ,ye;ij> Fy;yjp> Fy;typ> Nfhy;> Nfhw;nfhb> tjup>  
Botanical Name: 
   Ziziphus Mauritiania,  Lam . 
               Family:RHAMNACEAE 
Rit – Jtu;g;G 
,dpg;Gj; jd;ik> jlgk;>  
gpupT- ,dpg;G nra;if: 
gl;il – jtu;g;gp 
Alkaloids: 
  4 – 9% Tannins 
  Cyclopeptide Alkaloids 
  Amphibines B, B&F ; Mauritines  A-F[20&21] 
gpl;L 
muprpkhtpy; gpl;L nra;J cz;gUf;F> td;ikAk;> cs;Ns tsp  ntg;gKk; 
cz;lhFk;. ngz;fspd; kq;ifg; gUtfhyj;jpy; kpjkpd;wp xOFfpw FUjp fl;Lg;gl;Lj;  
njspit cWk; 
nrk;GdYq; fl;Lj; njspTk; cukhUk; 
ntk;gdpyk; cl;Gwj;jpy; tPWq;fhz; - nrk;goj;ij 
tl;ilg; gopf;Fk; td;Kiykh Nj! auprpg; 
gpl;ilg; Grpg;Nghu;f;Fg;  NgR 
                     -mfj;jpau; Fzthflk; 
gidnty;yk;: gid nty;yj;jhy;> Kf;Fw;wj;jhy; tUk; Neha;fSk;> Kg;gpzp> Ritapd;ik 
Fd;kk; ,itfSk; ePq;Fk; 
……………………………………………………jq;Fgid 
nty;yj;jhy; thjgpj;jk; tPWfgQ; rd;dpNeha; 
ty;yUrp Fd;kkw khy;”.         -mfj;jpau; Fzthflk; 
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BIO CHEMICAL 
ANALYSIS OF 
THE DRUG 
 
 
 
 
 
   
BIO CHEMICAL ANALYSIS OF PERUMPADUKKU PITTU  . 
The biochemical analysis of Perumpadukku Pittu  was done in Bio chemistry lab, National 
Institute of Siddha.  
S.No EXPERIMENT OBSERVATION INFERENCE 
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1.  Appearance of the sample Dark brown  in color  
2. Test for Slicate 
a. A 500mg of the sample was 
shaken well with distilled 
water. 
b. A 500 mg of the sample wa 
c. s shaken well with 
conc.Hcl/con.H2SO4 
 
Sparingly soluble 
 
 
Presence of Silicate 
 
3. Action of Heat: 
A small amount of the sample was 
taken in a dry test tube and heated 
gently at first and then strong. 
 
White fumes  
evolved. 
No brown fumes. 
 
 
Presence of 
Carbonate 
 Absence  of Nitrate. 
 
 
 
4. Flame Test: 
A small amount of the sample was 
made into a paste with con. Hcl in a 
watch glass and introduced into non-
luminous part of the bunsen flame. 
 
No bluish green 
flame appeared 
 
Absence  of copper 
 
5. Ash Test:  
A filter paper was soaked into a 
mixture of sample and cobalt nitrate 
solution and introduced into the 
bunsen flame and ignited. 
 
No yellow color 
flame appeared 
 
 
 
 
 
flame  
 
 
 
 
Absence of sodium 
 
Preparation of Extract: 
                 5gm of Perumpadukku Pittu was weighted accurately and placed in a 250ml clean 
beaker and added with 50ml of distilled water. Then it was boiled well for about 10 minutes. 
Then it was cooled and filtered in a 100ml volumetric flask and made up to 100ml with distilled 
water. This preparation was used for the qualitative analysis of acidic/basic radicals and 
biochemical constituents in it. 
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S.No EXPERIMENT 
OBSERVATI
ON 
INFERENCE 
 I. Test For Acid Radicals   
1. Test For Sulphate: 
a.2ml of the above prepared extract was taken 
in a test tube to this 2ml of 4%dil. ammonium 
oxalate solution was added. 
 
b.2ml of the above prepared extract was 
added with 2ml of dil.Hcl until the 
effervescence ceases off. 
Then 2ml of  Barium chloride solution was 
added. 
No cloudy 
appearance 
present 
 
No white 
precipitate 
insoluble in 
con. Hcl was 
obtained 
Absence of Sulphate 
 
 
 No Sulphate was 
confirmed 
 
 
2. 
 
Test For Chloride: 
2ml of the above prepared extracts was added 
with 2ml of dil.Hcl was added until the 
effervescence ceases off. Then 2ml of silver 
nitrate solution was added  
Cloudy 
appearance 
present. 
 
Presence of Chloride  
3. Test For Phosphate: 
2ml of the extract was treated with 2ml of 
dil.ammonium molybdate solution and 2ml of 
con.HN03 
No Cloudy 
yellow 
appearance  
 
Absence of Phosphate  
4.  Test For Carbonate: 
2ml of the extract was treated with 2ml dil. 
magnesium sulphate solution 
Cloudy 
appearance 
absent 
 
Absence of  carbonate 
5. Test For Nitrate: 
1gm of the extract was heated with copper 
turnings and concentrated H2SO4 and viewed 
the test tube vertically down. 
 No 
characteristic 
changes 
 
Absence of nitrate 
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6. Test For Sulphide: 
1gm of the extract was treated with 2ml of 
con. HCL 
 No rotten egg 
smelling gas 
was evolved 
Absence of sulphide 
7. Test For Fluoride & Oxalate: 
2ml of extract was added with 2ml of dil. 
Acetic acid and 2ml dil.calcium chloride 
solution and heated. 
  
No cloudy 
appearance. 
 
Absence of fluoride 
and oxalate 
8. Test For Nitrite: 
3drops of the extract was placed on a filter 
paper, on that 2 drops of dil.acetic acid and 2 
drops of dil.benzidine solution were placed. 
No 
characteristic 
changes 
 
Absence of nitrite 
 
9. Test For Borate: 
50mg of the extract was made into paste by 
using dil.sulphuric acid and alcohol (95%) 
and introduced into the blue flame. 
No bluish 
green color 
flame 
appeared 
 
Absence of borate 
 
 
II. Test For Basic Radicals 
1. Test For Lead: 
2ml of the extract was added with 2ml of 
dil.potassium iodine solution. 
No Yellow 
precipitate 
was obtained. 
 
Absence of lead 
 
2. Test For Copper: 
a. 50mg of extract was made into paste 
with con. Hcl in a watch glass and 
introduced into the non-luminous part 
of the flame. 
b. 2ml of extract was added with excess 
of ammonia solution 
 
 
 
 
 
 
No blue color 
precipitate  
No blue color 
precipitate  
   
Absence of    copper 
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3. Test For Aluminium: 
To the 2ml of extract dil.sodium hydroxide 
was added in 5 drops to excess. 
 No 
characteristic 
changes  
 
 
 
 
 
 
 
 
 
characteristic 
changes chara 
Absence of    
Aluminium 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. Test For Iron: 
a. 2ml of extract was added with 2ml of 
dil.ammonium thiocyanate solution. 
b. To the 2ml of extract added 2ml of 
ammonium thiocyanate solution and 2ml of 
con.HNO3 was added. 
 
 
 
 
 
 
ammoniumthiocyanate thiocyanate  
 solution and 2ml  of con HNo3 is added 
 Red color 
appeared. 
Blood red 
color 
appeared 
 
 
 
 
 
 
 
 
 
Presence of Iron 
 Presence of Iron 
 
5. Test For Zinc:  
To 2ml of the extract dil.sodium hydroxide 
solution was added in 5drops to excess and 
dil.ammonium chloride was added.  
                        
No white 
precipitate 
was formed 
 
 Absence of Zinc 
 
6. Test For Calcium:  
2ml of the extract was added with 2ml of 4% 
dil.ammonium oxalate solution. 
 No cloudy 
appearance 
and white 
precipitate 
was formed 
Absence of calcium 
 
 
7. Test For Magnesium:  
To 2ml of extract dil.sodium hydroxide 
solution was added in 5 drops to excess. 
No  White 
precipitate 
was obtained 
 
Absence of magnesium 
 
8. Test For Ammonium: 
To 2ml of extract 1 ml of Nessler's reagent 
and excess of dil.sodium hydroxide solution 
were added. 
 No Brown   
color 
appeared 
 
Absence of ammonium 
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9. Test For Potassium: 
25mg of extract was treated  with 2ml of 
dil.sodium nitrite solution and then treated 
with 2ml of dil.cobalt nitrate in 30% 
dil.glacial acetic acid. 
   
No Yellow 
precipitate 
was obtained 
 
 
 
Absence of potassium 
 
 
10. Test For Sodium: 
 50mg of the extract was made into paste by 
using HCl and introduced into the blue flame 
of bunsen burner. 
No yellow 
color flame 
evolved. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Absence of sodium 
 
11. Test For Mercury:  
2ml of the extract was treated with 2ml of 
dil.sodium hydroxide solution.  
 No Yellow 
precipitate 
was obtained 
   
 
Absence of Mercury 
 
12. Test For Arsenic:  
2ml of the extract was treated with 2ml of 
dil.sodium hydroxide solution. 
No  Brownish 
red precipitate 
was obtained 
  
Absence of arsenic. 
 
III. Miscellaneous 
1.
  
Test For Starch: 
2ml of extract was treated with weak dil.Iodine 
solution  
 
 Blue color developed 
 
Presence of 
starch 
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2.
  
Test For Reducing Sugar: 
    5ml of Benedict's qualitative solution was taken 
in a test tube and allowed to boil for 2 minutes 
and add 8 to 10 drops of the extract then again 
boil it for 2 minutes. The color changes were 
noted. 
  
 Brick red color was 
developed  
 
Presence of  
reducing sugar 
  
3. Test For The Alkaloids: 
a) 2ml of the extract was treated with 2ml of 
dil.potassium Iodide solution. 
b)  2ml of the extract was treated with 2ml of 
dil.picric acid. 
c)  2ml of the extract was treated with 2ml of 
dil.phospho tungstic acid. 
 
 
Yellow color 
developed 
 
 
Presence 
of Alkaloid 
  
4.
  
Test For Tannic Acid:  
2ml of extract was treated with 2ml of dil.ferric 
chloride solution  
  
 Black precipitate 
was obtained  
 
Presence of 
Tannic acid 
5.
  
Test For Unsaturated Compound: 
To the 2ml of extract 2ml of dil.Potassium 
permanganate solution was added.  
 Potassium 
permanganate was 
not decolorized 
  Absence of 
unsaturated 
compound 
6.
  
 
 
Test For Amino Acid: 
2 drops of the extract was placed on a filter paper 
and dried well. 20ml of Burette reagent was 
added. 
 
No violet color 
 
 
Absence of 
amino acid 
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 RESULT:  
                   Presence of  
Silicate,  
Carbonate,  
Chloride, 
 Iron, 
 Starch,  
Reducing Sugar,  
Tannic Acid. 
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